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MICRO$EC: Cost Effective, Whole-Genome Sequencing
Abstract
While the feasibility of whole human genome sequencing was proven by the success of the Human Genome
Project several years ago, the prevalence of personal genome sequencing in the medical industry is still elusive
due to its unrealistic cost and time requirements. Micro$eq is a startup company with the goal of overcoming
these limitations by sequencing a minimum of 12 complete human genomes per day at an error rate less than
ten parts in million at a profitable market price of less than US$1000 per genome. To overcome the
technology bottlenecks hindering current biotech companies from achieving these target throughput, error
rate, and market price goals, Micro$eq has developed an innovative sequencing technique that uses shortread
fragments with high coverage on a microfluidics platform. Short, amplified DNA fragments are generated
from an input of customer saliva. 6 base pair(bp) sequence hybridization is used for sequencing each of the
DNA fragments individually. The results are these hydridization reads are then assembled via de Bruijn graph
theory and the graphical reconstructions of each fragment’s sequence are then assembled to a complete
genome via shotgun sequencing with an expected error rate less than 1 in 100,000bp. Upon the completion of
financial analysis, both a small-scale business model producing 72 genomes per day at US$999 per genome,
and a largescale business model producing 52.2 genomes per year at a market price of US$299 per genome
were found to be profitable, yielding Micro$eq investors return margins of ~90% and 300% for the small and
large scale models, respectively. With a market price Micro$eq offers personal genome sequencing at one-tenth
of its nearest potential competitor’s cost. Additionally, its ability for bulk-sequencing allows it to profitably
venture into the previously untapped Pharmaceutical Industry market sector, enabling the creation of large-
scale genome databases which are the next step forward in the quest for truly personalized.
This working paper is available at ScholarlyCommons: http://repository.upenn.edu/cbe_sdr/29
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Abstract 
 While the feasibility of whole human genome sequencing was proven by the success of 
the Human Genome Project several years ago, the prevalence of personal genome sequencing in 
the medical industry is still elusive due to its unrealistic cost and time requirements. Micro$eq is 
a startup company with the goal of  overcoming these limitations by sequencing a minimum of 
12 complete human genomes per day at an error rate less than ten parts in million at a profitable 
market price of less than US$1000 per genome. To overcome the technology bottlenecks 
hindering current biotech companies from achieving these target throughput, error rate,  and 
market price goals, Micro$eq has developed an innovative sequencing technique that uses short-
read fragments with high coverage on a microfluidics platform. Short, amplified DNA fragments 
are generated from an input of customer saliva. 6 base pair(bp) sequence hybridization is used 
for sequencing each of the DNA fragments individually. The results are these hydridization reads 
are then assembled via de Bruijn graph theory and the graphical reconstructions of each 
fragment’s sequence are then assembled to a complete genome via shotgun sequencing with an 
expected error rate less than 1 in 100,000bp. Upon the completion of financial analysis, both a 
small-scale business model producing 72 genomes per day at US$999 per genome, and a large-
scale business model producing 52.2 genomes per year at a market price of US$299 per genome 
were found to be profitable, yielding Micro$eq investors return margins of ~90% and 300% for 
the small and large scale models, respectively. With a market price<US$1000, Micro$eq offers 
personal genome sequencing at one-tenth of its nearest potential competitor’s cost. Additionally, 
its ability for bulk-sequencing allows it to profitably venture into the previously untapped  
Pharmaceutical Industry market sector, enabling the creation of large-scale genome databases 
which are the next step forward in the quest for truly personalized. 
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CHAPTER 1  
 
Introduction to Personal Genome 
Sequencing 
 
Personal genome sequencing has become a research challenge and promising investment 
option for the past decade. The goal of the personal genome project is to allow individuals to get 
their own genome sequenced at a reasonable price. Personalized genomic information allows 
personal healthcare treatment, personalized medicine and individual disease risk projection. The 
benefits of personal genome sequencing to human health improvement and healthcare industry 
growth are tremendous. Upon its completion, personal genomics can possibly alter the nature of 
healthcare service industry and individuals’ approach to their health treatment. 
3 | P a g e  
 
Micro$eq – Chomvong, King, Mahmoud 
Human genome analysis was initiated in 1990. The two main goals of the Human 
Genome Project (HGP) were to identify all genes in human DNA and to determine the sequences 
of the 3 million different pairs of coding molecules that are unique in every individual. The 
project was completed in 13 years with many additional years required to analyze acquired data 
(HGP, 2011). The total cost of the project was reported to be $3 billion (HGP, 2004). With such 
a high sequencing cost and infeasible processing time, the Human Genome Project cannot be 
directly implemented for personal genomics purpose. Nevertheless, information provided by the 
project allowed improvements in advance medicine, human biology and knowledge of human 
origins. In addition, the technology platform developed for the project is applicable to personal 
genome project initiative.   
Upon the unprecedented achievement of the HGP, the Personal Genome Project was 
established. The goal of the Personal Genome Project extended from that of HGP. However, its 
emphasis was on allowing human genome sequencing to be available broadly for general public 
(PGP). In order to do so, the cost and time required to sequence each genome must be reduced 
significantly from that of the Human Genome Project. Many researchers have dedicated their 
work to improving feasibility of personal genome sequencing. With face-paced sequencing 
technology development, sequencing cost and time have decreased dramatically 
.  
1.1  MARKET ANALYSIS 
Micro$eq’s advanced technology has proven that personal genome sequencing is feasible 
at less than $1000/genome bulk retail price. Our design allows 12 genomes to be sequenced per 
day; however the plant can be scaled up to respond to high market demand. With  breakthroughs 
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in reduced cost and time required to sequence human genome, the personal genome project 
becomes achievable and provides a promising alternative healthcare approach. 
Micro$eq’s specialization is to deliver personal genome sequences at a relatively low 
price,  within reasonable time frame and with an acceptable error rate. Micro$eq’s products are 
sequences of coding molecules that are unique in every individual. However, it is important to 
note that Micro$eq does not provide sequence interpretation service. Besides the current market 
sector for personal genoming, which consists primary of private wealth individuals, two 
additional market sectors lend themselves to Micro$eq’s low-cost, high-throughput genome 
product.  
First, The Pharmaceutical Industry is as a main target market sector due to the potential 
application of personal genome sequencing to their existing clinical trial protocols. One of many 
expensive steps that pharmaceutical companies must complete before the launch of new drug is 
the testing of potential drugs on prospective patients. The cost of this process is reported to often  
exceed $25,000 per patient (PR Newsire, 2006). Depending on the drug type and condition, 
hundreds or thousands of patients are required for each trial. Personal genome sequencing can be 
incorporated as part of a clinical trial to identify relationships between variable genetic 
sequences and effectiveness of drug response. Drug response information against variation of 
genetic factors is incredibly valuable in healthcare service because it allows pharmaceutical 
companies to target appropriate patients. In the final consumers’ perspective, this database 
allows personalized medicine in which patients are at lower risk of being given ineffective drugs. 
The low cost and quick turnaround  time of Micro$eq’s technology makes incorporating personal 
genome sequencing  into clinical trials feasible. With the estimated market price of less than 
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$1000 per genome, the increase in cost per patient during a trial is minimal compared to its 
potential benefits to the Pharmaceutical companies. 
Second, Health Insurance firms are Micro$eq’s potential target market sector. In this 
case, personal genome sequencing can be integrated as part of health insurance plan. Individuals 
who choose to have their genome analyzed can receive supplemented personalized drug and 
treatment from their primary care physicians. Again, Micro$eq will provide only the sequence 
information while the Health Insurance firms will be responsible for its interpretation. In 2010, 
the average annual cost of health insurance coverage as part of a group plan is reported to be 
$4,824 for individual and $13,375 for family (Banning, 2010). With the addition of personal 
genome analysis option, the price of insurance coverage will increase by approximately 25% 
(including interpretation cost). Healthcare insurance is considered Micro$eq’s secondary target 
market because of two challenges associated with this business. First, the current average health 
insurance coverage cost is not high enough to make additional cost of personal genome 
sequencing negligible. Initially, individuals who choose personalized medicine options may have 
to pay the extra coverage cost on their own. However, if the cost of overall healthcare is reduced 
due to increased efficacy of personalized treatment, it may be beneficial for Healthcare firms to 
supplement the sequencing cost. Second, the system is designed so that health insurance firms 
have access to individual genome information. Ethical, legal and social issues could arise 
because of the firm’s ability to predict their customer’s risks of having diseases. With such 
powerful information on hand, Health Insurance firms might refuse to insure or increase 
coverage cost for customers who are like to have symptoms which are expensive to treat. 
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  OVERVIEW OF GENOME SEQUENCING 
Before any process for genome sequencing can be designed, it is important to understand 
the nature of the human genome and the available technology that allows it to be sequenced.  
1.1.1 The Human Genome Structure 
The human genome is 
comprised of double-stranded 
DeoxyriboNucleic Acid (ds-DNA). 
ds-DNA is an assembly of two single-
stranded polymers, called nucleotides, 
that are made up of alternating 5-
carbon sugar and phosphate residues 
which are connected by 
phosphodiester bonds. Each sugar is 
bound to the functional group of that particular monomer (called a nulecotide base, or base). 
Four different functional bases exist in human DNA. Adenine (A), Thymine (T), Guanine (G), 
and Cytosine (C). The functional groups of the bases are able to create hydrogen bond with one 
another in a base pair, thus binding the two single-stranded polymers to form ds-DNA as shown 
on the right of Figure 1.1. The tertiary structure of the ds-DNA is a double-helix, as seen on the 
left of Figure 1.1.  
The particular combination of the four different base pairs of the DNA sequence in a 
particular individual determines that person’s genetic makeup. Analysis of this sequence is 
Figure 1.1 DNA Structure showing the chemical structure of the 
phosphate-sugar backbone (right) and the dimensions of the double-helical 
structure (left) (Cummings). 
7 | P a g e  
 
Micro$eq – Chomvong, King, Mahmoud 
essential to discover the genetic abnormalities of any individual and how they might affect 
disease susceptibility, drug response, and a myriad of other biological phenomena. It is important 
to note that not just the base pair sequence of the DNA, but also particular aspects of its 3-D 
structure (termed epigenetic factors) act in both determining the genetic make-up and in 
regulating the genetic expression in any given human cell. The base pair sequence is identical in 
every single cell present in the individual. However, the 3-D structure of the DNA may vary 
between different cell types (i.e. a skin cell versus a brain cell). The scope of this project is only 
to investigate only the base pair DNA sequence and does not extend to any epigenetic 
considerations.  
1.1.2 The Human Genome Size and Sequencing 
A complete human genome contains approximately 3 billion base pairs in length – for a 
total of 6 billion bases in the genome. While many of these bases are conserved between 
different samples (one sample being defined as one individual) of human DNA, for an effective 
whole genome sequencing process, every single one of the 6 billion bases needs to be read from 
the sample DNA and used to construct the sample’s particular sequence. The length of the 
combined 3 billion base pairs of one genome is approximately 3m (Mitchell, 1997). For 
microbiology purposes, working with a molecule this long is completely impractical. DNA does 
not exist naturally in the cell as one continuous molecule, but is instead segregated into various 
subsections. Still, even when divided, the DNA exists in fragments of length on the order of 10 
million base pairs. Therefore, any sequencing process must begin by breaking the DNA into 
workable length fragments (<10,000bp).  
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1.1.3 Genome Sequencing 
From the broken down DNA fragments, their base pair sequence can be read using a 
variety of methods.  While different approaches to sequencing require the use of different sized 
fragments, almost all approaches involve the addition of a fluorescently-tagged molecules to the 
target DNA. Generally, the presence or absence of fluorescence is used to determine the presence 
or absence of a particular base pair or sequence of base pairs in the target DNA. The most 
commonly used method is the addition of fluorescently-tagged single base pairs where each type 
of base is tagged with a different color. The sequence is then analyzed one base pair at a time and 
the color at each base pair position indicates which base pair is present there.   
As sequencing of DNA is done in fragments, short sequence reads from each fragment 
will be generated and  then reassembled  into the longer complete sequence using a 
computational approach. 
1.1.4 Genome Assembly 
Currently, sequencing technology is not applicable to read the entire human genome at 
once. The length of human genome is too long to be read directly; thus, shorter reads are 
generated from sequencing step. Genome assembly is then required to reconstruct the original 
sequence. Generally, total length of all reads combined must be many times longer than that of 
original sequence. This is because genome assembly relies on over-generation of information. 
The short reads are aligned and merged using assembling algorithm or assembler software to 
regenerate meaningful original sequence. 
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1.2  COMPETITIVE ANALYSIS 
In order to move forward with the business model for Micro$eq, it is critical to perform 
an analysis of the competitive environment and the major companies that offer similar services, 
but with different techniques.  The major companies offering these technologies are Illumina, 
454 sequencing, and Pac Bio.  Since genome sequencing is a relatively new market and most of 
the products being offered are still in their infancy, not all of the information regarding the 
products, such as potential costs, is available to the public. This section includes some technical 
details which are not explained until later in the report. In the event that any of the molecular 
biology of the technology descriptions is unclear, please refer to Chapter 4 to a more detailed 
discussion.  
1.2.1 Illumina 
Illumina relies on Solexa technology in order to sequence their genomes.  Template 
preparation begins with solid phase amplification.  High density forward and reverse primers are 
covalently attached to a solid surface.  The ratio of the primers to the template on the support 
defines the surface density of the amplified clusters (Metzker, 2010).  Amplification takes place 
in two steps: intial priming and extension of the single-stranded template followed by bridge 
amplification of the immobilized template with adjacent primers to form clusters.   Illumina’s 
amplification approach can be seen in Figure 1.2.  
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Following amplification, fluorescently tagged reversible terminators are added along with 
the polymerase to the single-stranded solid-phase amplified DNA.  Reversible terminators halt 
DNA synthesis so that fluorescence imaging can take place.  llumina’s imaging technology then 
reads out the different wavelengths emitted for each nucleotide.  The dye and terminator groups 
are cleaved and the support is washed.  This process is repeated again until the entire strands are 
read. A summary of Illumina’s sequencing process is illustrated in Figure 1.3 on the next page. 
The fragments are then assembled into a genome sequence using an unreleased algorithm.  The 
complete overview of Illumia’s process may be seen  
 
Figure 1.2  Illumina’s Template Immobilization Strategy: Amplification takes place in two steps: intial priming and extension 
of the single-stranded template followed by bridge amplification of the immobilized template with adjacent primers to form 
clusters.    
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One of the advantages of the Illumina technology is the simplicity of the flow cell design.  
There are no specific wells or beads that need to be attached to, and the amplification of the 
clusters allows for a large viewing concentration.  The very nature of the clusters themselves 
Figure 1.3 Illumina’s Sequencing Strategy, Fluorescently tagged reversible terminators are added along with the polymerase to the 
single-stranded solid-phase amplified DNA.  Reversible terminators halt DNA synthesis so that fluorescence imaging can take 
place.  (Figure adapted from (Metzker, 2010)) 
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guarantee a strong signal, as they are very concentrated as opposed to the single fluorescent 
molecule that has to be detected for other designs.   
 A major disadvantage of this technology is the required washing step and large cost.  
Washing steps increase the variable costs associated with the process and decrease throughput.  
Furthermore, careful attention must be made to make sure that base additions are synchronous.  
If careful track of how many bases were added to each template, then a greater sequencing error 
rate is incurred.   Illumina advertises comprehensive genetic sequence information at a cost of 
$19,500 per genome.  If a group of five individuals ordered through the same physician: $14,500 
per genome.  Medical indicated cases approved through a 
subsidy program cost $9,500 per genome.   
1.2.2 Helicos Biosciences 
Helicos Biosciences uses a similar sequencing 
strategy as Illumina.  Native genomic DNA is sheared, 
treated with terminal transferase to generate a poly-A tail and 
loaded onto an instrument.  The tailed fragments hybridize to 
complementary strands anchored on the flow cell surface.  
Helicos Virtual Terminators are labeled with the same dye 
and dispensed individually in a predetermined order, 
analogous to a single-nucleotide addition method.  Following 
total internal reflection fluorescence imaging, a cleavage step 
removes the fluorescent dye and inhibitory groups using 
TCEP to permit the addition of the next dNTP analogue 
Figure 1.4 Helicos Biosciences’ Sequencing Strategy: 
Helicos Virtual Terminators are labeled with the same 
dye and dispensed individually in a predetermined order, 
analogous to a single-nucleotide addition method.  
Following total internal reflection fluorescence imaging, 
a cleavage step removes the fluorescent dye and 
inhibitory groups using TCEP to permit the addition of 
the next dNTP analogue ( (Metzker, 2010) 
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Figure 1.4.  This is followed by the next nucleotide addition.   
Helicos Bioscience’s sequencing approach requires a large number of flushing, scanning, and 
washing cycles, which results in very small throughputs.  In addition, the nature of the washing 
cycles limits the average read length to 35 to 400 
bases.  Also a large number of samples are usually 
required to justify machine operation (Pacific 
Biosciences).  
1.2.3 Roche/454 Sequencing 
Roche/454 pyrosequencing uses a titanium platform 
loaded with DNA-amplified beads in PicoTiterPlate 
(PTP) wells (Figure 1.5).  dNTPs are flown across 
PTP wells and a charged coupled device (CCD) 
camera detects light generated from the 
pyrosequencing reaction (Metzker, 2010).  This 
technology has proven to be very robust with very few 
substitutions errors, allowing denovo sequencing.  
However, the setup relies on PCR which may result in 
an amplification bias and requires a great deal of time.  
Furthermore, one nucleotide species is introduced 
during each cycle, which is detrimental to both 
throughput and reagent costs. 454 Sequencing quotes 
a run time of one billion bases in a day using the GS Figure 1.5 454 Sequencing: dNTPs are flown across PTP wells and a charged coupled device (CCD) camera detects light 
generated from the pyrosequencing reaction.  (Figure is 
adapted from (Metzker, 2010) 
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FLX Titanium series sequencing kit.  No complex optics or lasers have to be used (Roche 
Biotech).  
1.2.4 Pacific Biosciences 
Pacific Biosciences uses “Single Molecule Real Time” (SMRTTM) DNA sequencing 
technology.  This novel technology platform enables single molecule, real-time detection of 
biological processes.  Zero-mode waveguides (ZMWs) are employed which are tiny aluminum 
wells that house the growing DNA strands (Figure 1.6).  Phospholinked nucleotides enter the 
limits of detection zone as they are incorporated and a fluorescence pulse is detected  (Metzker, 
2010). 
Long reads promote simpler more accurate assembly because they can span varied 
genomic regions that can present problems for shorter read-length platforms.  However, the 
Figure 1.6  Pacific Biosciences Sequencing Strategy: This novel technology platform enables single molecule, real-time 
detection of biological processes.  Zero-mode waveguides (ZMWs) are employed which are tiny aluminum wells that house 
the growing DNA strands (Figure 5).  Phospholinked nucleotides enter the limits of detection zone as they are incorporated 
and a fluorescence pulse is detected 
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drawback of this sequencing approach is that expensive detection schemes and platforms must be 
made in order to real time sequence on the molecular scale. 
1.2.5 Competitive Analysis Conclusion 
The current bottleneck of technology is imbedded in the fact that the majority of 
sequencing approaches rely on single base pair additions which requires a large number of 
flushing, scanning, and washing cycles, and thus result in very small throughputs.  Furthermore, 
the nature of washing cycles limits the average read length from 35 to 400 bases, which are hard 
to generate without an immobilization step, which again decreases throughput.  Finally, a large 
number of samples are usually required to justify machine operation (Pacific Biosciences).  
Single molecule approaches to sequences require expensive machinery to maintain a reasonable 
signal to noise. 
 
1.3  CONCLUSIONS 
The field of personal genome sequencing research is one of the foremost challenges in 
the Biotechnology Industry this decade. The potential of having personalized medicine and 
treatment as well as individual disease risk projections hast the potential to transform the nature 
of the Healthcare Industry and people’s everyday lives. Because of the enormity of its potential 
benefits, many organizations have entered the whole genome sequencing market. Illumina, 
Helicos Biosciences, Roche/454 Sequencing and Pacific Biosciences are some of the current and 
most promising players in the personal genomics industry. With its proposed unique set of 
technologies, Micro$eq is confident that its approach is capable of delivering high quality 
personalized genome sequences at a large demand volume. In addition, Micro$eq’s technologies 
reap the benefit of first mover competitive advantage in the low cost personal genome 
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sequencing market. With an expected market price of less than $1000 per genome, Micro$eq’s 
product has potential marketability in the clinical trial sector of the Pharmaceutical Industry as 
well as in the Health Insurance Industry. 
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CHAPTER 2  
 
Micro$eq’s Proposed Challenge 
 
 With existing competitors in personal genome industry, Micro$eq’s mission is to deliver 
superior value of sequenced genome product. Customers’ demand specifications on delivered 
sequenced genomes are relatively simple—low cost and high accuracy. However, the challenge 
of the industry is how to respond to such demand with the current technology limitation. 
Nevertheless, innovative technologies have been developed constantly; thus, allowing an 
entrance to lower cost and higher accuracy regime which was previously inaccessible. In this 
chapter, Micro$eq’s initial scheme is presented along with an expected price range, minimum 
error rate and required throughput. In addition, relevant technologies required for proposed 
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process are introduced. Detailed discussions on how each technology is applied to Micro$eq’s 
process are further illustrated in this report. 
2.1   INITIAL SCHEME 
 Micro$eq’s goal is to design ‘$100 genome’ under a condition of a startup biotechnology 
company. Raindance Technologies’ microfluidic microreactor technology is proposed as a 
unique approach to genome sequencing. The scope of Micro$eq’s service as previously 
introduced in section 1.1 is to sequence client’s patient samples and deliver whole genome data 
to the client within 30 days. The delivered products are a sequenced genome with no associated 
interpretation. The delivered products are allowed to have no more than ten parts per million 
error rate for non-repeating intronic sequences. Initially, the expected throughput is 2500 
genomes per year with assumed series A funding. The market price is expected to be within the 
range of $100-300. Micro$eq’s throughput is expected to quadruple after series B funding to 
10,000 genome per year. Finally, after the market has adopted the application of personal 
genome sequencing, the expansion is expected to reach over a million throughput genomes per 
year.  
 The summary of Micro$eq’s  initial proposal is presented in Table 2.1. Specific goals, 
project scope, deliverables and timelines are clearly illustrated.  
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Table 2.1  Project Charter Summary of project champion, project leaders, specific goals, project scope, deliverables and 
timeline 
 
  
Project Name Removing the Personal Medicine Bottleneck: $100 Genomes using 
Raindance Technology 
Project 
Champion 
Dr. John Crocker 
Project Leaders Kulika Chomvong, Eyas Mahmoud, Amanda King 
Specific Goals Sequence 10,000 human genomes per year for less than $100 per sequenced 
genome, with an error rate of less than ten parts per million for non-
repeating intronic sequences. 
Project Scope In Scope: 
· Identify and investigate high throughput screening techniques 
· Provide in-house whole genome sequencing through application of 
the most promising technology 
· Select appropriate equipment and staff 
· Develop a working a profitable business model centered on the 
aforementioned production level, investment, and genome price. 
Out-of-Scope: 
· Fabrication of microfluidic chip 
· Synthesis of reversible terminator nucleotides 
· Focused screening of genome (such as SNP screening) 
· The provision of genetic or medical consultation 
· Synthesis of 6-base oligos library 
· Correlating sequence analysis to patient conditions 
Deliverables · Market assessment and competition analysis 
· Technical feasibility assessment 
· Full scale manufacturing requirements and protocol 
· Financial analysis over a 4-year project life cycle 
Timeline · Working sequencing prototype within 12 months 
· Scale-up operations within 2-years 
· Full-scale production in years 3-4 with simultaneous R&D 
· Liquidate or sell the company at the conclusion of the fifth year 
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 In order to achieve the project goals specified, Micro$eq must approach personal genome 
sequencing challenges in a distinctive fashion to generate barrier to entry against potential 
competitors. To take advantage of first mover in ‘$100 genome’ category, genome sequencing 
technologies which Micro$eq implements must minimize the process cost such that Micro$eq 
can set its retail price in the hundred dollar range and yet yield appreciable returns to its investor. 
To do so, necessary steps of genome sequencing are studied to explore potential technology 
improvement that results in lower processing cost.  
 
 
 
Figure 2.1 Project Charter A process flow sheet of Micro$eq’s approach to human genome sequencing.  The process flow 
walks through the planned progress of Micro$eq from patient’s sample acquirement, presequencing, DNA sequencing, genome 
assembly and finally delivered product. 
 
Figure 2.1 clearly illustrates the necessary steps Micro$eq plans to take in order to 
accomplish low cost human genome sequencing. Micro$eq receives input sample, patient’ saliva, 
from its clients such as pharmaceutical firms. The sample is then prepared to properly suit 
Micro$eq’s unique DNA sequencing approach during Pre-sequencing process. The typical 
sample preparation steps—DNA purification, DNA fragmenting and DNA amplification—are 
implemented. However, the application of Raindance Technologies’ droplet microreactor plays 
significant role during this process, minimizing labor and reagent costs required in normal 
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microbiology lab setting. Fragments of patient DNA are sheered then PCR amplified in large 
droplets (>1 nanoliter) that then broken down into thousands of smaller (~1 picoliter) droplets, 
each containing many copies of the original fragment. The prepared DNA fragments are then 
sequenced using 6mer oligonucleotide hybridization scheme. All 4,096 combinations of bases 
(A, T, C or G) with the length of 6 are generated, along with distinctive fluorescence barcode 
identifier to distinguish each one of them. The bases have specific binding system such that A 
always binds with T and C always binds with G. Thus, when droplets with inserted fragments 
from presequencing process are merged in 1:1 fashion with the oligo library droplets, the 
information of the fragment sequence can be determined. The merged droplets are then arrayed 
on a flat slide, and incubated to allow hybridization to occur in those droplets where the oligo 
finds a 6-base complementary section in the patient fragment.  After the oligos hybridize with the 
fragments, the droplets are scanned to detect whether certain oligo combination exists in the 
fragments using a custom made high speed charged coupled device (CCD) camera. The 
information on whether each of the 4,096 oligos bind with the inserted fragments are then passed 
along to Genome Assembly where de Bruijn graph assembly and shotgun sequencing recombine 
patient’s whole genome at acceptable error rate (10 parts in a million). Finally whole genome 
product is delivered to the client within specified 30 day time frame.  
 2.1.1  Technology Readiness Assessment 
 Genome sequencing technology development is possibly one of the fastest growing 
research fields. With tremendous potential benefits associated with personal genome sequencing, 
private and public organizations have invested time, money and personnel to certify their 
superior standing in the market. For example, in 2006, the X Prize Foundation, along with the J. 
Craig Vetner Science Foundation launched the Archon X Prize for Genomics, which was to be 
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awarded to the first team that can build a device which has the capability of sequencing 100 
human genomes in 10 days or less, with an error rate of 1 in 100,000 bases at the cost of $10,000 
per genome (Archon Genomics X Prize Overview). Since the launch of this challenge, a race to 
the commercialization of whole genome sequencing has lead to many of innovations.  
 
Figure 2.2  Innovation Map Customer value proposition, products, product technologies, technical differentiation, 
process/manufacturing technology and material technology of personal genome industry are illustrated.  
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The use of genetic information to predict disease has the power to revolutionize our 
healthcare system.  The possibilities of proactive care provide consumers with an impetus to seek 
out whole genome sequencing.  However, whole genome sequencing was initially very costly 
and non-accessible.  Subsequently, requirements were added for accuracy, high throughput, low 
cost, and clinical use.  In Figure 2.2, current material technology, process/manufacturing 
technology, technical differentiation, product technologies, existing alternative products and how 
they respond to customer value proposition are shown. Companies such as Illumina and Helicos 
Biosciences used reversible chain-terminating DNA sequencing technology.  However, these 
processes have large throughput times and large associated costs.  Recently, Pacific Biosciences 
announced a high-throughput design which used single-molecule real time DNA sequencing 
(SMRT).  Nevertheless, costs per sequenced human genome continue to be excessive.  Microseq 
seeks to design the next generation of whole human genome sequencing to meet customer 
demands by using Raindance Technology’s microfluidic platform to drive down cost.  Using 
very small amounts of reactants to gain sequencing information, drives down the cost of human 
genome sequencing per base. Currently, the use of microfluidic platform has not been 
implemented by any of Micro$eq’s potential competitors; thus, allowing Micro$eq to take full 
advantage of prospective low processing cost which satisfies customer value proposition at 
acceptable error rate.  
 2.1.2   Customer Requirements 
Customer value propositions are illustrated in Figure 2.2. The four main propositions are 
high throughput, low cost, accuracy and clinical use. Due to the scope of the project, the aspect 
of clinical use of the final genome is irrelevant because Micro$eq’s service does not include 
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genome sequence interpretation. The rest of the four customer value propositions are studied to 
design the process which responds best to what consumers are looking for.  
In the scope of the project, target market of Micro$eq is pharmaceutical firms. The use of 
personal genome sequencing can be incorporated in their essential clinical trials where large data 
sets are required to test efficiency and safety of newly developed drugs. Complete patient 
genome sequencing could be included as part of the clinical trials to acquire the complete 
relationship between drug response and individual’s genome variation. With such a large volume 
of data collected, pharmaceutical firms can potentially understand the origin of diseases and 
invent drugs directly attack the cause of the diseases. As discussed in section 1.1, average cost of 
a clinical trial per patient is estimated to be $25,000 (PR Newsire, 2006).  
With the aforementioned needs of pharmaceutical firms, their requirements on personal 
genome sequencing can be analyzed. First, pharmaceutical firms, with large number of patients 
per clinical trial require high sequencing throughput. The database of relationship between drug 
response and genome variation has little meaning if it is not statistically reliable. On average, 
2,186 patients are tested per new drug application (CISCRP, 2007). In order to deliver sequenced 
genome within 30 days, Micro$eq must have a minimum daily throughput of 73 sequenced 
genomes. The given example illustrated that high throughput yields competitive advantage and 
potentially increases Micro$eq’s market share if its competitor cannot meet such a high demand. 
Second, pharmaceutical firms prefer low costs. In fact, any customers would prefer low cost if all 
other factors are kept unvaried. However, pharmaceutical firms are not as price sensitive as 
individuals or smaller entities because their overhead costs for clinical trials are relatively high. 
The additional cost of less than $1000 per patient is most likely accepted considering valuable 
database they can acquire. Finally, customers value accuracy of sequenced genome. However, 
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there is a tradeoff between cost and accuracy. Higher accuracy results in higher cost. Hence, 
pharmaceutical firms would choose the highest error rate they would be willing to tolerate to 
minimize their expenses 
Overall, the three main customer requirements—high throughput, low cost, and 
accuracy—can be satisfied using Micro$eq’s technology platform. Potential high throughput due 
to implementation of Raindance Technologies’ droplet microreactor awards Micro$eq’s 
competitive advantage over its competitors because it can meet pharmaceutical firms’ demand. 
With expected price less than $1000 per genome, Micro$eq offers the lowest price thus far in the 
market at specified maximum error rate.   
 
2.2   RELEVANT TECHNOLOGIES 
Micro$eq’s initial approach to developing its own novel genome sequencing strategy 
begins with an analysis of what technologies are available on the marketplace and can adapted to 
fit Micro$eq’s project goals. This section aims to outline the necessary steps in DNA 
preparation, sequencing, and genome reassembly that Micro$eq will be using, and their 
feasibility given currently available technologies. 
 2.2.1 DNA Fragmenting 
While it is absolutely necessary to break down the genomic DNA into at least workable 
fragment sizes, as previously discussed, sequencing can be further optimized by specifying the 
length of the DNA fragments. This optimal length is determined by the methods of sequencing to 
be used as well as the reassembly. For now, it is assumed that the required fragment length is 
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feasible to produce within the limitations of molecular biology, and will be chemically stable 
during the rest of the process. This assumption will be discussed in detail in later chapters.  
Various mechanical, chemical, and biological methods exist for the digestion of DNA. 
The most common means of DNA digestion is sonication, which using hydrodynamic shearing 
of the covalent bonds in the DNA structure by exposing the DNA to brief period of sonication. 
This technique was originally used to break up kidney stones or larger tissues but has been 
adapted to DNA fragmenting. Typical sonication procedures today allow the generation of 
fragments between ~150-1500bp in length (Sambrook, 2001). This size of DNA fragments are 
standard in most sequencing processes and encompasses the ~1000bp fragment originally cited 
by this project as the optimum length for genome reassembly.  
 2.2.2 DNA Droplets as Microreactors 
As previously stated, the platform for operation in this project is microfluidics. Many 
current methods of sequencing involve handling the DNA in a batch-like manner which severely 
increases processing time. The use of microfluidic technology increases process efficiency by 
allowing a continuous process. Additionally, microdroplets can be thought of as microreactors. 
DNA may be isolated inside the droplet and processed in volumes on the nano- or even pico-liter 
scale. This drastically decreases required processes space and reagent volume. While the idea of 
microdroplet technology is fairly novel, the vast amount of research in this field over the past 5 
years has produced a variety of methods for generating and handling droplets in the context of 
biomolecular processes. 
 
27 | P a g e  
 
Micro$eq – Chomvong, King, Mahmoud 
 2.2.2.1 Droplet Generation 
In general, droplets are small bubbles of an aqueous 
solution and are suspended in a hydrophobic solution. The 
repulsion between the two different solutions and the surface 
tension of the aqueous droplets allows the droplets to retain their 
shape and their contents to remain isolated from the hydrophilic 
environment. Droplets are generated using a T-junction as 
shown in Figure 2.3 where the aqueous solution is forced through 
a small pore. The hydrophilic solution, which will be an oil in 
this case, interrupts the hydrophilic flow solution at uniform 
intervals, thus forcing separation of the flow stream into droplet 
suspended in the oil. The rate generation and droplet size are determined by both the T-junction 
pore size as well as the flow rate of the oil. Standard droplet size range is from 0.5pL -25µL and 
varies by ~1% from the specified volume (Theberge, 2010).  
 2.2.2.2 Droplet Stability 
The fluid dynamic concerns of microdroplet flow are far more complex than those of 
macrofluidics. The major criteria to be considered are droplet flow rate, flow channel size, and 
their effects on droplet stability. In order to maintain the integrity of the droplet as a 
microreactor, it is strictly necessary that the droplet does not break up, hence exposing its 
contents to the surrounding environment. Fluid dynamic limitations on the droplet flow rate will 
affect the droplet throughput, and size requirements for the channels will affect the required 
microfluidic plumbing for the process. These phenomena and how they relate to this specific 
process will be discussed in more detail in a later on.   
Figure 2.3 Droplets are generated by 
infusing aqueous samples at a 
perpendicular angle to opposing oil 
streams. Repulsion between the oil and 
aqueous solution supplement the 
droplet’s inherent surface tension, 
further stabilizing the droplets and 
providing a biocompatible environment 
for the contents (Theberge, 2010). 
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It is possible to further supplement droplet stability by the addition of surfactants to the 
hydrophobic solution or by the addition of polymers to the aqueous droplets. The addition of 
surfactants to the suspension oil is standard in droplet generation as it stabilizes the droplet 
without altering the droplet contents. It is 
also conventional to use a surfactant with 
a perluoropolyether (PFPE) tail. The 
fluorination presence in the oil offers 
many advantages over typical 
hydrocarbon oils, including improved 
oxygen permeability and immiscibility 
with organic compounds (Theberge, 
2010). A recent surge of research in this 
field has found many possibilities for oil 
and surfactant choice, dependent on the 
scale and goal of the microfluidic 
process. Additionally, the effect of 
different hydrophilic head groups such as carboxylic acid of poly-L-lysine (Theberge, 2010). The 
most commonly used modified surfactants can be seen in Figure 2.4.  
The presence of polymers in the droplet not only increases droplet stability, but also 
allows thermal control of this stability as the polymers will be in different conformations 
dependent on the droplet temperature. However, the addition of excess reagents to the droplet 
can complicate any reactions that take place inside, and thus are generally avoided unless 
absolutely necessary. 
Figure 2.4 Fluorinated surfactants that improve biocompatibility 
and droplet stability (Theberge, 2010). 
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 2.2.2.3 Droplet Handling 
As seen above, droplets are analogous to reactors in their ability to isolate reaction 
solutions. Additionally, droplets have the ability to merge or split, similar to the splitting or 
merging of solutions in 
macrofluidics.  
 Two distinct streams of 
droplets can be merged to 
create a unified steam of new 
droplets. In order for droplet 
coalescence to occur, the 
surface tension of each of the individual droplets must be temporarily broken and then reformed 
around the new aggregated droplet. Droplet merging may be performed in multiple ways, 
depending on the droplet makeup. Droplets stabilized by polymers may be merged via a 
chemically-induced temporary suspension of polymer stability. Hydrophilic droplets suspended 
in a hydrophobic medium such as oil can be merged with the use of an electric pulse  which 
temporarily disrupts the electrostatic interactions between the surface water molecules ( Figure 
2.5).   
 Droplets may be split using similar technology. The surface tension of the original 
molecule is momentarily broken and a single molecule is forced through a membrane or sieve 
whose pore size determines the new size of the droplets. Upon passage through these pores the 
surface of the new droplet is regained.  
 
 
Figure 2.5 Droplets are generated by infusing aqueous samples at a 
perpendicular angle to opposing oil streams. Surfactants present in the oil 
stabilize the droplets while providing a biocompatible environment for the 
contents of the droplets. 
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 2.2.2.4 Micro$eq and Droplet Technology 
The properties of microdroplet technology will be capitalized upon in Micro$eq’s 
sequencing process. Standard techniques that traditionally use batch reactors will instead be 
applied to a continuous process in which each droplet is its own reactor. The feasibility of 
droplet merging, splitting, and manipulation allows complex reactions and handling processes to 
be executed on the microscale level, thus significantly reducing the space and time that would be 
required were this process to take place in a macrofluidic platform. 
 2.2.3 DNA Sequencing 
DNA sequencing is used to determine the order of the nucleotide bases (A,T,C,G)—
adenine, guanine, cytosine, and thymine in a molecule of DNA.  Micro$eq’s sequencing 
approach involves combining a synthetic single-stranded, 6-base pair probe (6mers) with a single 
strand of the target DNA.   The probe fluoresces if all of the 6 base pairs on the 6mer are 
complementary to a 6 base pair sequence on the sample DNA, indicating that these 6 base pairs 
are present in the target DNA. If all possible 6 base pair combinations are tested against a 
fragment of sample DNA, a read out of all existing 6bp sequences and all non-existing 6bp 
sequences on each fragment of DNA can be obtained. This readout will then be reassembled via 
computer algorithim to generate the total sequence of the DNA fragment. 
 2.2.3.1 6mer Library 
In order to obtain a comprehensive analysis of each DNA fragment with each possible 
6mer, a library of droplets is created which contains all of the possible 6-base pair long strands of 
DNA.  Each 6-base pair long DNA fragment can have an adenine, guanine, cytosine, or thymine 
as its first base.  This gives four possible bases for the first base.  Similarly, four different bases 
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exist for the second base, and four different bases for the third base and so on.  In total there are 
46 or 4096 possible 6 base pair fragments of DNA.  However, 32 strands of 6-base pair DNA are 
palindromes.  This means that they read the same forward as backward.  4064 copies of an 
identical target DNA fragment must be combined with 4064 different 6-base pair long fragment 
in a 1:1 fashion. An important component of this droplet combination process is the idea that the 
4064 different 6mer droplets must be marked (“barcoded”) in some as to be able to keep track of 
which DNA fragment is in which drop in order to extract the binding versus non-binding reads 
for each 6mer.   
 2.2.3.2 Droplet Scanning 
The extraction of this binding information is performed during the final step of the 
sequencing process. The merged droplets containing one type of sample DNA fragment and one 
type of 6mer are optically scanned for fluorescence. The basic approach to this scanning method 
involves excitation of the fluorophores via a laser and detection of the subsequent fluorescence 
or lack of fluorescence in each merged droplet via high-speed camera, and is feasible to 
accomplish with current marketplace technology. 
 2.2.4 Genome Reassembly 
The reads generated from the sequencing step are the 6-mer oligos which are bound to 
the fragments in the drop. The 6 bp fragments are building blocks of the original genome. The 
reads are originally assembled using de Bruijn graph approach to generate secondary reads 
which are the length of fragments inserted into microdroplets. Secondary reads are then 
assembled using shotgun sequencing to regenerate original genome. The two step assembly is 
necessary because the reads with length of 6 bases are too short and not suitable for shotgun 
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sequencing algorithm. De Bruijn Approach, on the other hand, is capable of handling short reads. 
However, it is memory intensive if applied to assemble the entire genome. Hence, the mentioned 
strategy is selected. The two step assembling scheme is discussed separately. 
 2.2.4.1 De Bruijn Approach Overview 
One of the suitable assembling algorithms for 
6mer oligo library is de Bruijn Approach. Bruijn or 
Eulerian Path approach utilizes the concept of de Bruijn 
graph theory. It is a direct graph that represents 
sequence of symbols and the edge of the graph indicate 
where the sequence may overlap. 6mer oligo library 
raw sequencing data is suitable for this approach 
because de Bruijn is capable of handing small 
fragments. De Bruijn graph is constructed where the 
nodes for the graph represent the sequence of bound 
6mer and the paths in the graph represent connectivity 
condition among them. The two nodes are connected 
when their 6-1=5 bases overlap (Figure 2.6) (Abegunde, 
2010). The sequence of the fragment is interpreted from de Bruijn graph by walking through the 
directed path and visiting every node. For example, in Figure 2.6, by walking on the path, the 
assembled fragment is ‘A B C D E F G H’. This satisfies the de Bruijn requirement because the 
paths which assemble the sequence visit all three existing nodes in the graph.  
Figure 2.6 de Bruijn Graph Construction The 
overlapping scheme of de Bruijn Graph is shown. 
For the reads with 6 bp length, 6-1 = 5 bases of 
two nodes need to overlap in order for the two
nodes to be connected. The blue fragments 
represent reads derived from bound oligo library 
and the green fragment represented assembled 
secondary read which is an output of de Bruijn 
Graph Approach 
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The fragments inserted into the drops are assembled with the same algorithm to generate 
fragments with its original length. These assembled fragments are referred to as secondary reads 
which are used as inputs for subsequently shotgun sequencing assembly. 
 2.2.5.2 Shotgun Sequencing Overview 
The secondary reads generated from de Bruijn graph assembly are used as shotgun 
sequencing building blocks. Each secondary read is comprised of bases with expected length 
equal to that of original fragments inserted into the microdroplet. Shotgun sequencing employs 
the aligning and merging strategy of secondary reads to generate the entire genome (CBCB). 
The total length of all secondary reads must be many times longer than that of the original 
sequence. This is so that the each base in the final interpretation is covered by more than one 
fragment which vote to determine the base with satisfactory accuracy.   
 
Figure 2.7 Shotgun Sequencing Overview The overlapping scheme of shotgun sequencing assembly is shown. The secondary 
reads (represented in green which are the output from de Bruijn graph assembly are used as shotgun sequencing building blocks. 
The secondary reads are aligned and the original genome (represented in red) is generated using the overlapping information. 
 In Figure 2.7 shotgun sequencing aligning and overlapping scheme is presented. The 
original sequence (represented in red) is reassembled using overlapping information of the 
secondary reads (represented in green). Secondary reads must be random and cover all base 
positions of the original sequence in order for the reassembled sequence to be continuous with no 
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gabs in between. If number of secondary reads generated is not sufficient, gaps will occur upon 
completion of genome assembly. 
 Generally, gaps are allowed in human genome project. Based on acceptable error rate, a 
certain number of secondary reads is required. Since secondary reads are assembled from 
fragments inserted into microdroplets, the number of drops required to achieve specified total 
error rate is a function of number of secondary reads required to reconstruct original genome. 
 2.2.5 Relevant Technologies Summary 
An analysis on relevant genome sequencing technologies shows potential applications of 
aforementioned technologies in Micro$eq’s process. The necessary steps of typical genome 
sequencing – DNA presequencing, DNA sequencing and genome assembly—are outlined in this 
chapter. More specific technologies in which Micro$eq can potentially applied to its design are 
also outlined. DNA droplet as microreactor, 6mer hybridization, droplet scanning, de Bruijn 
graph assembly and shotgun sequencing are first introduced in this chapter. More detailed 
discussion on each technology can be found throughout the report. 
 
2.3 MICRO$EQ’S APPROACH CONCLUSIONS 
 In this chapter, Micro$eq’s proposal and introduction to relevant sequencing technologies 
are presented. The goal of the project is to offer ‘$100 genome’ at the rate of 10,000 genomes per 
year after the scale up. The acceptable error rate in this case is specified at 10 parts per million. 
Micro$eq implements Raindance Technologies’ droplet microreactor to achieve high throughput, 
low cost and high accuracy – satisfying customers requirements. Main target market for 
Micro$eq are pharmaceutical firms who conduct clinical trials for their newly developed drugs. 
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Micro$eq is expected to deliver whole genome sequences but not the interpreted information of 
the sequences. In addition, relevant technologies are analyzed in this chapter to effectively 
design Micro$eq’s process. Technologies related to genome sequencing steps—presequencing, 
sequencing and genome assembly—are introduced. Further detailed discussion on implemented 
technologies can be found throughout the report. 
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CHAPTER 3  
 
Micro$eq’s Base Case Approach 
 
3.1   INTRODUCTION OF BASE CASE 
 Micro$eq’s base case of personal genome sequencing is given by Weitz’s new startup, 
GnuBio. A library of 6 base oligonucleotides is selected. All combinations of the 6 base are 
generated and are combined with fragments of the patient’s DNA. As previously discussed in 
section 2.1, after the nanoliter droplets are broken into thousands of smaller (picoliter) droplet, 
the drops are merged in 1:1 fashion with the oligo libray drops. Roughly 1,000 base fragments of 
patient DNA are generated from 6 base oligonucleotide hybridization. These 1,000 base 
fragments are then reassembled to generate the whole genome. 
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 In this chapter, the infeasibility of the base case proposed is explored when one fragment 
of approximately 1000 base pairs long is inserted in the parent droplet. Presequencing, 
sequencing and genome assembly’s overview and results are discussed. Furthermore, solutions 
to existing difficulties are proposed at the end of this chapter and explored in detail throughout 
the report. 
  
3.2   BASE CASE PRESEQUENCING PROCESS OVERVIEW 
As discussed earlier, pre-sequencing preparation of the input sample must be performed 
so that the DNA is in optimal form for subsequent sequencing and reassembly. The input for this 
process will be the customer’s saliva. From the saliva the DNA must be extracted, purified, and 
then fragmented. Fragmentation to ~1000bp fragments will be performed via sonication as 
previously discussed in section 2.2.1.  For the 3 billion base pair human genome, a minimum of 
3 million 1000bp fragments will be required to cover the entire genome twice. While the actual 
number of fragments required to sequence an individual’s genome will be much greater than this, 
the details of these requirements will be discussed later in this chapter. For now, it can be 
assumed that our number of fragments to be processed is 3 million. These fragments will then be 
amplified (copied) in order to achieve the necessary concentration for optimal hybridization with 
the 6mer library during the sequencing process.  
3.2.1  Droplet Screening 
As the proposed reassembly step requires each fragment to be sequenced separately, it is 
essential that each droplet of DNA that is merged with the 6mer sequencing library contain 
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copies of only one type of DNA fragment. To achieve this droplet homogeneity, the fragment-
containing droplets will need to be screening prior to amplification so that only droplets 
containing single molecules are amplified, thus generating strictly homogenetic droplets to be 
used for sequencing. 
3.2.1.1 Single Molecule Droplet Generations 
Single-molecule droplets are generated by diluting the input DNA solution such that the 
average DNA per molecule is low enough to be able to yield single-molecule droplets. (l) = 
~0.3. The distribution of DNA molecules will be a Poisson distribution such that the 
probability(P) of having k number of DNA molecules per droplet is expressed in terms of the 
average number of DNA molecules per droplet (l) as seen in Equation 3.1:    ( ) =      !    
 
 
Equation 3.1  
 
When the concentration is diluted such that the average number of molecule per droplets of a 
given size is l=0.3, the distribution of DNA molecules will be such as is seen in Table 3.1: 
k 0 1 2 3 >3 
% droplets 90.0 9.00 0.45 0.015 3.8e-6 
Table 3.1  Pre-amplification DNA molecule distribution in droplets 
Generating accurate uniform droplet generation with an average number of DNA 
molecules less than 0.3% is virtually impossible, thus this droplet distribution in Table 3.1 is the 
closest to single molecule droplets that can be achieved. 
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3.2.1.2 Single Molecule Droplet Detection and Sorting 
A fluorescent-activated droplet sorting 
system (FADS) can be used to efficiently sort 
the droplets using dielectrophoresis. In order to 
detect the presence of DNA in the droplets, a ds-
DNA intercalating dye will be added during the 
DNA sample preparation and purification 
process described above. This die becomes 
highly fluorescent when intercalated into 
double-stranded DNA. The droplets are then 
analyzed using an optical setup of a 488 nm 
laser and photomultiplier tubes (PMT) which 
measuring epifluorescene in the wavelength 
range of emission by the ds-DNA dye. The full 
optical setup for this procedure is shown in Figure 3.1.  As seen in Figure 3.1, light is emitted 
from the laser (LAS) shaped into a laser line (LL) and transmitted through a multi-edge dichroic 
beam splitter (DBS) to the microscrope (OBJ). Inside the microscope, the laser light will pass 
through the beam splitter (BS) and is reflected up into the objective by a conventional mirror 
(M). The shaped laser beam is focused to a ~10x150 mm line across the sorting flow channel 
which is imbedded in a microfluidic chip (CHIO). The beam excites the droplets one at a time as 
they flow past. The fluorescent emission from each droplet is passed back along the path of the 
laser beam, but is reflected by the DBS to the sensor of the photomultiplier tube (PMT) via 
bandpass filter (F2). Filtered light from the microscope’s halogen lamp (LAMP) illuminates the 
Figure 3.1: Schematic Representation of optical setup (Nie, 
1997) 
40 | P a g e  
 
Micro$eq – Chomvong, King, Mahmoud 
channels and droplets, allowing the trajectories of droplets to be monitored by the high-speed 
camera (CAM). The filter (F3) removes wavelengths of light that were detected by the PMT to 
avoid a high background signal (Nie, 1997).  
 After the droplets pass through the laser-
excitation point, they reach a Y-shaped sorting junction 
(depicted in Figure 3.2). The junction consists of a larger-
diameter branch, which is the default path of the droplet 
due to lower hydraulic resistance, and a smaller-diameter 
branch, into which chosen droplets will be sorted. The 
sorting junction is adjacent to electrodes that are capable 
of producing a pulse of high-voltage alternating current 
(AC) in order to alter the path of the droplets.  
The high-speed camera frames are processed by MATLAB (see Figure 3.3). The green 
fluorescence of the ds-DNA intercalating dye is normalized against the background red dye 
fluorescence and these results are then communicated to the electrodes (see Figure 3.3). Droplets 
by default (without an AC pulse) will continue to the larger branch of the Y-junction. A DNA-
positive readout from the high-speed camera (CAM) sends a signal to the electrodes, which 
causes them to generate an AC pulse. This pulse deflects the DNA-positive droplet trajectories 
upward, causing them to be sorted into the smaller arm.  
Figure 3.2: Y-Shaped sorting junction. 
Droplets flow to larger branch by default due 
to lower hydraulic resistance. Droplets chosen 
for sorting are deflected via electric field to 
smaller branch when an AC is applied across 
the electrodes. 
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Empty droplets sorted into the larger branch and sent to waste, whereas DNA-occupied droplets 
sorted into the smaller branch will be sent to a droplet reservoir where they will enter into the 
next stage of pre-sequencing processing.  
3.2.1.3 Single Molecule Droplet Limitations 
For the droplet DNA-content distribution described above in Table 3.1 , 90% of the 
droplets will be DNA- and sorted to waste. The remaining 10% of droplets will be DNA+ and 
sorted to the remainder of the pre-sequencing process at a rate of 50 DNA+ droplets per second). 
Of these DNA+ droplets, 90% will have only a single DNA molecule, making them viable for 
eventual sequencing. The remaining 10% will have two or more different fragments and thus 
will yield heterogeneous droplet content upon amplification and will be ignored during the 
sequencing readout as their data will be muddled.  
This probability distribution in itself builds a 9% inefficiency rate into this approach to 
sequencing. For the total of 3 million minimum required fragments as discussed above, 33 
million droplets will need to be processed per genome. While the fluid dynamic limitations on 
droplet flow will be discussed in later chapter, current accepted maximum droplet flow rates in 
 
a) b) 
Figure 3.3 (a) Individual frames from the high-speed camera during sorting. In the first frame, the arrival of a green fluorescent 
droplet was observed and fluorescence is depicted by the blue box. The trajectory of this droplet is monitored through the 
junction by examining pixel changes in the two arms (second frame. The droplet is correctly sorted into the DNA+ arm (green 
box). In the third frame, a red (lower) fluorescence droplet is detected (blue box). This level of fluorescence does not trigger any 
sorting mechanism response and is correctly allowed to enter the DNA- arm (red box), as depicted in the fourth frame. (b) Time 
sequences of the PMT signal (U; volts) and the AC pulses applied in response to sorting decisions (Usort; volts. The field was 
applied on the falling edge of fluorescent peaks that exceeded the threshold voltage (in gray). U0 was a reference voltage (1 V) 
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the pL droplet size range are ~3000 droplets/second. This implies that the sorting process alone 
would take ~20 minutes (1200 seconds). While this processing time is not significantly limiting 
on overall process time, it is important to keep in mind the temporal implications of the required 
droplet throughput.  
Additionally, this process of droplet sorting is extraordinarily expensive. Each optical 
setup will cost upwards of $100,000 (Phototron USA Incorporated).  The most expensive portion 
of this process is the high-speed camera. A high-speed camera is already required for the 
sequencing portion of this to detect fluorescence associated with hybridization of DNA 
fragments with the 6mers. Thus, the use of single molecule technology essentially doubles the 
combined fixed costs of the pre-sequencing and sequencing processes 
3.2.2 Single Molecule Amplification 
 The details of DNA amplification will be discussed in the next chapter of this report. 
However, for the purpose of the present discussion, it is important to note that while the single-
molecule droplet sorting stage is a huge financial hindrance, single-molecule amplification is 
also a process design obstacle.  
 Because the droplets are generated randomly, the amplification must target all possible 
random sequences in order to guarantee amplification of each fragment. For complete targeting 
of the sequences, a minimum of 786 trillion different amplification reactions are required, which 
translates into 786 trillion different droplets. Only some of these droplets will contain amplified 
copies of the DNA and thus will be able to be used in sequence. Thus, before the sequencing can 
occur, the amplified droplets will need to be sorted again using the same method as described 
above in the droplet sorting section. Not only will this again add the immense cost of an 
additional optical detection setup, but processing the 786 trillion different required droplets will 
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take ~8335 years. This time could be reduced if processing were done simultaneously in parallel 
stations. However, the cost of adding, for example, eight thousand more optical setups is beyond 
the capability of Micro$eq.  
The details of these calculations will be discussed in the next chapter, but these 
estimations indicate that not only is the single-molecule approach financially crippling on the 
presequencing steps, but is temporally impossible.  
3.3   BASE CASE SEQUENCING PROCESS OVERVIEW 
3.3.1 Introduction 
Micro$eq’s sequencing approach is to hybridized known 6 base pair long 
oligonucleotides with a fragments of the patient’s DNA and detect hybridization fluorescence.  A 
microfluidic platform technology which uses microdroplets is well suited for this sequencing 
scheme.  Droplets containing fragments of the patient’s DNA and different oligonucleotides are 
merged (Figure 3.4).  The droplets are scanned to determine whether hybridization occurred.   
 
Figure 3.4  Depiction of Watson Crick Base Pair Hybridization sequencing using a microfluidic platform.  In a microfluidic 
platform, droplets containing fluorescent oligonucleotides are merged with fragments of patient DNA.  Subsequently, the merged 
drop is scanned for hybridization. 
Fluorescenct
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complementary 
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A design has to be created to combine 4064 copies of an identical target fragment with 
4064 different oligonucleotides.  However, one has to keep track of or barcode which 
oligonucleotide is in which drop in order to extract any useful information.  The second process 
sequencing task is scanning.  An optical system has to be designed which can scan 106 droplets 
per second for fluorescence. 
3.3.2 Barcoding the Oligos Library 
Barcoding the oligos library is a very unique but difficult task.  4064 unique signals have 
to be created and detected in addition to fluorescence due to hybridization.  Some proposed 
approaches are described in the following sections and a concluding statement is made regarding 
what makes an effective barcoding scheme. 
3.3.2.1 ‘Barcoding’ the Oligos Library Using Microscopic Beads/Dyes 
One proposed approach is to barcode the oligos library by using colored microscopic 
beads.  Microsphere and nanosphere manufacturers, such as phosphorex, produce polymer, 
fluorescent, phosphorescent microspheres ranging in size from 20 nm to 1000 microns 
(Phosphorex, 2010).  Their selection includes plain polymer microspheres and nanospheres, 
colored dye microspheres and nanospheres made of polystyrene, polystyrene fluorescent 
microspheres, and phosphorescent/luminescent nanospheres.   
Droplets produced by microfluidic chips such as Raindance Technologies are on the 
order of 30 nm in diameter.  Considering this, one can add one micron sized beads to each drop.  
4064 unique barcodes can be created by using a combinatorial approach to barcode the oligos 
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library.  The idea is that different colored microspheres and dyes are added to a microdroplet and 
each colored microsphere adds to the value of a certain digit (Figure 3.5). 
 
Figure 3.5 Combinatorial Approach using Colored Microspheres: Each colored microspheres represents a different digit.  
The number of microspheres of that color is used to denote the number in that ordinate. 
The number of blue microspheres signifies the number in the thousand digit while the 
number of red microspheres is equal to the number in the hundreds digit and so on.  Using this 
approach the maximum number of beads is 30, which corresponds to the number 3999.   
One can also add a dye to decrease the number of microspheres in each droplet.  If a red 
dye is added to an oligos library droplet, 3 units are added to the last 3 digits, if a blue dye is 
added, 5 units are added to the last 3 digits, and if a green dye is added, 7 units are added to the 
last 3 digits (Figure 3.6).  In addition to a dye, one can decrease the number of beads required by 
having two different sized beads, for example a 2µm sized beads and 1 µm sized beads.  The 
larger beads are used to represent the addition of 5 units to the corresponding digit (Figure 3.7).  
 
Figure 3.6 Sample Microdroplets with dyes: A red dye adds 3 units to the last three digits, a blue dye adds 5 units to the 
last 3 digits, and a green dye adds 7 units to the last three digits. 
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Figure 3.7 Example of a microdroplet with different sized beads.  Using the rules described in the text, the microdroplet 
above represents the 3327th oligomer. 
There are advantages associated with this barcoding scheme.  First of all the costs 
associated with colored beads and food coloring for the dye are very low.  However, the major 
drawback associated with this system is the engineering required to ensure that certain colors of 
microspheres are present in certain drops in certain amounts with certain dyes.  It was envisioned 
that Image J, which is an imaging program, contour function that can employed to locate and size 
the microspheres, detect the colors, count the microspheres and automatically read the barcode.  
However, many drops would be wasted in a prescreening process design to make sure that 
certain numbers of microspheres are present in certain amounts with certain dyes.  Furthermore, 
a large number of drops would have to be scanned because each fragment is copied and merged 
with 4,064 different droplets.  This decreases the throughput time because a larger number of 
drops have to be scanned.  Having a system which has complicated and costly engineering to set 
up is not efficient.  It was decided that using fluorescent polymers or spatial barcoding would be 
a lot simpler and involve less prescreening. 
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3.3.3.2 Finding an optimal strategy of 'barcoding' the oligos library using fluorescent 
polymers 
We also sought to barcode the oligos library proposed in the Micro$eq’s design by using 
fluorescent polymers that emit in three different colors.  In total 4,064 6-base oligos need to be 
labeled with distinctive fluorescent barcode identifiers.  This approach uses the red, green, and 
blue fluorophores at different wavelengths and intensities to ‘barcode’ the oligos library (Figure 
3.8).    
 
Figure 3.8 Combinatorial Approach: The Combinatorial Approach designed using fluorescent polymers seeks to multiplex the 
system by using wavelength and intensity. 
Bangs Laboratories Inc. manufactures fluorescent polymers with varying colors and 
intensities.  The fluorescent dye spectra of the polymers manufactured are given in the Appendix 
A. 
The Bangs Laboratories Inc. polymers were grouped based on the color of their emission 
(Figure 3.9). In reality, modern microscopes would not be able to resolve the emission signals 
associated with combinations of fluorophores because there is some overlap between the 
channels.  Modern microscopes typically image in four color channels by using rotating filters 
and measuring intensity in a particular wavelength.  This mechanism is not capable of capturing 
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all of the information captured by the barcoding scheme.  This can be resolved by having a 
spectrometer capture the emission spectra and then to deconvolute which signals are present by a 
curve fitting using MATLAB.  Spectrometers measure the emission intensity across a set of 
wavelengths.   
 
Figure 3.9 Combinatorial Approach using Fluorescent Polymers: Bangs Laboratories Inc.’s fluorescent polymers are divided into 
three pseudochannels based on their wavelength.  Each fluorescent polymer is present in prepared in four concentrations except 
the colors that are present in 5 intensities.  For those, the most intense and least intense polymers are carefully diluted or 
concentrated to give 10 combinations which do not overlap.  The absorbance and emission peak wavelengths are provided. 
However, the difficulty is still to get 4,064 unique signals.  To reach this number of 
combinations, each polymer is prepared in 4 different concentrations (1X, 10X, 100X, and 
1000X).  This is done for all polymers except the ones that are available in 5 intensities.  For 
these, the most intense and least intense polymers are carefully diluted into two concentration to 
give 10 combinations which do not overlap.   
According to this scheme, the total number of combinations is 4,752 (Figure 3.10).  By 
summing the signal and concentration, 12 different signals can be emitted in the pseudoblue 
channel.  Similar statements can be made about the red and green channel. 
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Figure 3.10 Combinatorial Results for Fluorescent Polymer: By multiplexing concentration and signal 4,752 distinct 
signals can be created.  
 The major drawback associated with this scheme is that there are a lot of noise issues.  
Particularly, can different signals be considered distinct with a reasonable amount of confidence?  
Will noise associated with the instrument make the multiplexed emission signals 
indistinguishable?  Furthermore, how will one be able to distinguish fluorescence hybridization 
emission from the barcoding scheme?  This second issue is particularly difficult to address and 
invalidates this scheme.  Although, the introduction of a spectrometer to map out an emission 
spectra provides interesting possibilities, ultimately signal to noise issues and detection of 
fluorescence hybridization invalidate this scheme. 
 What makes an effective barcode is multiplexing and reasonable signal to noise.  
Multiplexing allows one to use combinatorics to create large numbers of distinct signals to 
barcode.  At the same time one has to maintain a reasonable signal to noise to be able to 
distinguish the signals.  Maintaining a reasonable signal to noise makes sure that fluctuations in 
measurement and fluorophore concentrations do not give the wrong barcode. 
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3.3.3 Scanning 
 One proposed method of optical scanning was to pass droplets by a flow cytometer and to 
scan them for the barcode and hybridization using multiple detectors (Figure 3.11).  In this setup, 
laser light is aimed at a point where microdroplets pass through a capillary channel.  Multiple 
detectors are aimed at the point where the microdroplets pass through the laser light in order to 
detect hybridization fluorescence.  However, the current state of the art only allows us to scan 
droplets at a rate of 10,000 droplets per second (bdbiosciences, 2011).  This throughput is off by 
several orders of magnitude from the target throughput of 106 droplets per second. 
 
Figure 3.11 Flow Cytometer setup to scan microdroplets for fluorescence: light is aimed at a point where microdroplets 
pass through a capillary channel.  Multiple detectors are aimed at the point where the microdroplets pass through the 
laser light. 
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3.4   BASE CASE GENOME ASSEMBLY OVERVIEW 
According to proposed plan, the expected 
assembled throughput per microdroplet is 1000 bases. 
Statistically, the estimation is logical. Ambiguity in de 
Bruijn graph assembly occurs when two or more 6mers 
with identical first 5 bases are in presence (Figure 3.12). 
Since there are four possible bases in human genome, A T 
C or G, 6mer oligo library is used, the longest sequence 
which 6mers can reconstruct using de Bruijn approach 
before ambiguity arises is (Equation 3.2)  
 45 = 1024 bases 
 
Equation 3.2 
 This calculation means that 6mer reads generate one to one relationship between each 
reads until approximately 1024 bases are sequenced before branching or ambiguity arises. 
However, experimentally, the ambiguity arises much earlier than expected, yielding less than 
1000 bp secondary reads. In fact, MATLAB simulations show that the longest doubled strand 
sequence which 6mers can reconstruct using de Bruijn approach before ambiguity arises is 
approximately 35 bases.  [See Appendix D]. The experimental throughput per droplet is 30 times 
lower than the proposed plan. With the throughput of 35 assembled bases per drop and 10-5 
acceptable error rate, sequencing specification and required time are presented in Table 3.2: 
  
Figure 3.12  de Bruijn Graph Ambiguity
When  two or more than two 6-mer reads have 
identical 6-1 = 5 bases, ambiguity of graph 
interpretation arises. There are two probable 
interpretation of this graph ‘A T C T A A G’ 
or ‘A T C T A A T’ 
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Parameters Experimental Estimation GnuBIO Proposal 
Fragment Length 35 bp 1000 bp 
Number of Doubled Strand 
DNA Fragment per Drop 1 Frag/drop 1 Frag/drop 
Number of independent 
fragment per drop (nFrag) 2 Frag/drop 2 Frag/drop 
Throughput  70 bp/drop 2000 bp/drop 
Adjusted Throughput 35 bp/drop 1000 bp/drop 
Error Rate 10-5  10-5  
Required Coverage 11.55  11.52  
Required Secondary Reads 9.57x108 fragments 3.34x107 fragments 
Number of Parent Drops 7.86 x 1014 drops 786x1012 drops 
Number of Daughter Drops 2.0x1018 drops 1.69x1010 drops 
Pre-sequencing Time 7.3x107 hours 8335 years 
Sequencing Time 5.53x108 hours 63369 years 
Computing Time 12 hours 0.42 hours 
 
As seen in Table 3.2, the volume of required droplets and thus the required throughput time for 
this base case process is on the order of magnitude of 70,000 years. Clearly this timescale is 
unrealistic and thus the process cannot be accomplished using the same proposed method as 
GnuBio. 
 
3.5   BASE CASE FEASIBILITY CONCLUSIONS 
Sorting droplets for single molecules during presequencing requires costly control 
systems.  Furthermore, single-molecule amplification schemes are huge process obstacles.  Thus 
future work focused on engineering cost efficient system to circumvent these design challenges.  
In addition, the implementation of nonrandom PCR reactions provides an interesting way to 
reduce the number of PCR reactions. Micro$eq’s presequencing strategy is further discussed in 
chapter 5. 
Table 3.2 Experimental Estimation vs. GnuBIO Proposal  Experimentally, the longest sequence which can be reassembled 
during de Bruijn assembly is 35 bases of doubled strand DNA per microdroplet. This throughput is 30 times lower than the 
GneBIO claim.  
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Base case feasibility designs on the sequencing system determined that an effective 
barcoding strategy must take advantage of multiplexing to create many distinct signals and to 
package multiple oligonucleotides per droplet.  Also it was determined that state of the art 
scanning by flow cytometry cannot achieve our scanning rate goal of 106 droplets per second at a 
reasonable cost.  Thus, we decided to build our own optical system to scan the droplets. 
Micro$eq’s sequencing strategy is further discussed in chapter 6. 
 With respect to genome assembly, it has been demonstrated that if one 35 base pair, 
doubled stranded fragment is inserted per droplet, 1.83*1011 droplets need to be generate to 
sequence a whole human genome. However, the requirement is not feasible because process time 
and cost are not within the target range (12 genome/day and $100/genome).  
To accomplish the target goal, Micro$eq proposes a solution to decrease number of 
droplets required. Three steps are taken to accomplish this. First, non-random sequence 
amplification is performed such that only two different amplification reactions, which may take 
place in the same droplet, are used instead of the 768 trillion required for random amplification. 
Second, the number of different fragments processed in each droplet is increased from one, 
further decreasing the number of total droplets. Finally, the number of 6mers used for sequencing 
per droplet is increased from one, even further decreasing the number of required droplet. 
Because more than one randomized doubled strand fragments are inserted in each drop. The 
break between fragments should decrease ambiguity in de Bruijn graph interpretation; thus 
increasing de Bruijn assembly throughput. In other word, the accidental overlap between 
incorrect reads is less likely to arise. Statistically, the probability of finding ambiguity in 
assembling one 100 base fragment is higher than that of two random 50 bases fragments. 
Optimization of number of doubled strand fragment per drop, average fragment length, and 
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required number of secondary reads are studied to minimize number of drops needed to be 
generated; decreasing time required for DNA scanning process and minimize cost of production. 
A detailed outline of all technical aspects of Micro$eq’s modified strategy is in Chapters 5, 6, 
and 7 of this report. 
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CHAPTER 4  
 
Molecular Biology Limitations on 
Presequencing and Sequencing 
Processes 
 
While an outline of Micro$eq’s general approach to genome sequencing has been 
discussed in the context of the financial and temporal challenges presented by this process, the 
molecular biology limitations associated with all steps involving DNA processing have yet to be 
mentioned.  
The field of molecular biology is dynamic in that many of its basic principles are still 
being determined or altered as new research is being done. This chapter aims to outline a few of 
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the fundamental molecular phenomena associated with DNA and illustrate how these principles 
limit Micro$eq’s approach to the presequencing and sequencing steps of its genome assembly 
strategy. This chapter will also provide an outline of how Micro$eq has developed modified 
approaches to these steps will work around the limitations presented here and thus render its 
approach feasible on the molecular level. 
4.1 MOLECULAR BIOLOGY CHALLENGES IN THE PRESEUENCING PROCESS  
The required output from the pre-sequencing process is determined by the approach to 
sequencing (merging with 6 base pair sequences) and the optimization of the reassembly 
algorithm (to determine which combination of fragment size and fragment number allows for the 
lowest error rate and quickest processing time). However, it is important to remember that the 
requirements implicated by the later steps are determined by optimization of those steps and do 
not take into account the limitations of molecular biology.  
Two major challenges arise from the imposed requirements of the pre-sequencing output. 
The first challenge is the generation and processing of an extremely small (<25bp) fragment of 
DNA. Second, the generation and amplification of a precisely-sized DNA fragment. The 
challenge of the pre-sequencing process will be to capitalize on available molecular biology 
techniques and to design new molecular biology strategies based on known biochemistry in order 
to adhere as closely as possible to the required output. This section outlines the biological 
limitations that create these two major obstacles, and will discuss a proposed method of how to 
overcome these limitations.  
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4.1.1 DNA Thermodynamic Properties 
The most important molecular biology concept which affects the feasibility of  pre-
sequencing challenges is the stability of DNA molecule. While DNA exists naturally in the 
human body (37°C) and is stable in this state, these fragments are on the order of 10 million base 
pairs long. As previously discussed, the sequencing process requires the handling of much 
smaller DNA fragments (<100bp). These smaller fragments are much less stable and must be 
handled accordingly. Before a modified process can be designed to help deal with the potential 
instability of small fragments, it is important to understand what causes this instability and its 
impact on the pre-sequencing properties.  
4.1.1.1 DNA Hybridization 
The first consideration in terms of DNA stability is 
the thermodynamics of DNA hybridization. For the most 
part, DNA exists naturally in our body as a double-stranded 
complex. Each half of the complex is a single-stranded 
fragment referred to as an allele. The nucleotides in each 
allele are covalently bound to the adjacent nucleotides in 
that allele. The two alleles then form double-stranded DNA 
via intermolecular interactions between their sets of base 
pairs, referred to as Watson-Crick base pairing. These 
interactions occur in the form of Hydrogen-bonds between the complementary bases. Specificity 
of complementarity is determined by the chemical structure of the base pairs. As seen in Figure 
4.1, Adenine (A) and Thymine (T) can only complement each other, as they bind via the 
Figure 4.1 Hydrogen Bond Base Pairing by 
NucleotidesInvalid source specified. 
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formation of three hydrogen bonds whereas Guanine (G) and Cytosine (C) can only complement 
each other as they bind via the formation of two hydrogen bonds.  
As a result of the different number of hydrogen bonds between the two possible base pair 
bindings, binding affinities will differ with the relative percentage of A/T pairings versus G/C 
pairings.  In longer strands of DNA, the percentages of the two different pairings are relatively 
equal. However, in smaller strands of DNA, the representation of A/T versus G/C bases can be 
very biased. Thus a small(<25bp) fragment of DNA that is A/T rich will have a much higher 
binding affinity than one that is G/C rich. This variability in binding affinities makes it very 
difficult to batch-handle small fragments of DNA.  
4.1.1.2 DNA Melting Temperature Estimations 
In addition to its dependence on the nucleotide makeup of the fragment, the binding 
affinity of small fragments of DNA is already lower than that of larger fragments. These 
affinities are more commonly analyzed in the context of fragment melting temperatures. The 
melting temperature of a DNA fragment is defined as the temperature at which half of the DNA 
fragments will be hybridized (thus double-stranded) and half will be denatured (single stranded). 
The melting temperatures are crucial for any reaction involving DNA molecules, as (with the 
rare exception of the presence of an enzyme that can disrupt a double-stranded DNA complex), 
DNA must be single stranded such that its nucleotide’s reactive groups are exposed and may 
participate in a chemical reaction.    
For larger DNA fragments (>100bp), the melting temperature of the double-stranded 
DNA may be estimated via Equation 4.1: 
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Equation 4.1 Melting Temperature (°C) of Larger Oligonucleotides (Owczarzy R. ) where ΔH (Kcal/mol) is the sum of the 
enthalpy changes associated with base pair binding, ΔS (eu) is the sum of the entropy changes associated with base pair 
binding, A is a constant, R is the gas constant, Ct is the total concentration of DNA strands, and [Na+] is the solution salt 
concentration. 
Using Equation 4.1, along with empirically derived values for the entropy and enthalpy 
of base pair bindings, it can be found that for large fragments of DNA (>10,000bp) the melting 
temperature is around 95°C. It is also important to note that Equation 4.1 does not take into 
account the A/T and G/C make-up of the strand, as these effects are minimized in larger strands 
as discussed earlier. Additionally, it is important to note that the melting temperature depends on 
both the DNA fragment and salt concentration in solution. This process will take advantage of 
these dependencies in order to manipulate the melting temperatures, as will be discussed later in 
this chapter.  
4.1.1.3 The Nearest Neighbor Method 
For smaller DNA fragments (<30bp), the melting temperature is estimated using the 
Nearest Neighbor method (NN). This model assumes that the stability of a given base pair 
depends on the identity and orientation of neighboring base pairs (SantaLucia J. , 1998). For 
these smaller oligonucleotides, additional parameters for the estimation of duplex melting 
temperatures must be applied (Derivation of nearest-neighbor properties from data on nucleic 
acid oligomerse. II. Thermodynamics of DNA, RNA hybrids, and DNA duplexes, 1997). This 
initiation parameter encompasses all other sequence-independent effects, including differences 
between terminal and internal base pairs. In such small fragments, the terminal base pair, which 
initiates the denaturation (or reannealing) of the fragments, plays a significant role in the double-
strand thermodynamics. To account for the differences with terminal A/T versus terminal G/C 
  
Tm =
DHo ·1000
A + DS o + R ln(Ct /4)
ì 
í 
î 
ü 
ý 
þ 
- 273.15 + 16.6log Na+[ ]
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pairs, two different differentiation 
parameters have been developed (Allawi 
& SantaLucia, 1997). For self-
complementary duplexes (meaning the 
two alleles of the DNA are identical), an 
additional entropic penalty for the 
maintenance of the C2 symmetry is also 
included.  Recently, a study compiled  
unified oligonucleotide NN parameters set 
based on collection of 108 different 
nucleotide duplexes studied in seven different laboratories (Allawi & SantaLucia, 1997). The 
results of this compilation are displayed in Table 4.1 and are applied to the following 
calculations.  
The values in this table can be incorporated into Equation 4.4.2 below to calculate the total 
free-energy of a small fragment hybridization.  
 
 
The application of Equation 4.4.2 to a hypothetical 6bp oligonucleotide duplex binding 
event and comparison of the NN model’s result to empirically-derived value is displayed in 
Figure 4.2. 
  DGtotal
o = DGinit
o + DGT
o
i=1
5å (i) = DHtotalo + TDStotalo
Equation 4.4.2 Gibbs Free energy of double-stranded binding where ΔH is the sum of the enthalpy changes associated with 
base pair binding, ΔS  is the sum of the entropy changes associated with base pair binding, and T is the absolute reaction 
temperature 
Table 4.1 : Nearest-Neighbor Thermodynamic Parameters for 
Watson−Crick Base Pair Formation in 1 M NaCl (Allawi & 
SantaLucia, 1997) 
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Note: In general, if a large 
temperature extrapolation from 
37°C is required, then the 
difference between the heat 
capacities of the hybridized and 
quenched states, ΔC°p, should be 
accounted for. However studies 
have shown that ΔC°p is relatively 
small for nucleic acids 
(Rentzeperis, Ho, & LA, 1993), (Erie, Sinha, Olson, Jones, & Breslauer, 1987) between 25°C -
37°C. Due to enthalpy–entropy compensation, ΔG°37 is relatively insensitive to ΔC°p. Thus, for 
the purpose of the above thermodynamic estimation, the effects of temperature on the heat 
capacity, and thus the overall free energy, have been ignored 
From the comparison in Figure 4.2, it can be observed that the NN model adheres closely 
to empirical data and is feasible to use for the thermodynamic data to be estimated for the 
purpose of this project.  This model will be discussed in more detail later in this chapter to 
analyze the properties of interactions between the 6mers used for DNA sequencing. Additionally, 
the above discussion illustrates the challenges involved in preparation of the small (<25bp) DNA 
fragments.  
4.1.1.4 Potential Stabilization Methods 
Because of these thermodynamic challenges associated with small DNA fragments, most 
approaches to sequencing that require working with small DNA molecules modify the DNA by a 
Figure 4.2 Application of the unified nearest neighbor parameters to 
predict ΔG°37. The duplex used above is non-self-complementary and thus 
ΔG°(sym) is zero (SantaLucia J. , 1998) 
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variety of methods. As discussed earlier, some companies choose to immobilize the DNA either 
on slides, in well plates, or on the surface of beads. The immobilization process involves the 
addition of a synthetic oligonucleotide to the end of the genomic DNA fragment, which then 
binds complementary with another synthetic oligonucleotide on the surface, as previously 
discussed in the Competitive Analysis section of this report. This approach both elongates the 
DNA strand as well as inflates the free energy of reaction of the DNA as its orientation is fixed. 
Another approach to handling small DNA fragments is isolating single molecules of DNA in a 
microenvironment such as a droplet. If the DNA fragment is unable to interact with other 
molecules, the consequences of its denaturation are virtually insignificant, as exposing the 
reactive groups of each allele will not result in unwanted reaction. 
However, as previously discussed, this project’s approach to sequencing allows neither 
immobilization nor single molecule sequencing. Additionally, this project’s approach to genome 
reassembly requires small DNA fragments. Thus, a new approach to small DNA fragment 
handling must be designed in order to meet this project’s particular specifications, but the design 
must still operate within the limits of molecular biology phenomena. 
4.1.2 DNA Fragment Amplification  
As previously discussed, single molecule DNA sequencing is not feasible in the context 
of this project. Instead, a particular concentration of each DNA fragment must be present in 
order to optimize the thermodynamics of the interactions between the DNA fragments and the 
six base pair reads (6mers) that are to be used for sequencing. While the initial sample does have 
multiple copies of the entire human genome, it is important that the multiple copies of the 
fragments interacting with the 6mers are identical. If the copies are not identical, they will bind 
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to different sets of 6mers and will not be able to be reassembled as a single fragment. The only 
way to achieve multiple identical copies of any particular DNA fragment is to start with a single 
molecule and amplify it to the required concentration using current molecular biology methods.  
4.1.2.1 Polymerase Chain Reaction (PCR) 
Amplification of DNA fragments via polymerase 
chain reaction (PCR) is a standard protocol in the 
biological research field. PCR is a thermally-controlled 
cyclic reaction that generally takes place in solution. The 
solution consists of the genomic DNA to be amplified, 
short (10-25bp) oligonucleotides called primers, an excess 
equal representation of A, T, C, and G of single 
nucleotide bases (dNTP’s), a DNA polymerase enzyme, a 
and a buffer solution, which contains cations such as 
Magnesium to maintain a stable reaction environment. A 
summary of this process can be seen in Figure 4.3.  
As seen in this figure, the reaction cycle is 
comprised of three main steps. First, the double-stranded 
DNA is denatured to single-stranded DNA by heating the 
sample to about 95C. Second, the temperature is 
decreased to ~5°C below the melting temperature of the 
primers (which were also denatured during the 
denaturation step) so that the single stranded primers 
Figure 4.3 PCR Amplification Process. Blue 
denotes the original genomic DNA, red 
denotes the primers, and green denotes 
newly synthesized DNA. Steps 1-3 are 
repeated as required by target final copy 
number (Artistik). 
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anneal to each of the single-stranded DNA allele at the regions where they are complementary. 
Third, the DNA polymerase binds to the site where the primers annealed and, using the dNTP’s, 
extended the new DNA template to create two double-stranded copies of the genomic DNA. This 
cycle is generally repeated between 20-45 times (depending on the starting number of copies and 
desired ending DNA concentration), with each cycle doubling the number of DNA fragment 
copies. The final of DNA copies can be calculated using Copies(n - cycles) = 2n  
Equation 4.3 
Copies(n - cycles) = 2n  
Equation 4.3 Number of DNA copies present in solution after n PCR cycles 
4.1.2.2 PCR Limitations 
This technique to amplification is fairly straightforward and reliable. The error rate of the 
DNA polymerase enzyme used is generally around 1 in 10,000bp . For a 40 cycle reaction that 
generates ~1.1x1012 copies of a typically-sized DNA fragment (~50bp), the likelihood that a 
particular base will be incorrectly amplified is negligible.  However, as the (Innis M. G., 1988) 
optimal length of the DNA fragments to be amplified in this project is 22bp. In addition to the 
thermodynamic instability of small fragments as discussed earlier, this amplification of such an 
extraordinarily short fragment is virtually impossible. The absolute minimum primer size usable 
in PCR is 9bp, due to thermodynamic limitations as discussed in the previous section 
(Dieffenback, General Concepts for PCR Primer Design, 1993). This means that 18 of the 22 
bases in the 22bp fragment would be covered by primers. This 4bp gap makes it very difficult for 
the DNA polymerase to bind and perform extension of the ds-DNA copy. 
Additionally, in order for amplification to be unbiased across the whole genome, every 
possible combination of the 9bp primers would need to be made and used in a PCR reaction. For 
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the four different base pairs possible in each position on the primer, the number of different 
primers will be 49 =  262,124. For the minimum of 1.4x108 different 22bp fragments required to 
cover the entire 3x109bp human genome, this would mean an absolute minimum of amplification 
of 3.6x1013 different PCR reactions required to unbiasedly amplify the genome once. Similar to 
the previous chapter’s discussion of single-molecule amplification, this approach to 22bp 
amplification yields an unrealistic fragment number requirement and a processing task that 
would require a virtually impossible amount of time.  
For these reasons, while Micro$eq’s sequencing approach does not involve single 
molecules, its limitations on fragment size also do not allow it to employ the conventional PCR 
method as described above. Instead, a modified method of genomic DNA fragment amplification 
has been designed which allows unbiased amplification of 22bp fragments but at a fraction of the 
cost and reaction time. 
 
4.2 MICRO$EQ’S MODIFIED PRESEQUENCING APPROACH 
The general principle behind Micro$eq’s modified approach to presequencing processing 
relies on the addition of synthetic oligonucleotides to both ends of the genomic DNA. This 
creates a longer DNA fragment, which then overcomes the molecular biology limitations 
associated with the handling and amplification of small DNA fragments as described in the 
previous section. 
While the addition of synthetic sequences to genomic DNA is not a novel concept in 
DNA processes, Micro$eq’s approach has two aspects that make it rather unique. First, is the use 
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of small and exactly-sized genomic DNA fragments using restriction enzyme digestion? Second, 
is the efficient amplification of small DNA sequences?  
4.2.1 Restriction Enzyme Digestion 
As previously discussed, most approaches to DNA fragmentation involve non-specific 
mechanical shearing of the DNA using such methods as sonication. These methods generate a 
distribution of fragment lengths. Instead, Micro$eq uses a biological method of shearing – 
restriction enzyme digestion.  
Restriction Enzymes are a class of enzymes that, upon the presence of a specific 
nucleotide sequence in ds-DNA called a recognition site, cut the double stranded DNA. Each 
type of restriction enzyme has its own specific recognition sequence. The mechanism of cutting 
and the orientation of the cut from the recognition site are dependent on the type of restriction 
enzyme used. For the purpose of this project, a type II restriction enzyme, which cuts a short 
distance from its recognition site and only requires the presence of Magnesium in solution in 
order to be activated.  
4.2.1.1 Restriction Fragment Sizes 
While restriction sites do exist in the human genome, they are generally spaced 
~10,000bp apart. Additionally, they are not spaced equally apart, thus restriction enzyme 
digestion of the unmodified human genome would yield large fragments of variable lengths. As 
the Micro$eq approach requires uniformly-sized 22bp fragments, typical restriction enzyme 
digest cannot be used. Instead, the recognition sites of the MmeI will be attached to the ends of 
the genomic DNA via a synthetic sequence (adaptor). The MmeI enzyme then recognizes its 
restriction site at the end of the adaptor, and subsequently cuts a short distance upstream of this 
67 | P a g e  
 
Micro$eq – Chomvong, King, Mahmoud 
site, at a digestion site that will fall in the genomic DNA sequence. MmeI is used as it cuts 
exactly 22bp away from its recognition site (Dunn, McCorkle, & Praissman, 2002), thus 22bp 
fragments of DNA can be generated as shown in Error! Reference source not found.. 
 
Figure 4.3  Adaptor Ligation and Restriction digest to generate 22bp fragments on genomic DNA. Genomic DNA denoted 
in black, Adaptor sequences denoted in red, recognition sites denoted by blue triangles, digestion sites by orange stars 
As seen in Figure 4.3 , the generated fragments consist of a 22bp genomic DNA fragment 
ligated to a synthetic adaptor sequence. The practical implications of the presence of the non-
genomic DNA sequence will be discussed later in this section. However, the important outcome 
of this process is that 22bp of genomic DNA have been generated, but as a part of a longer 
sequence, thus the thermodynamic instability of having a short DNA fragment is no longer an 
issue. Additionally, because of the specificity of the restriction enzyme digest, all fragments are 
exactly-sized to 22bp in length, an advantage to this process that will be discussed later in 
chapter 7 of this report, the context of genome reassembly.  
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4.2.2 Adaptor PCR 
Now that the desired size of genomic DNA fragments have been precisely cut and 
thermodynamically stabilized via the addition of an adaptor, these biological challenges have 
been overcome. However, before amplification can take place, one final modification must occur 
in order to eliminate the need for a large number of primers that would be the case if un-adapted, 
non-specific DNA fragments were to be amplified.  
 As was seen in Figure 4.3, one end of the modified DNA fragment was bound to the 
adaptor. As the adaptor was synthesized and the sequence is known, a specific PCR primer may 
be designed to complement the end of the adaptor and allow initiation of amplification at that 
end of the 22bp fragment. However, as previously discussed in section 4.1.2, amplification 
requires primers to anneal to both ends of the fragment targeted for amplification. Thus, as one 
end of the current fragment construct is non-specific genomic DNA, amplification of this 
construct would still require all possible combinations of the 9bp primer sequence. To solve this 
problem, an additional adaptor is added to the other end of the 22bp fragments. This adaptor’s 
sequence is also known, and thus a specific PCR primer may 
be designed to complement the other end of the 22bp 
fragment, and thus amplification of the genomic DNA only 
required two different primers, and thus one total PCR 
reaction per fragment. This final construct with the strategy 
for primer placement is illustrated in Figure 4.4.  
Figure 4.4 22bp with terminal adaptor 
construct. Genomic DNA denoted by 
black, adaptor 1 denoted by red, 
adaptor 2 denoted by blue. 9bp 
complementary primer 1 denoted by 
pink arrow, 9bp complementary primer 
2 denoted by purple arrow. 
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It is important to note that not all of the two adaptor sequences will be amplified. The 
primers are positioned at the terminal ends of the adaptors such that minimum non-genomic 
sequence is present in the final fragments produced by the amplification reaction (amplicons). 
This strategy is important for the efficiency of the sequencing step. As the sequencing involves 
the hybridization of 6bp oligonucleotides (6mers) with fragments of the patient’s DNA, and extra 
base pairs present in the sequenced fragments, such as the terminal ends of the adaptors, will also 
hybridize with the 6mers, giving a potential false positive of binding of that particular 6mer with 
the genomic DNA. While the presence of some synthetic sequence is impossible to avoid, by 
using minimum primer size, its presence is minimized. Additionally, the two 9bp primer 
sequences are known, so the 4 different 6mers with which they will bind can be known. How this 
knowledge is used to correct the sequencing process for false positives will be discussed later in 
chapter 6 under the context sequencing.   
4.2.3 Summary of Micro$eq’s Modified Presequencing Approach 
The total final output of the Micro$eq’s modified pre-sequencing approach as outlined 
above will be a DNA fragment ~150bp in length, 22 base pairs of which are genomic DNA and 
the remaining terminal ends are known synthetic base pair sequences. These adaptors allow the 
handling of a small (<25) sample DNA fragment but in the context of a longer fragment which 
reduces thermodynamic instability issues.  
Using the designed primers as described above, the desired portion of this construct as 
shown in Figure 4.4 can be amplified using conventional PCR methods with only two required 
PCR reaction as outlined in section 4.1.1.  
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4.3 MOLECULAR BIOLOGY CHALLENGES IN THE SEQUENCING 
PROCESS 
 Similarly to the pre-sequencing process, the molecular and biological phenomena 
associated with DNA described in section 4.1 of this chapter provide obstacles in the sequencing 
portion of this project.  Many approaches, such as those used by companies cited in the 
competitive analysis, have worked on strategies to overcome these limitations. This section will 
outline some of those competitive strategies at the molecular level and address their molecular 
limitations. Additionally, this section will outline in further detail portion of Micro$eq’s unique 
approach to sequencing and both analyze how it overcomes biomolecular limitations as well as 
how it improves upon the previously derived sequencing strategies. 
4.3.1 DNA Sequencing Techniques 
 While an almost countless number of variations of DNA techniques have been explored, 
this section will describe only the most commonly used general strategies.    
4.3.1.1 Sanger Sequencing  
Probably the most popular method of DNA 
sequencing is dye-terminator sequencing or Sanger 
Sequencing. In dye-terminator sequencing, four 
dideoxynucleotide(ddNTPs) chain terminators are 
labeled with fluorescent dyes, which emit light at 
different wavelengths.  ddNTPs lack an OH group on 
the 3’-Carbon as well as the 2’C of the deoxyribose 
Figure 4.5 Dideoxynucleotide(ddNTP).  ddNTPs 
lack an OH group on the 3’ Carbon as well as the 2’ C 
of the deoxyribose sugar which prevents anew bases 
from being added to a DNA strand after ddNTP 
addition. 
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sugar which prevents new bases from being added to a DNA strand after a ddNTP has been 
added (Figure 4.5).  
 By reacting ddNTP’s and deoxy-
nucleotide(dNTPs) with copies of a 
single stranded DNA repeatedly, all the 
possible lengths of DNA would be 
represented with every piece of 
synthesized DNA containing a 
fluorescent label at its terminus (Kae, 
2003).  Amplified DNA is then separated 
according to its size via gel 
electrophoresis. This process involves the 
deposit of all DNA molecules along one 
edge of a polymeric gel. An current is run 
through the gel which generates an electric 
field that puls the DNA fragments toward the opposite side of the gel. Larger molecules of DNA 
have a harder time winding through the polymeric labyrinth of the gel, thus the strands will be 
segregated in order of increasing size along the distance of the gel.  A laser is used to pick up the 
different fluorescent signals along the gel.  The combinations of fragment size and fluorescene 
color are compiled using computational methods to generate a graph which represents the 
sequence of the strand.  The overall process of dye-terminator sequencing is illustrated in Figure 
4. 
 
Figure 4.6 Dye-Terminator Sequencing: DNA is unwound and 
combined with fluorescent ddNTPs and dNTPs and run through 
an agarose gel. 
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4.3.1.2 Variations of Sanger Sequencing 
 The basic process of dye-terminator sequencing as described above is relatively efficient 
and low in error. This is the major sequencing techniques used in automated sequencing. The 
most important approach used in this method is the addition of single base pairs to the sample 
DNA fragment to create a base pair by base pair approach to sequencing.  
 While other companies have adapted different variations of this approach, virtually all 
current successful genome sequencing techniques on the market use a single-base pair 
sequencing approach by tagging each of the four different base pairs with a different color 
fluorophore.  
 
4.3.2   Micro$eq’s 6mer-Hybridization Sequencing 
Instead of using the conventional single base pair method, Micro$eq has used the same 
idea of binding fluorescently-tagged complementary base pairs, but has extended it to a 6 base 
pair at a time sequencing approach.  
4.3.2.1 6mer Hybridization 
Another possible sequencing approach is to hybridize, or Watson-Crick base pair, 6 base 
pair oligonucleotides segments to target DNA.  In this approach a known single-stranded 6 base 
pair segment is combined with a single strand of the target DNA and a fluorescent label is 
designed to give off a signal only when hybridization between the 6mer and sample DNA occurs.  
Hybridization only occurs if the probe possesses bases complementary to the target DNA. Thus 
when a signal is emitted, one can deduce that a 6 base pair sequence, complementary to the 6 
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bases of the 6mer with which it binds, occurs somewhere along the target DNA. Repeatedly 
combining the same target DNA molecule with known 6-base pair 6mers allows the creation of 
an output of which 6 base pair sequences exist within the target DNA fragment and which don’t.  
 
The summary of this process is illustrated in Figure 4.7. From this output the entire target 
DNA sequence to be reconstructed via a bioinformatic algorithim by using the overlap between 
the segments.   
4.3.2.2 Sensing Hybridization 
Sensing hybridization is used to detect which oligonucleotides bind fragments of the 
patient’s DNA by using a fluorescence signal. As the hybrdization of 6mers with the sample 
DNA is very different than the hybridization of a single base pair with the sample DNA, the 
C A G T T C G G C T A T C G T A 
C C G A T A 
Customer ds-DNA 
G T C A A G C C G A T A G C A T 
C A G T T C G G C T A T C G T A 
C C G A T A 
G G C T A T 
ds-6mer 
Denaturation 
Fluorescence 
Complementary 
6mer-DNA 
hybdridization 
Figure 4.7 Watson Crick Base Pairing Based Sequencing: In Watson Crick based base pairing sequencing, an oligonucleotide of 
a known sequence is combined with target DNA. The oligonucleotide fluoresces when it Watson-Crick Hybridizes to the sample 
DNA. 
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conventional method of base-pair specific fluorescence labeling as described in section 4.3.1 
above cannot be used. Instead Micro$eq has designed a different method of detecting 6mer 
hybridization based on a fluorescence-quencher labeled nucleotide system.    
4.3.2.2.1 Hairpin Quenchers 
In this approach, a target nucleic acid reveals itself by 
separating the donor fluorophore from the acceptor fluorophore, 
precluding the transfer of energy.  Energy that is not transferred 
through fluorescence resonance energy transfer (FRET) is emitted as 
fluorescence.  Many formats exist for fluorescnence energy transfer 
contact-mediated quenching in oligonnucleotide probes (Salvatore 
A. E. Marras, Efficiencies of Fluorescence resonance energy, 
2002).  Hairpin structures which pair a quencher and a fluorophore 
on a single strand such as the one seen in Figure 4.8, exist, however 
these molecules involve pseudo- double-stranded DNA which 
complicates the thermodynamic effects of binding and leads to inefficient and error-ridden 
hybridization between the oligonucleotide and the sample DNA.   
4.3.2.2.2 Double-stranded quenchers  
An alternative method, involving the use of quenched fluorphores but without the hairpin 
structure described above, places donor and acceptor fluorophores on different complementary 
strands. When the donor fluorophore is brought within 20-100 Ǻ of the acceptor fluorophore, the 
intensity of the fluorescence of the donor fluorophore decreases while the intensity of the 
fluorescence of the acceptor fluorophore increases (Salvatore A. E. Marras, Efficiencies of 
Figure 4.8 Hairpin Structure: One 
proposed fluorescence-quencher 
labeled nucleotide format places the 
fluorophore and the quencher at the 
ends of a hairpin structure.  When 
the complementary strand is present, 
the hairpin structure opens up and 
the fluorophore is free to fluoresce. 
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Fluorescence resonance energy, 2002).   However, if the donor and acceptor are brought any 
closer, most of the absorbed energy is emitted as heat and only a small amount of energy is 
emitted as light.  Thus, by coupling the two moieties, one can completely suppress the 
fluorescence. As summary of this fluorescence-quenching method is shown in Figure 4.7. 
4.3.3 Thermodynamics of 6mer Annealing 
As discussed earlier in this chapter, the thermodynamics of DNA denaturation and 
annealing depend significantly on DNA fragment size. Section 4.1 of this chapter outlined a 
detailed method for estimating the melting temperature and other thermodynamic properties of 
small double-stranded DNA fragments. The same principles discussed in that section hold true 
for an analysis of the thermodynamics of the 6mer hybridization with the sample DNA.  
In order for hybridization to occur, both the 6mers and the sample DNA fragments must 
be denatured. Following denaturation, the strands are allowed to rehybridize.  The four single 
stranded fragments (two from the sample DNA and two from the 6mer) will recombine as they 
reanneal to form double-stranded fragments. This recombination allows some of the 6mers to 
bind to the sample DNA and thus emit a fluorescence signal which can be detected by scanning.   
As previously discussed, nucleic acid thermodynamics dictate how temperature affects 
nucleic acid structure. The denaturation and reannealing process described in the previous 
paragraph will be facilitated via thermal control. In order to determine the necessary thermal 
cycle, the melting temperatures of the 6mers must be determined.  
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4.3.3.1 Range of 6mer Melting Temperatures 
Using the application of Table 4.1 data as illustrated in Figure 4.2, predicted free energies 
of hybridization can be calculated for all of the possible 4064 6mers.  From this method, the 
6mers with the maximum and minimum free energies are found. It was found that the GCGCGG 
oligonucleotide has the largest free energy of hybridization and thus will have the highest 
melting temperature. This is expected as Guanine and Cytosine base pairings form three 
hydrogen bonds compared to the two formed by Adenosine and Thymine. Additionally, the non-
symmetry of the oligonucleotide increases the hybridization energy as the molecular orientation 
required for binding is more restrictive. Finally, the terminal base pairs are important for 
initiation of hybridization, Guanine and Cytosine’s having the highest initiation energies. 
Conversely, the TATTAT oligonucleotide was found to have the lowest hybridization energy, 
and thus the lowest melting temperature. As previously stated, the minimum temperature must be 
at least five degrees higher than operating temperature (assumed to be room temperature – 
298K). The melting temperature of TATTAT was found to be 275K. 
 In order to alter the melting temperature, the salt concentration of the droplet can be 
increased. Magnesium salts will be used, as is conventional in biological annealing processes. 
Magnesium is especially effective as it is a diionic salt, thus a smaller increase in concentration 
will affect melting temperature than would be required of a monoionic salt. These calculations 
can be estimated from an empirically-derived relationship as seen below (Owczarzy, Moreire, 
You, Behlke, & Walder, 2008): 
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Equation 4.4.4 – Empirically derived relationship for Melting Temperature with varying salt concentrations (Owczarzy, 
Moreire, You, Behlke, & Walder, 2008) 
Where a-g are constants whose values are depicted in Table 4.2 
 
Table 4.2 Constants for use in Equation 4.4.4 (Owczarzy, Moreire, You, Behlke, & Walder, 2008) 
However, for the purpose of this report, further calculations will be approached in a more 
standardized manner.  
4.3.3.2 Integrated DNA Technologies Hybridization Calculator 
While it is possible to perform the entire thermodynamic analysis of 6mer hybrdization 
using the methods outlined in section 4.1 of this chapter, for the purpose of efficiency and 
accuracy of calculations, the IDT Oligonucleotide Hybridization Calculator (IDT BioPhysics) 
will be used to optimize the Magnesium concentration in order to have a minimum melting 
temperature of 303K. This tool has the additional benefit of accounting for both 6mer and DNA 
concentrations in the droplet.  
With the input settings of 1mM and 7mM 6mer and DNA concentrations (these required 
concentrations will be discussed in more detail in chapter 6 of this report in the context of 
78 | P a g e  
 
Micro$eq – Chomvong, King, Mahmoud 
hybridization detection),  for the 6mer and sample DNA, respectively, the calculator is run with 
an baseline Magnesium concentration of 0mM.  The results of this calculation can be seen in 
Figure 4.9.  
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5'- T A T T A T -3' 
3'- A T A A T A -5' 
 
 Tm 
[°C] 
Gibbs Energy (ΔG37) 
[kcal/mol] 
Enthalpy (ΔH) 
[kcal/mol] 
Entropy (ΔS) 
[cal/(K·mol)] 
Exact match 8.65 0.13 -32.10 -103.91 
 
Duplex Length: 6 
Oligo Conc: 1000.00 µM Na+, K+ Conc: 50.00 mM dNTPs Conc: 0.00 mM 
Target Conc: 7000.00 µM Mg2+ Conc: 0.00 mM  
 
 
Figure 4.9 Hybridization of TATTAT Thermodyanmics at [Mg2+]=0 (IDT BioPhysics) 
 
It can be seen that these results are close to those found earlier in section 4.3.3.1 of this 
chapter using the NN method. From these results it can be seen that the melting temperature 
needs to be raised by ~22 degrees, which can be done by increasing the Magnesium ion 
concentration in solution. 
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4.3.3.3 Manipulation of Melting Temperatures via Magnesium Salts 
  The same calculator as in section 4.3.3.2 above is then run with the same inputs except 
with varying magnesium concentrations in order to find the necessary concentration to achieve a 
30°C melting temperature. The results of these trials can be seen in Figure 4.10 (Compiled using 
(IDT BioPhysics) results). 
 
Figure 4.10 Melting Termperature Sensitivity to [Mg2+] analysis 
 
From Figure 4.10 it can be seen that the at a Magnesium concentration of 40nM, the melting 
temperature exceeds 30°C, The complete results from the calculation at this concentration are 
displayed in Figure 4.11 
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5'- T A T T A T -3' 
3'- A T A A T A -5' 
 
 Tm 
[°C] 
Gibbs Energy (ΔG37) 
[kcal/mol] 
Enthalpy (ΔH) 
[kcal/mol] 
Entropy (ΔS) 
[cal/(K·mol)] 
Exact match 30.19 -2.38 -32.10 -95.82 
 
Duplex Length: 6 
Oligo Conc: 1000.00 µM Na+, K+ Conc: 50.00 mM dNTPs Conc: 0.00 mM 
Target Conc: 7000.00 µM Mg2+ Conc: 40.00 mM  
 
 
 
Figure 4.11 TATTAT Hybridiztion Thermodynamics at [Mg2+] = 40mM (IDT BioPhysics) 
Hence, the 6mer droplets merged with the DNA fragment droplets will have a combined 
Magnesium concentration of 40mM. The results of figure show that all the hybridization drops 
will be heated to at least 30°C. While it is known that the reaction mixture needs to be heated to 
~95°C in order to denature the DNA, the maximum temperature of the required in order to 
82 | P a g e  
 
Micro$eq – Chomvong, King, Mahmoud 
exceed all of the oligonuclelotides’ melting temperatures needs to be calculated to determine if it 
is above 95°C. the calculation is run for the GCGCGG 6mer, the results of which are shown in 
Figure 4.12 
5'- G C G C G G -3' 
3'- C G C G C C -5' 
 
 Tm 
[°C] 
Gibbs Energy (ΔG37) 
[kcal/mol] 
Enthalpy (ΔH) 
[kcal/mol] 
Entropy (ΔS) 
[cal/(K·mol)] 
Exact match 82.53 -9.32 -48.60 -126.64 
 
Duplex Length: 6 
Oligo Conc: 1000.00 µM Na+, K+ Conc: 50.00 mM dNTPs Conc: 0.00 mM 
Target Conc: 7000.00 µM Mg2+ Conc: 40.00 mM  
 
 
 
Figure 4.12 Hybrdiziation of GCGCGG at [Mg2+]=40mM (IDT BioPhysics) 
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As seen in Figure 4.12, the maximum melting temperature is 82.5°C. Thus, the maximum 
required temperature by the oligomers is ~5°C above this maximum – 88C – and is still below 
the DNA required temperature of 95°C.  
After denaturation, as the reaction mixture cools, the 6mers with the highest melting 
temperatures will reanneal first. As reannealing occurs, approximately half of the 6mers will 
anneal to other 6mers and the remaining half will anneal to the fragment DNA, yielding ~0.5mM 
of 6mer-bound DNA per each 6mer in the droplet. As previously discussed, it is these binding 
events that will be detected during the scanning step and used to sequence the sample DNA. 
 
4.4 SUMMARY OF MICRO$EQ’S APPROACH TO OVERCOMING 
BIOMOLECULAR LIMITATIONS  
Several key biomolecular properties of DNA that present challenges in the presequencing 
and sequencing steps were presented in this chapter. In respect to each limitation, Micro$eq’s 
approach to overcoming this obstacle was described. A few key results of Micro$eq’s approach 
are important to reiterate in the context of the overall process. 
First, Micro$eq’s ability to use conventional PCR methods, as outline in section 4.2, is 
juxtaposition with the random amplification that required millions of different PCR reactions as 
outlined in chapter 3 of this report. The use of conventional PCR methods allows an enormously 
significant increase in sample throughput, bringing sample processing time and cost to a 
reasonable level from the originally proposed single-molecule approach as outlined in chapter 3.  
Second, Micro$eq’s use of restriction enzymes to generate exactly sized sample DNA 
fragments allows optimal reassembly of the fragment sequence via computational methods. This 
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reassembly process is often the temporal bottleneck of genome sequencing, and producing its 
optimum input helps minimize the computational process time and thus overall process time. 
Third, Micro$eq’s adaptation of conventional sequencing techniques to a multi-base pair 
sequencing method via the hybridization of 6mers allows a continuous instead of batch 
sequencing process. This drastically decreases sequencing time – another potential bottleneck in 
the overall process – and thus decreases overall process time. 
As a whole, Micro$eq’s approach innovatively overcomes traditional biomolecular 
limitations to optimize the presequencing, sequencing, and reassembly steps in its overall 
genome sequencing process. Micro$eq’s unique approach also allows it to significantly decrease 
temporal requirements for the two potential process bottlenecks – DNA sequence scanning and 
fragment reassembly. 
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CHAPTER 5  
 
Presequencing Processes 
 
As previously discussed, the first part in the sequencing process is the breakdown of the 
genome to the appropriate fragment sizes that will then be sequenced and reassembled. For the 
scope of this project, the approach  to these beginning steps was determined by the requirements 
of the later (sequencing and reassembly steps). While the details of these requirements will be 
discussed later, the overall goal of the pre-sequencing preparations is to generate the optimal 
length (22bp) and number of fragments (10 per droplet) of the customer’s genome for the later 
steps in the overall process. The input to the pre-sequencing steps will be the customer’s saliva, 
which contains their cells and thus DNA can be extracted from this sample. The output of these 
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steps will be micro droplets, each containing the required concentration and number of 
specifically-sized DNA fragments.  
The required output from the pre-sequencing process is determined by the approach to 
sequencing (merging with 6 base pair oligonucleotides) and the optimization of the reassembly 
algorithm (to determine which combination of fragment size and fragment number allows for the 
lowest error rate and quickest processing time). However, it is important to remember that the 
requirements implicated by the later steps are determined by optimization of those steps and do 
not take into account the limitations of molecular biology. Hence, the challenge of the pre-
sequencing process will be to capitalize on available molecular biology techniques and to design 
new molecular biology strategies base on known biochemistry in order to adhere as closely as 
possible to the required output. This chapter will outline the biological limitations that make 
achieving these requirements difficult, and will discuss a proposed method of how to overcome 
these limitations.  
 
5.1 DNA EXTRACTION AND PRELIMINARY PREPARATION 
Now that the basic approach to achieving the required output of the pre-sequencing 
process has been outlined, a detailed process design will be explained. The explanation of this 
process design is aimed at highlighting how the previously outlined general approach will be 
executed. This discussion will include explanation of existing technologies that may be adapted 
for the process’s purposes, as well as new technologies that are required for our design and while 
feasible, do not yet exist on the market place. While the major molecular and biological 
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challenges have already been discussed, this detailed process design will highlight even more 
molecular and biological nuances and obstacles that must be addressed.  
5.1.1 Initial DNA Extraction and Purification 
The DNA sample is received from the customer as a 
saliva sample. The DNA Genoteck Oragene® kit (full 
protocol found in Appendix C) is used for both collection and 
initial DNA purification.  A kit is mailed to the customer and 
he or she spits into the prepared sample and mails the kit back 
to Micro$eq. The sample is then loaded into the Magtration 
12GC (PSS Bio Instruments) which uses paramagnetic-
particle technology to purify the DNA from the Oragene® 
solution.  
The elution volume is 200ml with a median yield of 3.8mg/200mL of DNA and a median 
A260/280 ratio of 1.95 (Lem, 2009). The full range of DNA concentration yields is shown in Figure 
5.1and this translates into a median DNA concentration of 3.0x10-9M with a range of 1.610-9M to 
6.310-9M (calculation done using source (Ambion’s Appendix)). The details of the required 
initial concentration will be discussed in this chapter, but it is important to note that this starting 
concentration is much greater than the required initial concentration of this process (1.8 x10-15M 
– calculations of this requirement will be discussed in section 5.4.1 of this chapter). This implies 
that even with significant loss of DNA during the preliminary preparation steps, achieving the 
initial droplet concentration is very feasible by simply diluting to this concentration. 
Figure 5.1  Scattergram of DNA yield from 
200μl of Oragene/Saliva sample. The 
horizontal line represents the median yield at 
3.8μg. (Lem, 2009) 
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Additionally, the expected variability between customer samples as illustrated in figure 6.6 will 
not render samples on the lower end of the concentration scale unusable.  
5.1.2 Preliminary DNA Fragmentation 
 While the final fragments used for sequencing will be fragmented biological via 
restriction enzyme digest as discussed earlier in this chapter, the preliminary DNA input must be 
reduced to smaller fragments for optimum efficiency of generating the modified 22bp genomic 
DNA fragments.  
 The purified DNA from above is then fragmented using the s2 Shearer (Covaris), where 
Adaptive Focused Acoustics energy (used more commonly in the process of breaking up kidney 
stones or larger tissues) shears the double stranded DNA. By using the specifications found 
below in Table 5.1, a target peak length of 1000 base pairs is achieved (full protocol may be 
found in Appendix C).  
Parameter Setting 
Base Pair Size 1000(bp) 
Duty Cycle 5% 
Intensity 3 
Cycles per burst 200 
Power Mode Frequency Sweeping 
Z Height 6mm 
Temperature 6-8 ( °C) 
Time 40 (s) 
Degassing mode Continuous 
Volume 200ml 
DNA mass <5mg 
Starting material >50kb 
Water level(FILL/RUN) S2 – level 12 
E210 – level 6 
AFA Intensifier Yes 
Table 5.1  Covaris s2 shearing specifications to achieve a median DNA fragment size of 1000bp (Covaris) 
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DNA fragments will be sheared into a distribution of sizes, as displayed in Figure 5.2 
It can be seen in Figure 5.2 that the fragment size varies between ~50-1600 bp, with the 
distribution being centered at 
1000bp. However, the size 
distribution of these fragments 
is relatively insignificant on 
the overall process, as the 
actual fragments to be 
sequenced will end up as 22 bp 
in length (Dunn, McCorkle, & 
Praissman, 2002), and their 
length is determined by 
enzyme activity and not by the original size of the fragment. The only means by which this size 
distribution will affect the rest of the process will be discussed in a later section of this chapter in 
the context of DNA circularization. While the concept of circularizing the DNA has yet to be 
introduced, it will be explained how this is in fact necessary at one point in the pre-sequencing 
preparations. At the circularizing step, the size distribution of the DNA fragments will affect the 
process, as the smaller DNA may have difficulty forming a circle compared to the larger 
fragments, This error is taken into account and will be discussed in more detail later. 
The fragmented DNA strands are then purified using the QIAquick Purification Kit  
(Quiagen) (see Appendix C for protocol) and are ready for the next step in presequencing 
processing. These 1000kbp fragments are the starting genomic DNA fragments in Micro$eq’s 
Figure 5.2 Covaris Fragment size Distribution for 1000bp target fragment size 
(Covaris) 
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outlined approach in section 4.2 of the previous chapter, and will undergo adaptor ligation and 
restriction enzyme digest, as previously discussed. 
 
5.2 ADAPTOR LIGATION AND PRELIMINARY AMPLIFICATION 
While the idea of adding adaptor sequences, which contain the recognition site of the 
MmeI restriction enzyme, to the genomic DNA has been previously discussed, the actual details 
of how these adaptors are ligated to the genomic DNA was glossed over. Here, the chemical 
interactions between the nucleic acids that allow this ligation process to take place and the 
practical execution of these steps will be discussed in more detail.  
While Figure 4.4 in chapter 4 depicted the ligation of adaptors as two separate sequences 
on the termini of linear DNA, the key step to the adaptor ligation process actually involves the 
circularization of the 1kbp sheared DNA fragments prepared above around a synthetic insert-
linker. The Restriction Digest will re-linearize the DNA, but the circular DNA structure is the 
optimal template for restriction enzyme activity. While a point that does not affect this process, it 
is interesting to note that while restriction enzymes are indeed short sequences of DNA base 
pairs that exist in the human genome, the enzymes themselves are not coded for in the human 
genome and thus do not exist naturally in human cells. Restriction enzymes actually occur 
naturally in bacteria, and are harvested for use in human molecular biology work. Bacterial 
DNA, unlink human, is actually circular in form, hence why restriction enzymes operate most 
efficiently on a circular DNA structure. For the MmeI restriction enzyme, it has been found that 
~1kbp long circular DNA are optimal for enzymatic activity (Porreca, Shendure, & Church, 
2006), thus the genomic DNA was prepared accordingly as described in the previous section.  
 
91 | P a g e  
 
Micro$eq – Chomvong, King, Mahmoud 
5.2.1 Circularization of DNA 
Step 1: Addition of Adenosine tail 
Before the fragmented DNA generated above can be ligated to the adaptor sequence, their 
ends must be modified. The sheared genomic DNA fragments will have different terminal base 
pairs, depending on where the fragmentation occurred in on the original DNA sample. However, 
as the same adaptor sequence must be ligated to the ends of all DNA molecules, a single base 
pair will be added to the ends of the DNA fragments such that all DNA fragments will have the 
same terminal base pair and thus ligated with equal affinity to the adaptor sequence. The adaptor 
sequence ends in a single-stranded 5’-Thymine (T) base, thus an Adenosine (A) base (which 
binds complementary to the T base) will be added to the 3’ end of the genomic DNA in a 
template-independent fashion. 
 
This addition of a single-stranded base to the terminus of a double-stranded DNA 
molecule creates what is termed a “sticky end” to the DNA. As seen in Figure 5.3, both the 
Figure 5.3 Genomic DNA-Adaptor Ligation via Sticky ends. Genomic DNA denoted by black, Adaptor sequence denote by red, 
hydrogen bonds between complementary sequences denote by dotted lines. 
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adaptor (which is synthesized with a stick T base end) and the genomic DNA (which has a sticky 
A base added to it) now have complementary single-stranded DNA termini. As DNA is more 
thermodynamically stable in the double-stranded conformation, the adaptor will spontaneously 
anneal to the genomic DNA (under the proper reaction conditions), as shown in Figure 5.4 
 
The addition of an Adenosine to the genomic DNA is a relatively simple procedure. Free 
adenosine nucleotide (dATP’s) are added to a solution of the DNA fragments with a solution 
buffer, a Taq DNA polymerase enzyme, and Magnesium chloride which provides the 
Magnesium ions necessary for the polymerase activity. The solution is then incubated for 30min 
at 70°C and then cooled to 4°C. The DNA is extracted out of the reaction solution via a 
phenol/chloroform mixture and then precipitated using ethanol. The extracted DNA is 
resuspended in a standard elution buffer and is ready for the next step in the process. (full 
Figure 5.4 Genomic DNA Circularization with Adaptors using sticky end ligtation. Genomic DNA denoted by black, 
adaptors denoted by red, dotted lines denote hydrogen bonds between complementary base pairs 
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protocol for this as well as all of the following steps in Appendix C – Note: some modifications 
have been made to adapt this protocol for use in this specific project). 
Step 2: Circularization of Genomic DNA around Synthetic Oligonucleotide Insert. 
 As described above, the generated fragments are combined with the two halves of a 
synthetic 250bp oligonucleotide which anneals to each end of the fragment. The choice of length 
for this synthetic adaptor will be discussed later in this chapter. It is important to note the 
terminal ends of the two halves of the 250bp oligonucleotide which do not contain the sticky T 
base end, also contain a sticky end. The sticky ends of the two halves are in fact complementary 
such that in adition to annealing with the genomic DNA at one terminus, the two halves will 
anneal to each other at the other terminus, thus creating a circular genomic DNA fragment with 
the 250bp synethic insert. This process is illustrated in Figure 5.4.  
The ligation of the synthetic oligonucletoide is also a relatively simple process.  
The DNA fragments and oligonucleotides are combined in a solution containing a T4 
DNA ligase ezyme along with a ligation buffer. The T4 ligase facilitates the ligation of the sticky 
ends to create a continuous double-stranded DNA. The solution is heated in a thermal cycler 
(Biometra) to 95°C for 10 min, thus denaturing both the oligonucleotides and the genomic DNA. 
The solution is then slowly cooled to 25°C over the course of an hour. During this cooling 
process, the two halves of the synthetic oligonucleotide are ligated to both the other half and the 
genomic DNA to create circularized DNA, as described above. The solution is then incubated at 
room temperature for 10 min and then the enzyme is heat-inactivated for 10 min at 65°C.  
Step 3: Exonucelolysis 
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While this process is relatively efficient, their will be excess reagents as well as the 
smaller DNA fragments that were unable to be circularized still remaining in solution. All 
noncircularized material is therefore eliminated via exonucleolysis. Exonucleolysis in a 
biological process by which exonucelase enzymes digest linear DNA into single dNTP’s by 
cleaving the covalent bonds between adjacent bases. Exonucleases act by binding to the terminal 
end of the DNA and moving along the linear stucture. As all DNA of interest in now 
circularized, the exonucelase’s cannot digest this, and instead will only digest undesirable non-
circularized material. 
This process is also relatively straight-forward. Exonuclease I and III are added with their 
associated buffers to the reaction solution from step 2 above. The solution is incubated at 37°C 
for 45 min and the remaining material is ready to be used directly in the next step without further 
purification. 
5.2.2 Restriction Enzyme Digestion 
 As previously discussed, the desired 22bp genomic DNA fragments will be generated via 
restriction enzyme digest using the MmeI enzyme that cuts 22bp from its recognition sites. The 
MmeI recognition site is the 5bp nucleotide sequence 5’-AGGYT-3’ bound to its complementary 
sequence 3’-TCCRA-5’ where the Y denotes either pyrimidine base (T or C) and the R denotes 
either purine base (A or G) (AK7). For the purpose of this process, the purine has been chosen as 
A, with its complementary pyrimidine being T. the 5’ end A on the recognition site corresponds 
to the A base ligated onto the genomic DNA, with the remaining 4 base pairs of the site being the 
5’ terminal end sequence of the adaptor such that when the modified genomic DNA and 
sequence are ligated, the AGGTT sequence is the directly adjacent to the genomic DNA 
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sequence. Similarly, the 3’ end T of the complementary recognition site corresponds to the 3’ 
terminal sticky end of the adaptor sequence, with the remaining 4 base pairs of the site being 
directly upstream in the adaptor such that when the DNA and adaptor are modified, the 
complementary site also exists directly adjacent to the genomic DNA, implying that restriction 
site are present directly adjacent to both ligation sites between the adaptor and the genomic 
DNA. This allows the MmeI to digest 22bp upstream in either direction of the restriction site, 
thus generating a linear fragment consisting of two 22bp fragments of DNA linked by the 250bp 
adaptors between. This scheme of digestion is 
illustrated in Figure 5.5  
The restriciton enzyme digestion process 
is fairly simple. The circular DNA solution from 
step 2 is combined with the MmeI digestion 
enzyme, its co-substrate S-Adenosyl Methionine 
(SAM) and the appropriate buffer solution. The 
solution is heated to 37 °C for 30 min, then the 
DNA is immediately extracted and then the DNA 
is immediately extracted out of the reaction 
solution via a phenol/chloroform mixture and 
then precipitated using ethanol. The extracted DNA is resuspended in a standard elution buffer 
and purified using the QiAquick purification kit (Qiagen) as in section 6.3.2 of this chapter.  
Before these DNA fragments can be used in the next step of the processes, the ends must 
be repaired. During digestion, he restriction enzyme cleaves the final base pair (the 22nd genomic 
Figure 5.5 Restriction enzyme digest of Circularized 
construct. genomic DNA denoted in black, synthetic 
adaptor denoted in red. 
96 | P a g e  
 
Micro$eq – Chomvong, King, Mahmoud 
DNA base pair) such that it leaves a 1bp sticky end. In order to preserve the integrity of the 
genomic DNA sequence, a full 22bp ds-DNA must be present to be sequenced. Thus the ends are 
repaired via the End-It DNA end repair kit (EpiCenter Biotechnologies). 
This repair process is trivial and involves the addition of ss-dNTP’s with a mix of ligase 
enzymes and their appropriate buffer solution to the purified DNA fragments generated by the 
digest above. The reaction mixture is incubated at room temperature for 45 min, during with the 
ligase enzymes ligate the ss-dNTP’s from the mixture to the ss-sticky ends of the DNA 
fragments in a complementary base pair fashion in order to create fully double-stranded 22bp 
genomic DNA sequences on either sides of the adaptor. The repaired DNA is again extracted out 
of the reaction solution via a phenol/chloroform mixture, precipitated using ethanol and then 
resuspended in a standard elution buffer. These repaired linear adaptor-DNA fragments are now 
ready for the next step in the process.  
5.2.3 Addition of FDV/RDV PCR adapters 
The two terminal adaptors (FDV on one end and RDV on the other) which will be added 
to the ends of the genomic DNA fragments must be similarly ligated to the new terminimal ends 
of the genomic DNA. For the sake of the adaptors’ stability, the full FDV and RDV sequences to 
be added are 44bp long – much longer than the required 9bp primer sequences. The excess 
sequence beyond the 9bp primer sequence is insignificant however, as they will not be amplified 
as they are beyond the scope of the amplification process and therefore will not exist in the final 
amplicons to be sequenced (this point was illustrated earlier in Figure 5.5). Identical to the first 
set of adaptors added in section 5.4.1 above, the terminal adaptors also contain a single T base 
pair sticky end. Thus, the genomic DNA fragments will require the addition of a single A base 
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pair to their termini before they can be ligated to the FDV and RDV adaptors. This single base 
pair additon will be performed identically to step 1 in section 5.4.1 above.  
The terminal adaptors will be then be ligated to the sticky-end DNA fragments in the 
exact same manner as the first adaptors were ligated in step 2 of section 5.4.1 above. However, 
the FDV and RDV adaptors only have one sticky end, which will be used to ligate to the DNA 
fragment, and therefore cannot ligate to each other. This allows the final DNA fragment with the 
terminal adaptors added to remain linear. The 
output DNA fragments from this process is 
therefore a 344bp long fragment with two 
25bp terminal adaptors, one 250bp internal adaptor, and two 22bp genomic DNA fragments 
between the adaptor sequences as seen in figure Figure 5.6. These fragments are ready for the 
next stage in the process. 
5.2.4 Internal Adaptor Shearing 
 From the modified fragment in FIGURE it can be seen that two different 22bp genomic 
DNA fragments exist in each single adaptor-DNA construct. However, the goal of the process is 
to be able to handle each genomic DNA fragment individually, thus this construct must be cut in 
some fashion such that the two genomic DNA fragments are separated.  
Figure 5.6 22bg Genomic DNA fragments flanked by 
adaptor sequences. Genomic DNA denoted by black, 
internal adaptor by red, terminal adaptors by blue. 
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As previously discussed, there are four different PCR primer-annealing sites in this construct, 
two sets of two, each flanking the two 22bp fragments. If this entire fragment were to be PCR 
amplified using the two sets of primers, three different PCR  products would result, as any 
combination of a forward and reverse primer will produce an amplicon, as can be seen in Figure 
5.7. 
As the large middle PCR product in Figure 5.7 is undesirable, the internal adaptor must 
be cut so that the middle product cannot be formed. While it would have been possible to do this 
digestion by restriction enzyme digest in a fashion similar to the original digestion described 
earlier in this chapter, the size specificity of the cutting is not a huge issue. The only requirement 
for specificity is that the 9bp primer anneal sites on the two ends of the internal adaptor are 
preserved. Thus, fragment sizes must range between 56bp (25bp terminal adaptor, 22bp genomic 
DNA, and 9bp internal adaptor primer sequence) and 288bp (25bp terminal adaptor, 22bp 
genomic DNA, and 241bp of internal adaptor – excluding its other 9bp primer site).  
The Magtration shearing device used in preliminary DNA shearing in section 5.1.1 will 
be used again in this step. This time, the target base pair length will be set to 150bp (see 
Figure 5.7 Adaptor-DNA construct potential PCR products. Genomic DNA in black, internal adaptor in red, terminal 
adaptors in blue 
99 | P a g e  
 
Micro$eq – Chomvong, King, Mahmoud 
Appendix C for full adjusted protocol). The fragment size distribution from this target base pair 
can be seen in Figure 5.8.  
 
Figure 5.8 Fragment distribution for target size of 150bp (Covaris) 
As seen from the distribution, the generated fragment size range is contained mostly 
within the 56-288bp size range, with ~90% of fragments within this range. This inefficiency will 
be built into the droplet generation step of the process. 
5.2.5 Initial Amplification 
 As the presequencing process continues, it is important to note what is present in the 
reaction solution. After the internal adaptor shearing described in the previous section, there will 
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exist in solution fragments of DNA, particularly portions of the internal adaptors, that are not 
desirable. The droplet generation stage, as it requires only 5 double-stranded fragments per drop, 
is very sensitive to DNA concentration. Thus, it is important that when the concentration of the 
solution to be made into droplets is measured, it measures only the DNA fragments that will 
count towards the total of 5 fragments per droplet. As there is NO way to distinguish between the 
desired and undesired fragments at this point, and initial amplification step, which will select for 
the desired products, will take place. 
 The two sets of 9 bp primers complementary to the 9bp primer sequences on the adaptor 
sequences, as portrayed in Figure 5.7 will be used to amplify the targeted 22bp genomic 
sequences.  As the DNA has been sheared in the middle of the internal adaptor sequence, only 
the left-most and right-most PCR products will be produced. If 15 cycles of PCR are run, this 
will amplify the targeted DNA 210 = 1024 times.  Thus, on average, only 1 out of every ~1000 
fragments in the amplified solution will be an undesired product. This efficiency will also be 
taken into account during the droplet formation step. 
 This preliminary PCR protocol will follow a standard PCR format as previously outlined 
in chapter 4.  The reaction will be thermocycled using the same Themal Cycler (Biometra) as 
was used in the preliminary steps of DNA processing described in section 5.1 of this chapter. 
Post amplification, the DNA will be extracted out of the reaction solution via a 
phenol/chloroform mixture and then precipitated using ethanol. The extracted DNA is 
resuspended in a standard elution buffer and is ready for the next step in the process. 
A summary of the DNA fragment preparation process up to this point is illustrated on the 
next page in Figure 5.9. It can be seen that at this stage in the process, the DNA has been 
transformed from raw genomic DNA to selected 22bp genomic DNA fragments with 9bp primer 
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annealing sequences on either end. These preliminary preparation steps have already achieved 
one of the necessary outputs of the pre-sequencing process: 22bp genomic DNA Fragments. The 
steps necessary second presequencing requirement (particular concentration of 5 different DNA 
fragments per droplet) will be described in the follow sections of this chapter. However, the two 
9bp primer annealing tags on each fragment make the necessary DNA amplification to achieve 
desired concentration feasible.  
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Figure 5.9 Summary of Pre-amplification DNA processing. Genomic DNA denoted by black, Internal adaptor sequence denoted 
by red, terminal adaptor sequence denoted by blue. 
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5.3 DNA FRAGMENT DROPLET GENERATION 
 The remainder of the pre-sequencing process will be done in droplet form on a 
microfluidics platform. The fragments generated above in section 5.2.5 are the final fragments to 
be sequenced. However, as previously discussed, these fragments need to be amplified to 
required final concentration for the sequencing step. In order to ensure that the sequencing reads 
for a fragment are from only one (or a defined number of) particular fragments at a time, 
amplification must target only one (or a defined number of) certain fragments such that the 
copies of each fragment are isolated for subsequent sequencing. To achieve this isolation, 
amplification will take place in droplets to be used as microreactors which allows the generated 
fragment copies to be contained in droplet form and thus will not mix with different fra gments 
which would be detrimental to the sequencing process accuracy.  
5.3.1 Droplet Concentration 
The optimal number of different droplets per droplet for sequence reassembly is found to 
be 10 single-stranded fragments, or 5 double-stranded fragments (discussion of this number is 
found in Chapter 7 of this report). However, the inefficiencies in the pre-sequencing preparation 
steps require that the target concentration of the droplet will generate more than 5 double-
stranded fragments per droplet such that the average total usable number of fragments per droplet 
is actually 5. As discussed above in section 5.4.5, a 0.1% inefficiency in built into this process. 
as discussed in section 5.4.4, a 10% inefficiency in built into this process, making the total pre-
sequencing process efficiency to be ~10.1%. Thus the average number of fragments per droplet 
will be targeted to be 5.5 ds-fragments, so that the overall number of usable (able to be 
sequenced) ds-fragments will be ~5. 
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The DNA concentration in the reaction solution from step 5.4.5 is analyzed using a 
NanoDrop ND-1000 spectrophotometer (Thermo Scientific). The DNA fragment droplets to be 
generated will be 0.5nL in size, thus the required concentration for the solution is 5.5 
droplets/5nL (1.8x10-15 M). The original reaction solution will then be manually diluted using 
deionized water such that its final concentration is 1.8x10-15 M. 
5.3.2 Droplet Generation  
As previously stated, the average 
DNA per molecule (l) = 5.5. The distribution 
of DNA molecules will be a poison 
distribution, as discussed in section 2.2.2 of 
this report.  
Using l=5.5, the distribution of DNA 
molecules is displayed in Figure 5.10 
While the droplet distribution is not as tight as necessarily desirable, this error will have 
negligible effect on the remainder of the pre-scanning process and will only significantly affect 
the process in the reassembly stage (see chapter 7).  Additionally it should be noted that it is 
impossible to generate a non-integer number of fragments (such as 5.5 fragments), but the goal is 
to average as close to the required output as possible.  
 
 
 
Figure 5.10 Fragments per Droplet Distribution for target average 
of 5.5 fragments/droplet 
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5.4 PCR AMPLIFICATION IN DROPLETS  
As previously discussed, PCR amplification will involve two different sets of primers. 
The exact same amplification process will take place as in section 5.2.5 of this chapter with two 
major modifications. First, the primers to be used will be quenched, to avoid binding with the 
6mer and thus sequenced in the sequencing step. Second, the amplification process will be run to 
completion. Completion of the amplification reaction will be defined as the complete exhaustion 
of the limiting reagent, which in this case, are the primers. 
5.4.1 Primer Quenching and Exhaustion 
 As previously discussed, the presence of the 9bp primer annealing sites on each side of 
the genomic DNA fragment will present a challenge in the sequencing step. If amplification were 
performed as in section 5.2.5 without any further modification, these primer annealing sequences 
would bind with equal affinity to the 6mers that are used for sequencing as would the genomic 
DNA and thus will be incorrectly taken to be part of the genomic sequence. Two modifications 
in the pre-sequencing process are made to minimize the effect of this issue. Additionally, a 
modification in the sequencing process, which will be discussed later in Chapter 6 of this report, 
will adjust the sequencing readout as to account for this complication.  
5.4.1.1 Primer Quenching 
First, the primers will be tagged with quenchers, using the same oligonucleotide 
quenchers as described in section 4.3.2 of this report.  As the final DNA fragments will contain 
the original primers used (as described in the context of PCR amplification in Chapter 4 of this 
report), the presence of these quenchers will increase their affinity for binding to the DNA 
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fragment. In the sequencing step, the quenched primer tags on each end of the genomic DNA 
fragment will denature, as explained in section 4.3 of this report. However, the when the 6mers 
anneal to the 9bp quenched sequence, they will not fluoresce as the quencher prevents this (as 
described in section 4.3.2). thus, the presence of these 6mers in the will not be detected unless 
the . the concentrations of the particular 6mers that will bind to the primer sequence will need to 
be increased in order to maintain the thermodynamics of the sequencing hybridization. These 
adjustments will be discussed in the context of the 6mer library preparation in Chapter 6 of this 
report.  
5.4.1.2 Primer Exhaustion  
A second modification is made to the amplification process in order to minimize required 
adjustment 6mer concentration. In general, such as with the amplification in section 5.3.1.1, after 
PCR processes are completed, the generated DNA amplicons are extracted from the remaining 
reactants. Thus, it is conventional in PCR processes to use the cycle number to determine the 
number of DNA copies generated and have all reagents exist in excess. However, as the PCR 
reactions are performed in droplets and must remain in droplets to continue into the sequencing 
step, it is impossible to extract the isolated DNA without rupturing the droplet structure. Thus, all 
remaining reagents will exist in the droplets that are sequenced. This presents two potential 
issues. First, the primers will bind with the 6mers. While these will not fluoresce, as discussed in 
section 5.5.1.1 above, they will increase the required concentration of their complementary 
6mers to maintain the 6mer-DNA binding thermodynamics. Second, if all available reagents are 
present, a pseudo-amplification step may take place during the heating step required for the 6mer 
hybridization.  
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Hence, to avoid these two problems, the primers will be used as the limiting reagents in 
this process. The required output concentration of the DNA in each 1nL droplet (0.5nL from the 
generated DNA fragment Droplet and 0.5nL from the PCR reagent droplets) is 14mM (as 
discussed in Chapter 4 of this report) which subsequently requires 43 of PCR cycles as seen from 
the calculations below.  
[   ] =   ×      =                       ×      ×       .    ×                                     =  .  ×     =                         ×   =  ×     =   .          
                                        
As the concentration of each primer must be at least that of the final target DNA 
concentration, the input concentration of each primer in the reaction mixture will be just slightly 
greater than this, ~14.1mM. The PCR will then be run for an additional 3 cycles to ensure that all 
primers are used, and thus the two potential complications described in the previous paragraph 
are avoided. 
5.4.2 PCR Reagent and DNA Fragment Droplet Merge 
The master PCR mix (with the necessary reagents and primers, as discussed in Chapter 4 
of this report) will be prepared independently of the DNA fragments in solution form. This 
solution will then be generated as droplets in the same fashion as used for all droplet generation 
in this process.  
The number of total required DNA fragment droplets is 3.6x108 (the calculation of this 
number will be discussed in section 7.4 of this report). Each DNA fragment droplet will be 
merged with a single PCR reagent droplet (each 0.5nL in size).  The two libraries of droplets will 
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be merged in a 1:1 fashion using an electric field as depicted in Figure 2.5 in Chapter 2 of this 
report). These droplets are now ready for the thermally controlled amplification step. 
5.4.3 Reservoir-based PCR Amplification in Droplets. 
As previously stated, each combined droplet containing the PCR reaction mixture and the 
DNA fragments will be 1.0nL in size. The merged droplets will then be shuttled off the 
microfluidic chip which performed the droplet merge and into a standard 0.5mL cap tubes to be 
used in the same thermal cycler (BioMetra) as used in the previous presequencing processes. The 
thermal cycler will cycle the tubes through the 46 PCR cycles allowing each droplet to contain 
the required 14mM concentration of DNA by the end of the ampliciation  It is important to note 
that during the amplification process, as the droplets are emulsified in oil, they will remain intact 
even if they exist in the same tube, allowing isolated amplification to occur inside each droplet.    
PCR will be performed in a batch processes. For 3.6x108 1.0nL droplets, suspended in oil, 
the volume occupied by all droplets can be calculated. Assuming the oil suspension occupies the 
same volume as the droplet, the total volume is 7.2mL, which required 8x0.5mL tubes for each 
sample. As the Biometra Thermal Cycler can accommodate 60x0.5mL tubes at a time, ~7 
complete genomes can fit into the Thermal Cycler at a time. At the completion of the cycle, 
droplet suspension will be reintroduced into a new microfluidic chip where the droplets will be 
split in preparation for the sequencing process.  
Another important consideration in whole genome amplification that has yet to be 
discussed is heterogeneous single nucleotide polymorphism (SNP) representation. SNP’s occur 
when a single base pair is mutated on either one of both alleles. Some SNP’s are enough to cause 
an entire disease, such as the Sickle Cell Trait. Heterogeneous SNP’s are when the base on one 
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allele is mutated and the other is not.  When the two alleles have different base pairs as the same 
location of a SNP, primer and dNTP adhesion rates vary between the two alleles. Most 
approaches have been shown to have ~ 97% equal representation of each of the two alleles 
containing a heterogeneous SNP, implying an input error rate to the sequencing of a 
heterogeneous SNP of 3%.  (Brayer, 2009) However, as the sequencing approach described 
above to amplification does not involve primers annealing directly to the genomic DNA, but 
rather instead to the synthetic end adaptors, this amplification bias is eliminated.  
 
5.5 PARENT DROPLET SPLIT AND COMPLETION OF 
PRESEQUENCING PROCESS 
Once the DNA fragments are amplified, these droplets (from hereon referred to as parent 
droplets) must be split into daughter droplets. The splitting on each droplet is required so that the 
exact same fragments are presence in each drop that is merged with all 505 drops in the 6mer 
library.  
Each parent droplet will be split into 508 daughter droplets so that they may be paired in 
a 1:1 fashion with each droplet in the 505  droplet 6mer library set. When the parents droplets are 
reintroduced to the microfluidic chip an air bubble will be inserted in the flow stream between 
each droplet such that each set of 505 droplets may be maintained separately, for the purpose of 
sequencing later on. The necessity of this separation as it applies to the sequencing process will 
be further discussed in Chapter 6. All parent droplets will reside in a larger diameter reservoir, 
which will then be funneled toward a droplet splitter (as described in Chapter 2 of this report). 
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The target droplet size will be 2.0pL so that each 1nL parent droplet splits into NUMBER 
daughter droplets.  
The generation of these daughter droplets concludes the presequencing steps of this 
process. The fate of these daughter droplets which will be merged with the 6mer library set, will 
be continued in Chapter 6 of this report with the sequencing process. A summary of the entire 
presequencing process is illustrated in Figure 5.11 
 
 
 
 
5.6 PRESEQUENCING THROUGHPUT 
 While the laboratory steps of presequencing have been outlined in detail in this chapter, 
the sample throughput in the context of a commercialized setting have not been discussed. For 
the scope of this project, it is important to examine the time and labor requirements of the 
presequencing processing to see if the proposed design above can actually be executed. This 
section aims to outline the overall timeframe of the presequencing steps and show that, with a 
few adjustments, the presequencing process in this step is feasible for use in the context of 
Micro$eq’s product output.  
 
 
Amplification
Droplet Splitting
Parent 
Droplet 
Generation
Sequencing
Daughter 
Droplets
Figure 5.11 Presequencing Process Flow Diagram 
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5.6.1. Parallel Sample Processing 
While it has not been discussed, it is important to note that the entire presequencing 
process as described above will be performed simultaneously on multiple different samples. The 
initial Magtration purification machine can process 12 samples in parallel, thus this will be the 
base throughput number per process completion (integer multiplications of this base throughput 
number will be completed based on the financial analysis of throughput numbers, as discussed in 
Chapters 8 and 9 of this report). The steps that take place in solution will be performed 
simultaneously for all 12 samples. The steps that take place on the microfluidic platform will 
take place in 12 parallel channels on the microfluidic chips. The initial streams of droplets will 
be generated from 12 different droplet generators (1 per sample), which will feed into the 12 
identical parallel microfluidic processes described. The number of parent droplets being 
processed per each sample is 3.6 x108. At a flow rate of 1x106 droplets per second (the fluid 
dynamics of which will be discussed in Chapter 6 of this report), it will take 360 seconds to 
generate all droplets from one customer sample. The 6 hours required to generate droplets is 
impractical for the overall efficiency of the process, thus each sample will be split into 10 
sections, and will be processed on the microfluidic chip in 10 parellel process, for a total of 120 
parallel processes on each chip for each base set of 12 samples. 
5.6.2 Presequencing Timeline 
 For each step in the above outlined process, an estimated execution time was given. A 
summary of this basic timeline for the presequencing preparation of 12 samples simultaneously 
is summarized below in Table 5.2. 
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Step Time (min) 
Magtration Purification 30 
DNA Shearing 1 12 
Qiagen Purification 1 5 
A-tail Addition 1 30 
Adaptor Ligation 1 80 
Exonucelosis 45 
Restriction Enzyme Digestion 45 
Qiagen Purification 2 5 
A-tail Addition 2 30 
Adaptor Ligation 2 80 
DNA Shearing 2 10 
Amplification 1 45 
Droplet Generation 1 10 
Amplification 2 200 
Droplet Generation 2/Splitting 25 
Total 652 ( 10.9hrs) 
Table 5.2Summary of basic timeline for the presequencing preparation 
As each batch of 12 samples takes a total of 10.9 hours (assumed to be one full day, as 
the ligation step is incubated overnight), this base process can be performed over the course of 
one full work day (with two shifts of workers). This timeline is as ideal as, while not necessarily 
required, the optimal treatment of the input sample in the Oragene-Saliva (Genotek) kit is an 
overnight incubation at 50ºC before sample processing (Chemagen, 2011). This allows the 
sample to be received at any point on day 1, incubated overnight, and the complete 
presequencing process will be completed at the end of day two. 
While ideally this process would lead directly into the sequencing step, which could be 
performed overnight, it is important to note that the presequencing process has the flexibility to 
be able to pause overnight. The products of the Amplification 2 step may be stored, in their 
suspension in the original 10ml tubes used for amplification overnight at 4ºC.    
It is important to note that, while manual-labor intensive, this base presequencing process 
for 12 samples may be feasibly completed by a two lab technicians (1 for each shift). In fact, it is 
feasible for a lab technician to complete two complete base processes (24 total samples) in one 
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day, if the two processes are staggered by 3.5 hours as to avoid any machine overlap. Therefore, 
the true base presequencing process is 24 replicates for each set of workers. Any integer increase 
in this base throughput number will require an equal integer increase of all required machines 
and personnel.  
 
5.7 PRESEQUENCING PROCESSING SUMMARY 
This presequencing process achieves the requirements imposed upon it by the later stages 
of the project. From the input of patient DNA, this process generates the required 3.6x108 1nL 
parent droplets, which are split into the 505 daughter droplets at a DNA concentration of 14nM 
to be merged with the 6mer library droplets and continue on with the sequencing process.  
A huge benefit of the above described process is that a very minimal amount of input 
DNA is required. As discussed earlier in this section, the amount of DNA provided by the 
customer sample is significantly greater than the amount required for the process. This allows a 
wide range of customer samples (i.e. amount of saliva, density of cells in saliva) that will all be 
able to process in the same manner.  
Additionally, this approach to sequencing allows the generation and amplification of 
22bp fragments in droplet form– a nearly impossible task to accomplish without this type of 
protocol. The unique scanning and reassembly methods that will be described in the following 
chapters require these small fragments. All other companies that use small fragment (<40bp) for 
sequencing assembly do so by immobilization of the fragments.  This immobilization not only 
drastically increase the cost of processing, as microfluidic chips are required to anneal the 
fragments and must be disposed of after each use, but also significantly increase the throughput 
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time of the process, as scanning must be done in batch rather than continuous process. The 
ability to amplify small fragments in droplet form allows a continuous process both pre and 
during sequencing which severely decreases the cost and throughput time of both steps.  
An final benefit of this process is that it allows the simultaneous preparation of several 
samples, which minimizes throughput time as well as required lab personnel. Additionally, the 
entire presequencing process can be accomplished in under a day, which is competitive with any 
other presequencing processes described by competing companies.  
Overall, the above described process meets the requirements of this particular project 
design, as well as avoids some of the hindrances found in alternative processes 
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CHAPTER 6  
 
Sequencing 
 
6.1 INTRODUCTION 
 Micro$eq’s sequencing approach involves merging an oligos library of 6-mers with 
fragments of patient DNA, denaturing and annealing the fragments, and scanning fluorescence 
hybridization.  An offchip, macroscale process has been designed to both denature and 
continuously anneal the probing fragments (the oligomers) with target DNA by using a gradient 
block.  Using fluorescent dyes, a barcoding scheme has been developed to both keep track of 
which oligomers are in each drop, but also sense hybridization.  Finally, Micro$eq’s scanning 
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approach is discussed, which uses a back-thinned CCD image sensor and fancy microfluidics to 
achieve the desired scanning throughput of 106 droplets per second.     
 
6.2 DENATURIZATION AND ANNEALING 
The downstream process begins following droplet merging.  Daughter droplets with 
double stranded fragments of the patient’s DNA are merged with droplets containing the oligos 
library.  In order to sequence the fragments in each drop, the combination of 6-mers that bind the 
fragments of patient DNA must be determined.  In order for hybridization to occur, fragments of 
the patient’s DNA must be denatured or unwound to allow the oligos library fragments to 
hydrogen bond with the single stranded DNA.  Following denaturation, the strands are allowed 
to continuously.  Fragments from the oligos library that bind emit a fluorescence signal when 
hybridized which can be detected by scanning.  A figure depicting the downstream process is 
shown in Figure 6.1.  
 
 
 
Figure 6.1 The Downstream Process.  The downstream process follows droplet merging.  Following merging, droplets are 
heated to denature fragments of the patient’s DNA. The temperature is then decreased to allow for rehybridization.  Oligos 
library are tagged with fluorophores which can be scanned to sequence the fragments in each daughter drop. 
Droplet Merging 
with Oligos Library Denaturization Rehybridization Droplet Scanning
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Nucleic acid thermodynamics dictate how temperature affects nucleic acid structure.  As 
defined previously, the melting temperature of double stranded DNA is defined as the 
temperature at which half of the DNA strands are in double-helical state and half are in the 
random coil state (SantaLucia J. , 1998).  Thermodynamic calculations were completed (section 
4.3.1.1) in order to determine the melting temperature of the 6-mers taking into account the 
concentration of DNA and number of base pairs in each fragment.  These calculations 
demonstrate that in order to denature the oligos library as well as fragments of the patient’s 
DNA, a temperature of 95⁰C must be reached. 
An offchip, macrosized process was designed to gradually denature and anneal the DNA 
in each drop (Figure 6.2).  Sets of droplets enter the system in plugs separated by air pockets.  
These sets of droplets are the combination of an amplified fragment of patient DNA from many 
daughter drops and all 4,064 oligos.  The droplets enter the system in plugs and their 
temperatures are increased to the desired temperature to denature the DNA and cooled at a rate 
of 1 ⁰C/sec for continuous anneal. Based on this heating rate and expected scanning throughput 
of 1 million drops per second, the cold side of the gradient block responsible for decreasing the 
temperature was sized: 
 
                    ℎ          ℎ                   ℎ                =           ℎ    ℎ   ∗                          Equation 6.6.1  
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Figure 6.2 Gradual Denaturization and Annealing Process.  An offchip, macroscale process was designed to ‘house’ 120 
million droplets and to give a droplet residence time of 120 seconds.  As droplets move down the length of the gradient block 
their temperature is increased at a rate of 1 ⁰C/min.  The droplets move down a capillary tube made of Teflon that is 1 mm wide.   
 
The residence time in each plug can be determined by the cooling rate and the 
temperature difference between the initial temperature and the final temperature. Thus the 
number of droplets housed on the host side of the gradient block equals: 
= 1 ∗ 10            ∗ 95  − 25  1     = 70              
 The merged droplets are 5 pL each.  Thus, the total volume occupied by 70 million drops 
is: 
= 70 ∗ 10 ∗ 5  ∗   10     = 0.00035 ∗  1  1000  ∗  1000     = 350    
Assuming a standard sized Teflon tube with a diameter of 1 mm and that the air bubles 
take up an equal volume as the droplets in the pipe, a 22.3 cm Teflon pipe is required.  The red 
portion of the block in Figure 6.2 is used to ramp the temperature up to denature the fragments 
while the other half is used to cool the drops back down to room temperature and continuously 
anneal the fragments. The latter process allows oligomers to bind to the target fragment if the 
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complementary sequence is present.  If this is the case, the oligomer fluoresces.  The cooling 
temperature region ‘houses’ 70 million drops and the total residence time for the system is 
roughly 70 seconds.  The gradient block is heated on one end electrically.  The heat exchange 
across the tube is assumed to not be limiting.  The gradient block used to heat the samples is 
separated from the gradient block used to cool the samples.  This system would be manually 
built using Teflon tape and an electrically powered heating block or heated oil reservoir 
 
6.3 SENSING HYBRIDIZATION 
 The sensing hybridization technique used in Micro$eq’s sequencing approach is based on 
fluorescence-quencher labeled nucleotide system (Section 4.3.2.1). Oligos libraries can be made 
to fit these specifications and quencher fluorophore systems can be purchases from biotech 
companies such as Integrated DNA Technologies (IDT) and Jena Biosciences. 
 Fluorescent 6-mers are packaged with their complementary quencher sequences in the 
oligos library droplets to suppress the signal in the absence of hybridization to the fragments of 
the patient’s DNA.  Once the 6-mers are denatured and continuously annealed with a patient 
fragment DNA, either the complementary fragment won’t exist and the strands will rehybridize 
and the hybridization fluorescence signal will be absent, or it will exist and if equal 
concentrations are present, half of the fluorophore will bind the patient fragment and the other 
half will bind the quencher (Figure 6.3).  The fluorophore will then emit a signal which will be 
detected.  It is important to note that all of the fluorophores in the oligos library are excited by 
same wavelength and emit in different channels.   
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Figure 6.3 Possible results of Denaturization Annealing Cycle:Fragments of patient DNA are combined with 
oligonucleotides from the oligos library.  The oligomer droplets do not give off a hybridization fluorescence because of the 
quencher emitter complementary pairing of the library.  When combined with the library and denatured and annealed, 
rehybridization may only yield a a signal if there exists a complementary strand to the fluorophore containing oligomer. 
Additionally, a random sampling of 6-mers was used to assess the stability and 
thermodynamics of the 6-base pair oligomers (Section 4.1.1) 
  
6.4 SCANNING APPROACH: AN OVERVIEW 
 We are at the point in the process in which the daughter droplets have been merged with 
the oligos library, denatured, and annealed.  It is now necessary to scan the droplets to detect 
which of the 4,064 possible six base pair oligomers hybridized with a parent sequence at a target 
rate of 106 droplets/sec. However, there are some difficulties associated with this 
implementation.  For one thing, the oligos library needs to be barcoded.  That is to say, a system 
needs to be designed in order to keep track of which oligomer or oligomers are in each drop and 
whether or not they have hybridized with a particular fragment of patient DNA.  Secondly, the 
Fluorescenct 
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droplets have to be scanned at a target rate of 106 droplets per second.  This encompasses the 
design challenge.  These constraints have lead to the design of an optical system that is beyond 
the state of the art.  That is to say, one cannot simply purchase the optical system.  Thus, the 
purpose of the following sections is to outline how we would build an optical system with 
available optoelectronics.  
 A roadmap of the scanning strategy is described below.  We decided to ‘barcode’ the 
oligos library using fluorophores.  The optical band width limits us to 7 distinct emissions signals 
from fluorescent dyes.  These emissions have to be read using a spectrometer.  In order to 
barcode the oligos library, combinatorial calculations show that it is necessary to have at least 10 
distinct fluorophores.  This can be achieved by multiplexing the emission signal.  Therefore, two 
intensities for each fluorophore were prescribed, thus giving us 12 distinct signals. 6-mers are 
tagged with fluorophores and combined them into a droplet.  The resulting distinct fluorescent 
signal barcodes the drop, while hybridization is measured by the intensity of the fluorescence for 
each fluorophore .  Fluorophore bifunctionality adds an additional constraint to the system: each 
signal must remain distinct given the fluctuation or noise associated with the process.  Signal to 
noise calculations were performed to make sure that the signals would remain distinct.  These 
calculations set the requirements on minimum concentration of fluorescent fluorophores needed 
to maintain a reasonable signal to noise.  Furthermore, the laser power required is 
correspondingly set.  That completes the first portion of the scanning system. 
In addition to engineering the fluorescent system, it was also necessary to delve into the 
theoretical fluid mechanics of droplet coalescence and break up.  This was necessary in order to 
determine how quickly droplets can flow by a scanner.  Given the desired throughput of 106 
droplets per second, it was necessary to array the droplets in order to scan the droplets using a 
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line scan CCD camera.  By having a line scan camera which can scan at a rate of about 2000 
frames per second, and aligning about 500 droplets onto the semipermeable electrode gated 
platform one can reach the desired throughput of 106 droplets/sec.  Finally, an overview of the 
optical system is given.  It is important to note that this optical system is beyond the state of the 
art and the purpose of the following sections is to outline how we would build an optical system 
with available photoelectronics.  
 
6.5 BARCODING SCHEME 
 The oligos library is barcoded using bifunctional fluorophores which are used to barcode 
the droplet and detect oligomer hybridization.  Multiple fluorescent, non-interacting 
oligonucleotides are placed in a drop.  The drop will emit a distinct signal and through curve 
fitting the individual fluorophore signals may be deconvoluted.  The intensity of the fluorophore 
signals can be used to determine whether the particular oligomer has hybridized or not.   
But how many distinct fluorophores are necessary to barcode 4,064 oligonucleotides?  
Consider a simpler problem of barcoding 32 oligomers using four fluorescent signals.   
Color 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 
R X    X  X  X        X   X   X      X 
B  X    X     X  X     X   X     X   X 
G   X     X    X   X    X     X   X  X 
Y    X      X    X  X      X   X   X X 
Table 6.1 Barcoding Scheme using fluorescent labeling of oligos library.  Combinatorics are used to package more oligomers 
per droplet and to create a larger number of distinct droplets.  The vertical lines in the table are used to border the contents of a 
drop.  32 oligomers can be packaged into 15 drops. 
Consider binding oligomer R1 to a red fluorescent tag.  When the droplet is scanned, an 
overall emission signal is read that corresponds exactly to the emission spectrum for the red 
fluorophore.  The intensity of the emission signal determines if oligomer R1 has hybridized with 
the target DNA.  Similarly, if only the blue channel shows up, then only oligomer B2 is present 
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in the droplet and its hybridization state can be determined by the intensity of its emission.  
However, this approach will only allow one to barcode as many oligomers as fluorophores.  It is 
not possible to have 4,064 distinct fluorophores due to the size of the detected band width.  
Instead, combinatorics is used to layer the system.  Multiple signals and fluorophores are 
combined into one droplet.  For example, if an overall emissions signal comprised of the sum of 
the red and blue emission signal is detected, then it means that oligomers R5 and B6 are present 
in the droplet.  The overall emissions signal can be deconvoluted to give its constituent spectra 
through curve fitting.  The intensity of the red fluorophore is associated with oligomer R5’s 
hybridization state, and the intensity of the blue fluorophore is associated with B6’s 
hybridization state.  Different combinations of two channels can be used to increase the number 
of barcodes (Table 6.1).  Similarly, three fluorophores and three oligonucleotides can be added to 
a drop as well as four.   One of the advantages of this barcoding scheme is that it decreases the 
number of drops required for the oligos library.   
Mathematically, the number of oligos that can be barcoded using four different 
fluorophores is a combinatorial problem.  The number of different signals that result by 
packaging one oligos tagged with one of four possible fluorophores is: 
  ( , ) =  !( −  )!  ! =  (4,1) = 4!3! ∗ 1! = 4 Equation 6.2  
 
Similarly, the number of different signals that result by packaging two oligos tagged with two 
different fluorophores out of a possible four fluorophores is: 
 (4,2) = 4!2! ∗ 2! = 6 
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Each signal is made of two different fluorescent oligomers, which allows one to package: 
 (4,2) ∗ 2 = 4!2! ∗ 2! ∗ 2 = 12 
different oligomers. 
The total number of distinct signals (or number of droplets) created by packaging one to four 
fluorophores into one droplet is: 
 
Correspondingly, the total number of oligos that can be packaged in 15 drops is: 
 
The total number of drops is really the sum of a binomial distribution: 
Number of drops =                                                                        .      
Number of oligos =      k                                                               .      
For an oligos library of 6-mers we need: 
4 = 4,096        
However, 32 of the oligomers are palindromes. 
Thus the total number of unique oligos that need to be packaged is 4,064.  It turns out, 
that a minimum of 10 fluorophores are required in order to barcode the oligos library.  
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  As mentioned previously, the optical band width limits us to seven distinct emissions 
signals from fluorescent dyes.  We decided to barcode our oligos library by multiplexing six 
different fluorophores.  Therefore, six different fluorophores were prepared in two different 
intensities.  However, since we used 12 fluorophores instead of the minimally required 10, it is 
possible to remove certain combinations that decrease the degree of multiplexing.  Consider 
using 8 of the 12 possible fluorophores to multiplex and 11 of the 12 possible fluorophores to 
multiplex.  The number of oligomers and droplets associated with this combination is: 
 
 
However, only 4064 oligomers need to be packaged.  Therefore, it is possible to remove certain 
combinations.  Consider removing two droplets from the oligos library that have 11 oligomers in 
each: 
 
 
Only 9 combinations of 11 fluorophrores are required.  This results in a decrease in the number 
of droplets by two. 
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6.6 COLOR CHANNELS  
The current approach is to use 6 color fluorophores at two different intensities to barcode 
the oligos library.  Each emitted signal is resolved by a spectrometer and the combination of dyes 
present in each microdroplet is resolved by curve fitting (Figure 6.4).   
These two intensities are generated by varying the concentration of fluorescently tagged 
oligomers.  As previously mentioned, the hybridization scheme implemented for the Micro$eq 
design is a quencher-fluorophore type system.  Thus for the lower intensity, there exists a case in 
which the oligomer does not bind the patient fragment DNA, and this is unhybridized case.  For 
the case in which the oligomer binds the patient fragment, this is called the hybridized. 
 
Figure 6.4 Resolving the Overall Emissions Signal: The overall emissions signal is resolved into its constituent emission 
signals using curve fitting. 
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The unhybridized state gives off a certain muffled signal which can be spectroscopically 
resolved.  The bound state gives off a different signal because fluorophore emissions are no 
longer as quenched by the complementary quencher because they can now bind the patient 
fragment DNA.  Similarly, at the higher intensity the bound and unbound state have their own 
distinct signals. (Figure 6.5).   
 
Figure 6.5 Relative Intensity of a single fluorophore presented in all its intensities:   The unhybridized state gives off a 
certain muffled signal which can be spectroscopically resolved.  The bound state gives off a different signal because fluorophore 
emissions are no longer as muffled by the complementary quencher because they can now bind the patient fragment DNA.  
Similarly, at the higher intensity the bound and unbound state have their own distinct signals.  Relative intensities are drawn to 
scale 
   The concentrations of fluorophore are adjusted such that the lower intensity in the 
unhybridized case has a relative intensity of 1, the lower intensity hybridized case has an 
intensity of 2, the higher intensity unhybridized case has a relative intensity of 4, and the higher 
intensity hybridized case has an intensity of 8.  This intensity scale can be created by adjusting 
the concentration of fluorophore and quencher in the oligonucleotides.  Combinations of a single 
fluorophore at both intensities in a single droplet lead to eight different intensities.  From a 
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design perspective, it is important to make sure that each signal is distinguishable, and that one 
signal may not be exchanged for another. 
 
6.7 SIGNAL TO NOISE 
Noise associated with the back end of the process can be attributed to deviations 
associated with photoelectron emissions and noise associated with the instrument.  At the front 
end of the process, noise fluctuations can be attributed to deviation in the number of 
fluorophores, i.e. deviation associated with the number of fluorophores per microdroplet.  
Noise is added in quadrature.  Thus for this process, the total noise associated with hybridization 
detection is:  
      =             +             +                                                   .   
where            is the standard deviation assoiciated with electron emission,             is the 
noise associated with the detection device, and               is fluctuation associated with the 
concentration of fluorophores. 
 Statistically speaking, the standard error associated with electron emission is simply the 
square root of the number of electrons.  For example, if on average 4000 electrons are emitted 
for the lower intensity unbound state, the standard deviation or noise associated with this signal 
is 40001/2 or 63 electrons.  As shown in Table 6.2, the number of electrons detected for each level 
is chosen so that emission spectra of the first and second level are separated by 4000 electrons.  
Typically, deviations from the mean emission value are evaluated half way in between the two 
adjacent spectra.  Thus, to spectroscopically resolve levels one and two, the amount of noise 
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emitted is compared to 2000 electrons, which is half of the number of electrons that separate the 
two levels.  Thus, the 63 electrons associated with noise are compared to the 2000 electrons that 
separate the spectra.  In this case, the design was configured so that these spectra are about 31 
standard deviations apart.  Higher intensity signals give off more noise.  Thus the noise 
associated 40,000 photoelectron detection was compared to the separating line between levels 
(2000 photoelectrons), and was found to be 10 standard deviations away.  Thus, based on the 
number electrons detected for the higher intensity, bound state this system is spectroscopically 
distinct and resolvable.  Table 6.7.1 also gives the fractional error associated with each level.  
The fractional error is a ratio of the deviation in the number of electrons to the total number of 
electrons: 
                = (          )                                                       .   
 
Level 1 2 3 4 5 6 7 8 9 10 
Electrons 4000 8000 12000 16000 20000 24000 28000 32000 36000 40000 
Fractional 
error 
.016 .011 .0091 .0079 .0071 .0065 .0060 .0056 .0052 .005 
Table 6.2 Error associated with barcoding scheme.  The fractional error associated with photoelectron detection of 
multiplexed fluorophores used to barcode the oligos library. 
A Hamamatsu, high-speed operation, back-thinned FFT-CCD was selected as the image 
sensor.  It has a quantum efficiency of of 90% or more at the peak and its pixel size is roughly 
the same dimensions as a 5 picoliter sized drop.  Its complete specs are given in the appendix.  A 
custom camera can be bought from Hammamatsu which is compatible with this chip. 
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To determine the fluctuation in signal associated with fluctuations in the concentration of 
fluorophores per droplet one first has to calculate the number of fluorophores at 1µM in a 5 pL 
droplet is: 
= 1 ∗ 10   ∗ 5 ∗ 10    ∗ 6.02 ∗ 10               = 3.01 ∗ 10           
  Error due to molecule fluctuation is simply the square root of the number of molecules.  In this 
case 
 3.01 ∗ 10 = 1734.94          
In order to get an error rate in terms of the total number of photoelectrons detected, first divide 
by total number of molecules  to get error fraction: 
1734.943.01 ∗ 10^6 = 0.000576 
Then, multiply by total number of photons emitted on average to get error associated with 
fluctuations in molecules.   
0.000576 ∗ 40000 = 23.04 
As far as instrument error, for this chip the error rate is 23 e- rms.   
The greatest signal noise is associated with the largest intensity.  The total error rate for a droplet 
which leads to the detection of 40000 photoelectrons is: 
      =  40000 + 23 + 23.04^2 =202.6               
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As mentioned in the subchapter titled channels, the total noise associated with a signal must be 
small enough relative to the distance between two distinct signals.  This “distance” was 
calculated to be 2000 photoelectrons.  In this case, the signals are about 10 standard deviations 
from their midline.  Thus, there is a very small error associated with this configuration.   
 
6.8 CALCULATING LASER POWER 
As previous calculations have shown, the required laser has to have enough power to 
emit 32,000 photons per microdroplet at the highest fluorescence concentration to maintain a 
reasonable signal to noise.  A spreadsheet has been prepared to calculate laser power based on a 
given concentration of fluorophores.  BODIPY dyes will be used as the fluorophores and 
monochromatic laser at 405 nm will be used for excitation.  The calculations are described 
below: 
Beer-Lambert’s law is defined as: 
 =                                                                           .   
where is ε is the molar absorbtivity or molar extinction coefficient with units of Lmol-
1cm-1, b is the path length of the sample and c is the concentration of the compound in the 
solution expressed in M.  A fluorophore absorbs the energy of a photon and emits a electron at a 
certain quantum efficiency ηquantum .  The quantum efficiency is the ratio of photoelectrons 
emitted to photons absorbed.  In addition to the quantum efficiency, there is a collector 
efficiency ηcollector associated with the instrument’s capacity to capture the emitted photons.  It is 
simply the ratio of the total photoelectrons emitted to the number of photoelectrons absorbed.  
The necessary power a laser must possess is also a function of the exposure time.  As one can 
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imagine, increasing the exposure time at a certain power increases the number of photoelectrons 
emitted.  For these calculations, an exposure time of 100 µsec was selected.  In addition, it is 
important to note that the absorbance of a given fluorophore varies as a function of wavelength.  
Particularly, the molar absorbtivity is given at the maximum absorption wavelength, therefore it 
is necessary to correct the molar absorbtivity to the wavelength of interest. This is done by taking 
the absorbance spectra and taking the ratio of the peak height at the wavelength of interest to the 
maximum peak height in the absorbance spectra (Figure 6.6).   This ratio of max absorbance, to 
the absorbance of interest is defined as ηmax/min . 
 
Figure 6.6: A sample absorbance spectra of BODIPY Dye D100001.  As can be seen, absorbance varies as a function of 
wavelength.  The excitation wavelength is 405 nm.The maximum absorbance is given by the absorbance of the largest peak. The 
absorbance of interest is given by the intersection of the lower horizontal line and the intensity axis.  A ratio of these two 
quantities allows one to calculate absorbance at the wavelength of interest 
 
The energy of a photon can be determined using the Planck relation:  
 = ℎ                                                                           .   
The question that has to be asked is what is the required laser power at a given 
concentration of fluorophores that would result in the emission of 32,000 photoelectrons.  Taking 
the required laser power and multiplying it by the exposure time gives the total amount of energy 
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the laser gives off.  However, not all of that energy is absorbed by the fluorophores.  To account 
for the various inefficiencies the quantum efficiency, the collector efficiency, and the ratio of the 
absorbance at the wavelength of interest to the wavelength  of the molar absorption coefficient is 
given at are multiplied.  This is multiplied by the molar absorbtivity, the path length, and the 
concentration of fluorophore.   
                    ∗   ∗      .     .∗               .∗        ∗  ∗  ∗                  .   
This gives the total amount of energy that is absorbed and reemitted by the fluorophores.   
This should equal the energy of the photoelectrons emitted multiplied by the number of 
photoelectrons emitted.  Solving for the required laser power: 
                     =   ,   ∗     ∗ ∗ ∗ ∗     .    .∗              .∗    /                   .    
The exposure time was chosen to be 100 µsec, the collector efficiency was chosen to be 
0.5, also the quantum efficiency was chosen to be 0.5.  5 pL sized droplets were used to calculate 
the path length.  The BODIPY dye spectra are shown below.  The BODIPY dyes used are: 
Emission Wavelength (nm) Cat. # E.C. 
511 D2183 91,000 
551 D2187 77,000 
591 D2228 136,000 
618 D6116 68,000 
640 D10000 101,000 
660 D10001 102,000 
Table 6.3  Emision wavelengths of dyes chosen to barcode the library. E.C. is the extinction coefficient otherwise known 
as the molar absorbtivity 
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The calculated laser powers required for each dye is given in table V.10.2 below 
Cat. # Required Laser Power per 
drop at 1 µM hybridized 
oligomer to DNA fragment, 
Higher Intensity [Watts] 
D2183 0.000493 
D2187 6.4*10-6 
D2228 1.09*10-5 
D6116 0.00178 
D10000 1.73*10-5 
D10001 7.4*10-6 
Table 6.4 Required laser power at higher concentration.  Using equation 6.10 the required laser power was calculated for the 
different BODIPY dyes used. 
To calculate the overall laser power required the required laser power per drop is 
multiplied by 1000.  This is to account for the fact that there are 505 arrayed droplets onto the 
microfluidic platform which are separated by their diameter to avoid cross fluorescence.  It is 
important to note that for a given laser power, the strength of fluorescence emissions will be 
different for different dyes.  That is to say that certain dyes are not as efficient as others.  This 
can be easily seen in the table Table 6.4.  To get a fluorescence emission spectra like the one 
shown in Figure 6.7 below, the concentration of the more active dyes will be decreased.  The 
reason this is done is to prevent a very bright dye from “shadowing” a relatively dark dye.  It 
might completely drown out the signal of the adjacent dye and these differing spectra would be 
indistinguishable.   
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Figure 6.7: Emission spectra of BODIPY dyes.  Normalized fluorescence emission spectra of 1)BODIPY FL, 2) BODIPY RG6, 
3) BODIPY TMR, 4)BODIPY 581/591, 5)BODIPY TR, 6)BODIPY 630/650 and 7) BODIPY 650/665 fluorophores in methanol. 
However, it is still possible to weed out large differences in deviations of intensities by 
curve fitting.  Further investigations would relate the difference in relative intensities of different 
color channels to some critical relative intensity in which some color channels would be lost.  
It is important to note that 32 of the oligonucleotides are palindromes.  This means that 
they read the same forward as backwards.  Thus both the forward and reverse sequence are 
automatically placed in a drop where they compete for sites and the output signal differs from the 
expectations for the scanner.  It is possible to deal this by putting in a higher fluorescent 
oligonucleotide concentration in order to match the expected fluorescence.  Once the fluorophore 
concentration is determined, the corresponding laser power required at this concentration for a 
given exposure must be determined. 
 
6.9 SCANNING APPROACH: AN OVERVIEW 
Once the oligos library is merged with fragments of the patient’s DNA, it is denatured 
and rehybridized to canonical Watson-crick base pair the library with the patient DNA.  The 
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hybridization scheme allows the user to sense hybridization through fluorescence.   The 
hybridized plugs of 505 drops are then sent through a microfluidic apparatus to line them up to a 
line scanning CCD.  The scanning approach a shines monochromatic laser onto all 505 
microdroplets and the emission is collected and relayed to the bioinformatic portion of the 
process.  The heart of the design is that large numbers of molecules are used and signal to noise 
because noncritical.  This allows one to use a high speed camera and to have increased design 
control and throughput. 
The difficulty associated with this design is achieving the target throughput of 106 
droplets/sec.  The high speed CCD chip chosen has a scanning rate of 1777 frames/second 
(Hamamatsu, 2011).  By arraying 505 droplets for a line scanner, the throughput can be increases 
to about 106 droplets per second.  Achieving the droplet configuration requires a fluid mechanics 
consideration to line up the droplets.  
 
6.10 THEORETICAL AND NUMERICAL INVESTIGATIONS OF 
DROPLET BREAK UP AND COALESCENSE  
Droplet breakup in flow is the result of the competition of viscous stresses associated 
with the imposed flow field, and capillary stresses due to surface tension between two phases.   
Consider an arbitrary drop of size D, in a matrix fluid of viscosity µ undergoing flow with 
characteristic magnitude G of the local velocity gradient, and with surface tension σ.  It is 
important to note that viscous stresses scale and µG and capillary stresses scale as σ/D.  
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The relevant dimensionless number characterizing this flow is the capillary number: 
  = µ ∗  ∗                                                              .    
which is the ratio of viscous-to-capillary stresses.  Viscous stresses deform the droplet and 
breakup may occur.  Higher flow rates demand smaller droplet sizes or droplet break up will 
occur. 
The expression above can be further simplified.  The velocity gradient in a micro channel 
of hydraulic diameter~ Di and flow rate QO can be estimated as G~QO/Di3 .  This gives a simple 
relationship between generated droplet size and imposed flow rate: 
 ~ ∗    µ ∗                                                                        .    
The larger the flow rate, the smaller the droplet size.  Droplets are stable once they are formed, 
so this also provides the criteria for droplet stability. 
As shown in the Figure 6.8, a larger flow rate associated with the oil phase leads to 
smaller ratios of droplet diameters to channel diameter. 
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Figure 6.8:Two different is scalings are shown for droplet generation. D/Di is the ratio of droplet diameter to the width of the 
orifice.  Q0 with units of µl/min is the flow rate of the oil phase.  The flow rate of the water phase is 0.5 µl/min. Larger oil 
flowrates lead to smaller ratios of droplet diameter to width of the orifice. Figure adapted from (Tan, 2004) 
  
For Micro$eq’s applications, droplet volumes are typically are on the order of 5-25 pL, 
while the well radius is on the same order as the diameter of the well (Figure 2.3).  Based on the 
portrayed chip technology, a D/Di of one is assumed.  For 5 pL droplets, the number of droplets 
per second that can be flowed: 
. 5µ    ∗ 1000000   1 µ ∗ 1   60   ∗     5   = 1666.67        /    
For a water liquid phase, σ=10^-3N/m, µ=30*10^-3 kg/ms.  Assume the diameter of the 
well can be made to be: 
5   ∗ 1 10    ∗   1000   = 43 ∗  ∗    
R=.00001061 m so D=.00002122 m. 
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 ~ ∗    µ ∗    
Using the critical capillary number this equation gives flow rates at which droplets become 
unstable. 
Assuming a QO of 12µL/min: 
 ~ 10    ∗. (. 00002122 ) 30 ∗ 10     ∗    ∗ 12µ    ∗  10  µ ∗ 1  1000 ∗ 1   60   = 1.59252 ∗ 10    
That volume of microdroplet would be: 
= 43 ∗  ∗   =  43 ∗  ∗  1.59252 ∗ 10  2   = 2.11472 ∗ 10      
2.11472 ∗ 10     ∗ 1000    ∗ 10    1 = .002105    
Calculating number of drops /sec assuming well is a cylinder: 
        = 2 ∗ 10        ∗ 3.14 ∗ (. 00001061 m) = 0.5655 /    
Diameter of droplet~1.59252*10^-6 m 
           = 0.5655 /   1.59252 ∗ 10   = 3.6 ∗ 10         /    
An excel spreadsheet was prepared using these principles and further designs downstreams such 
as the tree root design where validated by the underlying fluid mechanics. 
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6.11 MICROFLUIDICS 
Stage-two microfluidics are tasked with lining up 505 droplets for the S11071 series high 
speed CCD line scan camera.  When considering a design, theoretical and numerical 
investigations of droplet breakup and coalescence must be considered.  Principally droplet 
breakup is determined by the relevant dimensionless number-the capillary number.  As 
mentioned earlier, the capillary number is the ratio of viscous stresses associated with the 
imposed flow field, and capillary stresses due to surface tension between two phases.  At higher 
flow rates, only droplets of smaller radius are stable.   
6.11.1 Preprocessing 
Heading into microfluidic device 2 is a microdroplet array separated from the previous 
array by a sheet of air.  Because the fluid mechanics in the downstream process dictate bubble 
breakup, a preprocessing system was designed. Preprocessing removes the air pockets by 
applying a correctly timed vacuum and injects oil to add increased distance between two arrays 
and to give the scanner increased time between scans (Figure 6.9).  The exposure time for the 
arrayed microdroplets was chosen to be 100 µsecs.  Based on the velocity of the fluid through 
the 1.80 cm tube, the amount of injected oil was calculated to be 0.007 µL.   
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Figure 6.9: Preprocessing system.  Time lapsed display of preprocessing system.  Air pockets are removed from the flowing 
fluid and oil is injected to separate out different arrays of 505 droplets.  
 
6.11.2 Droplet Setup before Electrode Gated Scaffold 
Heading into microfluidic device 2 is a microdroplet array separated from the previous 
array by a sheet of air (Figure 6.10).  Preprocessing removes the air pockets by applying a 
correctly timed vacuum and injects oil to add increased distance between two arrays. 
 
Figure 6.10: Microdroplet array-heading into the tree root design is a “package” of 505 droplets in a row 
In order to array the droplets onto a platform for the high speed CCD line scan camera an 
innovative method of lining up the droplets must be employed.  One way to do that would be by 
employing a tree-root type design to evenly distribute the droplets and then to array the droplets 
onto a permeable platform. (Figure 6.11).   
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Figure 6.11 Tree Root System: The tree root system is used to evenly distribute the array of 505 droplet across the electrode 
gated permeable scaffold used to line up the droplet for the line scan camera. 
The stem of the tree root is 1.8 cm in diameter with an oil flow rate of 35 µL/sec.  The 
droplets are sent down the tree root system and are further subdivided until there exist 16 
channels with on average 32 droplets.  Bifurcations alter the bell curve type distributions heading 
out by eliminating cross over.  Another way to say it is that bifurcations partition the probability 
distributions.  Heading out the tree root system is a droplet’s probability of landing vs. axial 
position centering the exit tube (Figure 6.12). 
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Figure 6.12 Bell curve depicting probability of a drop landing vs. axial position with respect to the exit tube. 
It is important to note that similar microfluidics have been constructed before (Figure 
6.13), these validating the feasibility of this design. 
 
Figure 6.13 Microfluidic apparatus which uses a similar tree root type design.  This apparatus validates the feasibility of the 
design. (Ethan Schonbrun, 2011) 
The exit channels are 1.1 mm wide and microfluidic calculations considering the viscous 
stresses associated with the imposed flow field and the capillary stresses due to surface tension 
between the two phases have determined that 5pL sized droplets are stable in these flows.  The 
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droplets flow of a rate of 62500 droplets per second and considering that there are 16 channels, 
the total droplet flow rate is 1*10^6 droplets per second.  
6.11.3 Permeable Electrode Gated Barrier 
 Two difficulties exist in lining up 505 droplets for the S11071 series high speed CCD line 
scan camera using the droplets exiting the tree root system: the droplets exit with a probability 
distribution of landing which must be perturbed and the droplets must be arrayed for a certain 
period of time and then released.  
These challenges can be resolved by employing a permeable electrode gated barrier 
(Figure 6.14).  On average 32 droplets will exit each root and will be deposited onto a permeable 
electrode gated barrier that is inclined.  The electrodes are turned on and droplets disperse 
themselves across the surface.  Cross flow is added to eliminate stacking of the droplets.  Once 
the droplets are imaged the electrode voltages are removed and the droplets are washed away by 
the cross flow.   
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Figure 6.14 Permeable, electrode gated barrier.  This permeable, electrode gate barrier is used to array microdroplets onto a 
straight line.  Cross flow is used to skew the exit probability distributions. 
It is important to note that there are complicated fluid mechanics problems associated 
with this design.  Potentially, this design has the right throughput but this is a nonconventional 
implementation compared to published fluid mechanics.  Therefore, there needs to be an at scale 
demonstration verifying the feasibility of this design  and more information need to be collected 
and tests need to be made-to see state of the art.  
 
6.12 OPTICS 
Below is a depiction of the optical setup for sensing fluorescence hybridization for the 
Micro$eq platform (Figure 6.15).  Microdroplets are lined up in an array for imaging and are 
shined with a laser at 405 nm for 100 µsec.  Photons emitted from the sample are collected and 
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shined onto a prism.  The prism refracts light into a 1.325 mm rainbow.  The image is 
deconvoluted by curve fitting and the barcode is identified and hybridization is detected based on 
the output.   
 
Figure 6.15 Optical System: The optoelectronics of this system consist of the laser, a prism, and two lenses. 
 
It is important to note that for any optical setup magnification must be larger than 1.  In 
the design above the magnification is one.  Both lenses are the same size.  However since the 
scanning area is about 1.8 cm wide, relatively large optical devices must be sought which are 
typically found in optical microlithography field. 
  A dimensionless number that characterizes optical lenses is the numerical aperture.  
Numerical aperture (NA) is defined as : 
  =  ∗ sin( )                                                                 .    
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Where n is the index of refraction and θ is the half-angle of the maximum cone of light that can 
enter or exit the lens.  For air, n=1. 
 
6.13 SEQUENCING THROUGHPUT 
 Based on scanning rate of the CCD line scan camera and the number of droplets arrayed 
onto the electrode gated platform, the droplets per second that can be scanned is: 
1777         ∗ 505              = 897385         /    
The number of parent drops determined by assembly optimization is 3.63*108 (Section 7.4).  
Each of the DNA fragments in the parent drops are amplified and the droplet is split into 505 
drops.  These 505 droplet are then merged with the 505 droplets that make up the oligos library 
giving the total number of daughter droplets.  In general, the total number of daughter droplets is: 
              ℎ         =                       ∗                                                 .   
  Thus the total number of drops to scanned per human genome is: 
3.63 ∗ 10 ∗ 505 = 1.83 ∗ 10        
The total scanning time is thus: 
1.83 ∗ 10       897385         sec = 204277            56.7 ℎ     
The number of stations required to sequence one genome per day is: 
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56.7 ℎ  24 ℎ  = 2.36          
6.14  SEQUENCING CONCLUSIONS 
A bifunctional barcoding system was created to keep track of which oligos are in each 
drop and whether or not they are hybridized.  The key to barcoding is multiplexing fluorescent 
oligomers.  Adding more than one fluorophore per drop allows one make a larger number of 
distinct signal to be detected by a spectrometer. 
The target scanning throughput of 106 droplets/sec was achieved by using a high speed 
CCD image sensor with a scanning rate of 1777 frames/second (Hamamatsu, 2011).  By arraying 
505 droplets for a line scanner, the throughput can be increases to about 106 droplets per second.  
Achieving the droplet configuration requires a fluid mechanics consideration to line up the 
droplets.  It is important to note that this is a custom made design and that it is beyond the state 
of the art.  Further investigations are required into the fluid mechanics of the microfluidic design, 
particularly the tree root design and a real time chip with this configuration must be tested. 
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CHAPTER 7  
 
Genome Assembly 
 
Previously, genome sequencing strategy is discussed. The process of sequencing begins 
by physically breaking DNA into many random fragments. The small fragments are then read 
and passed on to the next step—genome assembly. Genome assembly, a fundamental area of 
bioinformatics, is essential to personal genome sequencing because it reconstructs the original 
sequence from many small fragments. Without this step, the output from DNA sequencing has 
little meanings. With microfluidic approach to DNA sequencing, genome assembly scheme for 
Micro$eq is customized to accommodate unique raw sequencing data.  
 In this chapter, two main assembling strategies which are implemented in series are 
discussed—de Bruijn graph assembly and shotgun sequencing. Raw sequencing data for 
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Micro$eq is a set of 6-mer oligos which bind to the fragments inserted into the droplets. These 
bound oligos are assembled to generate secondary reads via de Bruijn graph assembly. The 
average length of secondary reads is identical to that of original fragments inserted into 
microdroplets. Secondary reads are then used as input in shotgun sequencing to generate contigs 
which are contiguous sequence of original genome. The number of contigs depends on 
acceptable error rate, which is specified at 10 in a million in Micro$eq proposal. 
 With an ultimate goal to minimize number of drops required to regenerate original 
genome at an acceptable error rate, number of fragments per drop, fragment length, and required 
coverage are optimized. In this chapter, each variable is studied separately prior to optimization 
step to thoroughly understand relationship among assembling variables. Finally, specified 
sequencing requirements are used to estimate assembling time and computational demand. 
 
7.1 SIMULATION OVERVIEW 
Due to particularly short reads generated during 
sequencing process, Micro$eq developed a strategy to 
accommodate unique type of assembling input. The 
simulation of genome assembly was conducted in 
MATLAB with randomized original genome sequence. 
The goal of the simulation is to find the optimal values 
of fragments per droplet, estimated fragment length and 
required coverage for a given set of oligo library. These 
variables are optimized to minimize number of drops 
Figure 7.1 Overall Assembly Scheme The raw 
sequencing data is translated to only those which 
bind to the fragments within a droplet. De Bruijn 
graph approach reconstructs the initial reads (length 
= kmers) into elongated secondary reads (length ≈ 
nBp = fragment length). Shotgun sequencing is 
applied as the secondary assembly scheme to 
construct contiguous sequences for specified error 
rate. 
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required in sequencing process.  
 Micro$eq assembly algorithm integrates Eulerian path approach and shotgun sequencing. 
The initial reads from oligo library (k-mers) are aligned using de Brujin graph to generate 
secondary reads. The secondary reads must have sufficient length so that the contigs generated 
from shotgun sequencing algorithm is feasible at acceptable error rate (Figure 7.1).  
 For future ease of reference, assembling variables and their definition are clarified: 
kmers    – number of base pairs in each set of oligo library 
nFrag                         –  2 x number of doubled strand DNA fragments within a droplet. 
The doubled strand DNA are comprised of 2 strands which are 
both analyzed via assembly algorithm 
nBp    –  estimated number of base pairs within one fragment 
Initial reads   –  sets of oligo library which bind to portion of any fragments 
Secondary reads  –  assembled initial reads, using de Bruijn graph approach 
Contigs   –  assembled secondary reads, using shotgun sequencing 
Efficiency (Eff) –  (number of independent outputs) ÷ nFrag 
Throughput (Th)  –  number of bases assembled per drop  
            (nFrag x nBp) x Eff    
 
As discussed in previous chapter, the output from sequencing process is a binary 
indicator whether a given oligo library binds with original genome sequence. Due to a limitation 
on barcoding scheme, the length of each oligo library is proposed to be 6 base pairs. With four 
possible types of bases—A, T, C and G, 46 - 32= 4064 sets of oligo library exist [See 3.3.2.1]. 
Since the output is binary, if the indicator shows that a particular set of bases binds with the 
original sequence, it is undetermined whether the set binds once or more than once. In other 
words, the information on repeats is not captured in Micro$eq’s sequencing scheme. Thus, the 
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initial reads are derived from the oligos which bind to the inserted fragments. These initial reads 
are the building blocks of final assembled genome product. 
 
7.2 DE BRUIJN GRAPH ASSEMBLY 
7.2.1 de Bruijn Graph Overview 
 Eulerian Path approach utilizes the concept of de Bruijn graph. A de Bruijn graph is a 
direct graph that represents sequence of symbols and the edge of the graph indicate where the 
sequence may overlap. DNA fragment is present in smaller pieces (kmers). De Bruijn graph is 
constructed where the nodes for the graph represent the kmers and the paths in the graph 
represent connection and relationship between two nodes. The two kmers nodes are connected 
when their (kmers-1) bases are identical (Figure 2.6). The structure of de Bruijn graph is suitable 
to demonstrate the overlaps between kmers (Abegunde, 2010).  
 To find a path in a de Bruijn graph, each node must be visited as least once. Therefore, 
high redundancy challenge is handled by the graph without an increase in number of nodes. One 
of the Eulerian path’s advantages is its ability to accommodate sequences with very different 
lengths. Because of one-to-one relationship between each node, overlapping sequences have to 
follow the same path. On the other hand, the disadvantages of Eulerian Path approach are 
physical memory requirement. De Bruijn has heavy structure which requires considerable 
amount of physical memory. However, it was proven that the requirement can be distributed on a 
cluster of small commodity computers (Zerbino, 2009). In addition, since the arches of the graph 
are determined based on overlapping kmers-1 bases, false sequences can be generated.  
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 Generally, kmers used are between 21-25 bp in length (Zerbino, 2009).  Smaller k-mers 
increase connectivity, and thus increasing number of overlaps between each node. As length of 
kmers increases, the chance of overlapping between each node decreases because the two nodes 
are connected only when (kmers-1) bases are overlapped. As length of kmers decreases, the 
probability of accidental overlaps increases. Length of kmers is a critical value which results in a 
tradeoff between sensitivity and specificity.  
 Some of the existing assembler tools have been developed to address assembly problem 
based on this approach; for example, Euler and Euler-SR (Abegunde, 2010). 
7.2.2 Micro$eq Application of de Bruijn Graph Assembly 
Eulerian Path approach is suitable for shorter reads. The length of reads acquired from 
sequencing process is equal to the length of oligo library, kmers, which was proposed to be 6 
base pairs. The ultimate goal of Eulerian Path approach for Micro$eq is to assemble initial reads 
to secondary reads. There are two variables that can be adjusted to maximize assembling 
throughput per droplet: number of fragment per drop (nFrag) and fragment length (nBp). 
7.2.2.1 de Bruijn Graph Interpretation  
Three main steps are to convert raw sequencing data to secondary reads (Figure 7.2): 
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Figure 7.2 Micro$eq’s Eulerian Path Approach This part of the strategy is comprised of three steps – (I) Derivation of Initial 
Reads, (II) de Bruijn Graph Construction, and (III) de Bruijn Graph Interpretration. The goal of Eulerian Path Approach is to 
reassemble Initial Reads to Secondary Reads which will be used as an input for the following shotgun sequencing assembly 
algorithm 
Step I: Derivation of Initial Reads 
 Raw sequencing set of information is comprised of a binary indication whether each 
oligo binds with genome fragments (Figure 7.2: last column of Oligo Library (k-mers) matrix: 1 
indicates that the oligo and 0 indicates that oligo does not bind with genome fragment(s)). If the 
oligos are indicated to bind with genome fragments, they can be classified as Initial Reads. 
However, since the indication is binary, number of repeats cannot be determined. Initial Reads 
are crucial to Micro$eq’s assembly process since they are the basic building blocks of a complete 
genome sequence. 
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Step II: de Bruijn Graph Construction 
 Initial Reads derived from raw sequencing data are used to construct de Bruijn Graph. 
Each initial read is presented as a node with k-mers bp in length. The node can be directionally 
connected if (kmers – 1) bases overlap (Figure 7.2: top right region: it can be observed that initial 
read #3 is connected to initial read #4 because the last (kmers -1) bases of #3 are identical to the 
first (kmers – 1) bases of #4).  
Step III: de Bruijn Graph Interpretation 
 de Bruijn graph interpretation yields set(s) of secondary reads for each droplet. The 
interpretation of de Bruijn graph is challenging due to algorithm applied to connect any two 
initial reads. Since the (kmers – 1) overlapping bases are used as criteria to connect two nodes, it 
is possible that the connection is incorrect, However, the correct connection is always presented 
among alternatives. The challenge of repeats further complicates the reassembling process. Since 
it is possible that the initial read is presented more than once in the genome sequence, additional 
connections cannot be eliminated. 
 The reassembling process from de Bruijn graph is memory intensive. With more than one 
probable path to connect the graph, all possibilities are generated. The set of assembled reads 
which do not include all of presented initial reads are incorrect and can be removed. This is 
because initial reads are those which bind to the genome fragments. None of them should be left 
out when secondary reads are assembled.  
 To reduce memory required in assembly process, three main strategic algorithms are 
introduced so that incorrect connections are eliminated during the time of secondary read 
generation.  
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Figure 7.3 Three Strategic Algorithms in de Bruijn Graph Reassembly Figure 7.3.a – Eliminate paths which exclude at least 
one initial read. Figure 7.3.b – Eliminate paths which create infinite loop. Figure 7.3.c Eliminate self-connecting paths. 
1) Eliminate paths which exclude at least one initial read. To illustrate, in Figure 7.3.a, since 
node #3 must be included as part of secondary read, the path chosen is node 1 – 3 – 2. 
Without this algorithm, two possible paths exist, (1 – 3 – 2) and (1 – 2).  
2) Eliminate paths which create infinite loop. Since human genome is not circular, the path 
which allows infinite secondary read interpretation is eliminated. For example, in Figure 
7.3.b, the path from NODE 1 to NODE 2 is eliminated. The secondary read derived from 
this case would be (5 – 3 – 2 – 4 – 1). It is possible that the fragment is comprised of 
repeated initial read (5 – 3 – 2 – 4 – 1 – 2 or 5 – 3 – 2 – 4 – 1 – 2 – 4, etc.). However, it 
cannot be determined because indication of initial read presence is binary. The shortest 
fragment assembled is always guaranteed to be present in the original fragment; thus, 
introducing no additional error to the process. The disadvantage of this strategy is that it 
potentially decreases the length of interpreted secondary reads, which results in an 
increase in required coverage.  
3) Eliminate self-connecting paths. From Figure 7.3.c, it can be observed that 
kmer-1 bases of NODE 3 overlap with itself. However, since information on number of 
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repeats of initial reads is not available, the self-connecting path is eliminated. This 
algorithm can lead to severe errors in assembling interpretation. From this elimination 
strategy, the sequence is interpreted as “T A A A A A A G”; however it is possible that 
more than 6 bases of ‘A’ exist in this fragment. This example clearly demonstrates the 
well known challenge in genome assembly – repeat. However, in the scope of our study, 
the possible repeat problems are out of scope and the error rate associated with this case 
is assumed to be negligible.  
 
Figure 7.4 Acceptable de Bruijn Graphs Figure 7.4.a)  Unambiguous (I and II) and acceptable ambiguous (III and IV) de 
Bruijn graphs are selected to generate secondary reads and counted toward throughput per droplet (Th). Figure 7.4.b) ambiguous 
but acceptable graph are those with only one crossing point. This type of ambiguous graph generates two possible combinations; 
both of which are passed along to shotgun sequencing step. 
 
After the three main algorithms are applied to eliminate certain type of paths from de 
Bruijn graph, the final criteria used to assemble secondary reads is executed. Since the 
secondary reads are the building blocks of the final contigs in shotgun sequencing, only those 
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which are unambiguous or ambiguous at acceptable rate are selected. The unambiguous graphs 
are those with no crossing between two fragments (Figure 7.4.a : I and II). The ambiguous but 
acceptable graphs are those which consist of one crossing between two fragments (Figure 7.4.a : 
III and IV). In the later case, two possible combinations are assembled and passed along to 
shotgun sequencing as secondary reads (Figure 7.4.b). The number of acceptable ambiguous 
graphs is estimated to be 50% of all secondary reads generated from de Bruijn step. This is a 
significant error rate which is passed along to shotgun sequencing step. 
After the acceptable graphs are selected, complimentary sequence of genome fragment(s) 
are generated by walking through the path of the graphs. The kmerth base from each initial read 
is added in order of the graph’s path, generating secondary reads. This set of secondary reads 
are used as inputs for next assembling step, shotgun sequencing, to reconstruct contiguous 
sequences; thus original genome sequence. 
7.2.2.2 Throughput Maximization 
It is beneficial to determine optimal number of fragment numbers per droplet (nFrag) and 
expected number of bases per fragment (nBp) for a given size of oligo library (kmers). Crucial 
parameter used to determine nFrag and nBp is throughput per droplet (Th). As defined earlier: 
  ℎ = (      ×    ) ×     
 
 
Equation 7.1 
    =          
 
 
Equation 7.2 
Where Th is throughput per droplet, nFrag is number of individual input genome fragments per 
droplet from nFrag/2 doubled strand DNA fragments, nBp is expected number of bases per input 
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genome fragment, Eff is efficiency rate of assembly per droplet, and ind is the number of 
acceptable graphs which are selected as secondary reads. 
Initial study is conducted with suggested value of k-mers equals to 6 bases. The 
relationships betweem nBp, nFrag and throughput per droplet are studied individually while 
holding other variables constant. 
  
Figure 7.5 Throughput Maximization Figure 7.5.a – For a given length of fragments and size of oligo library, optimal number 
of fragments to be inserted in a droplet exists. At this value, maximum throughput is achieved. For expected fragment length of 
20 bp with 6-mers oligo library, optimal number of fragments per droplet is 10 fragments. The de Bruijn assembly throughput is 
maximized to be ~ 105 bases per drop. The simulation was run 30 times for each nFrag value to calculate standard error bars, 
thus confidence level of the results. Figure 7.5.b – for varied numbers of expected bases per fragment, maximum throughput 
increases as nBp decreases. 
1) Throughput per droplet vs. number of fragments per droplet  
For k-mers equal to 6 bases, nBp is held constant to study the effect of nFrag variation. In 
this case, expected number of bases per fragment (nBp) is randomly assigned the value of 20 
bases. The result from simulation is presented in Figure 7.5.a.  
    It can be observed that initially the throughput increases as number of fragments 
increases. However, the assembling throughput reaches its maximum value where 10 
fragments, equivalent to 5 doubled strand DNA pieces, of approximately 20 bases are 
deposited in one droplet. If more fragments are inserted into a droplet beyond this value, 
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assembling throughput decreases drastically. This result is observed because as more 
fragments is inserted in a droplet, the probability that initial reads are repeated or overlapped 
increases. Thus, assembling efficiency rate (Eff) decreases as number of fragment increases 
(Equation 7.2). Nevertheless, the process goal is not to maximize efficiency rate but 
throughput. Since higher number of fragments in a droplet provides more initial reads to be 
reassembled, maximum throughput can be achieved with optimal values of nFrag for a given 
nBp. In other words, for a given length of fragment, optimal number of fragment which 
maximize throughput can be derived (Equation 7.3). 
                          =  (   ,     ) 
 
Equation 7.3 
 
2) Maximum throughput per droplet vs. expected length of fragment (nBp) 
Since optimal value of nFrag depends on specification of nBp, the relationship between 
nBp and maximum throughput is studied. By repeating the pre6ous simulation, each time 
with different value of expected bases per fragment, maximum throughput and optimal value 
of nFrag can be determined for each nBp. The result from repeated simulation is shown in 
Figure 7.5.b. It can be observed that maximum throughput increases rapidly as expected 
length of fragment decreases. However, nBp cannot be decreased indefinitely because 
secondary reads, which have expected length of nBp, are used as inputs for the next 
assembling step (shotgun sequencing). As the length of secondary read decreases, the 
assembling throughput in shotgun sequencing step decreases (this relationship is explored in 
more detail in section 3.2.4) Since de Bruiji assembly prefers smaller fragment length but 
shotgun assembly prefers larger fragment length, sensitivity analysis is required to determine 
the optimal fragment length. Nevertheless, according to pre-sequencing process, the 
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minimum length of fragments that could be cut with acceptable deviation is 17-18bp. This 
limitation must be taken into account since it underlies the feasibility of genome sequence 
fragmentation.  
3) Consequence of k-mers variation 
k-mers has been kept as suggested at 6 bases to study relationship between throughput 
vs. number of fragments per droplet and maximum throughput per droplet vs. length of 
fragment. Although variation of k-mers has more constrains associated with it due to the 
limitation during sequencing process, its consequence on de Bruijn assembling throughput is 
significant. 
   
Figure 7.6 Consequences of k-mers Variation Figure 7.6.a – as kmer increases, the de Bruijn assembling throughput increases 
dramatically. The optimal number of fragment per droplet also increased from 4 individual fragments for 5kmers, to 10 for 6mers 
and to 50 fragments for 7mers.  Figure 7.6.b – The  maximum throughput when 20bp fragment is used increased by 5.3 fold 
when 7mers is used instead of 6mers. The effect of elongated kmers accelerates as number of base pairs per fragment decreases. 
The simulation for each data point is repeated 30 times to generate standard error bars, identifing level of confidence associated 
with the results.  
As k-mers elongates, expected de Bruijn assembling throughput per droplet increases. 
This is because with increased number of oligo library (4k-mers), the potential repeat problem 
decreases. For example, while 6-mers generates 4096 unique sets of oligos in the library, 7-
mers generates 16384 sets. The 4-fold increase in burden of barcoding scheme results in 
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approximately 5.3-fold increase in maximum throughput in de Bruijn assembling process for 
fragments with nBp = 20 bases. De Bruijn assembling throughput with k-mers = 7 and nBp = 
20 reaches its maximum, 560 bases reassembled/drop, when 40 individual fragments, which 
is equivalent to 20 doubled strand DNA fragments, are inserted within a droplet (Figure 
7.6.a). In comparison to the throughput result when kmer  = 6 bases is used, the de Bruijn 
throughput increases drastically. In Figure 7.6.b, it can be observed that the effect of 
elongated kmers on maximum throughput accelerates as number of base pairs per fragment 
decreases. Therefore, regarding de Bruijn assembling throughput, the smaller number of 
bases per fragment and the longer kmers are preferred. The optimal number of fragment per 
droplet is chosen so that the throughput is maximized as shown in Figure 7.5.a and Figure 
7.6.a.  
Elongated kmer increases throughput during de Bruijn assembly as well as that during 
shotgun sequencing assembly. However, the tradeoff is the cost and time required to create 
and maintain larger size of oligo library which decreases the throughput in genome 
sequencing process. Currently, it is determined that the potential margin gain of using 7mer 
instead of 6mer is not sufficient to invest time and effort in higher fixed cost of oligo library 
maintenance. 
In Figure 7.6.a, the blue data point represented the throughput when oligo library with 
5kmer is used. The maximum throughput is reached at 45.33 bases/drop when 2 doubled 
strand DNA fragments (nFrag = 4) are inserted in the drop, each with approximately 20 base 
long. The throughput which is meaningful to shotgun sequencing assembly is only half of the 
raw value because the doubled strand DNA fragment yields repetitive information. Thus, 
only 23 bases/drop is relevant to the final assembling process. This value is less than that in 
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the original proposed base case where the throughput per droplet was experimentally proven 
to equal 35 bases/drop (Table 3.1) As explored earlier in Section 3.3, the adjusted throughput 
of less than 35 bases/drop is not feasible. Thus, the 5mer oligo library which yields 
throughput in the range lower than the specified threshold is not selected. Even though 
maintaining oligo library with the 5mer is simpler than that with 6mer the later is selected 
chosen because of the higher assembled throughput it delivers.   
 To conclude, the two critical variables in de Bruijn assembling process – number of 
fragments per droplet and expected length of fragment– are determined using MATLAB 
simulation to maximize assembled throughput per droplet. The simulation shows that the optimal 
number of fragment per droplet exist for a given value of fragment length (Equation 7.3). The de 
Bruijn graph assembling yields highest throughput when expected fragment length is short. 
However, the shearing limitation prohibits fragments which are smaller than 17 bp (New 
England Biolabs). Shorter fragments also results in higher coverage required during shotgun 
sequencing process which possibly decreases overall assembling throughput. The relationship 
between length of fragment and shotgun sequencing throughput is explored in the following 
section.  
 
7.3 SHOTGUN SEQUENCING ASSEMBLY 
7.3.1 Shotgun Sequencing Overview 
 Shotgun sequencing was introduced in 1982 by Fred Sanger. In shotgun sequencing, 
DNA is first shredded into smaller fragments which can be sequenced individually. The 
sequences of these fragments are then reassembled into their original order, based on overlaps, 
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yielding the complete sequence. The algorithm went through many major developments and has 
been used in majority of genomic sequencing projects. The International Human Genome 
Sequencing Consortium, 2001, was conducted using shotgun sequencing strategy (Pop, Salzberg, 
& Shumway, 2002). 
Generally, the sequence is randomly sheared into small pieces with approximately 1000 
bp in length (Rogers, 2007). The overlapping reads of these small pieces are presumed to come 
from the same area of the genome. By aligning and merging DNA fragments, long contiguous 
sequences, contigs, are formed Figure 2.7.  
Main challenge associated with shotgun sequencing is that the assembly is only possible 
when enough DNA reads are generated to cover the original sequence. Mathematically, this 
limitation was studied by Eric Lander and Michael Waterman in 1988 (CBCB).  The correlation 
between the oversampling of genome, coverage, and the number of contigs which can be 
successfully reconstructed was published.   
 Let G, n, L, c, and t represent genome length, number of sequences (fragment and its 
complementary count as one), length of sequences, depth of coverage, and the amount by which 
two sequences need to overlap in order to computationally detect this overlap, respectively.  
  =     
 
Equation 7.4 
 
                           =  ×    ×     Equation 7.5 
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 To demonstrate the degree of 
dependence of shotgun method on an 
over-generation of DNA reads, the 
expected number of contigs is plotted 
against coverage. When G = 3 gbp, L = 
1000 bp, t = 5, Figure 7.7 shows that 8-
10 fold overage is required to assemble 
fragments into a small number of 
contigs. The smaller numbers of contigs 
result in smaller number of gaps, 
enabling final contig assembly (CBCB). 
7.3.2 Micro$eq Application of Shotgun Sequencing Assembly 
Secondary reads assembled via de Bruijn graph are used as input fragments for shotgun 
sequencing. The base at each position is determined using aligning and merging algorithm. Since 
shotgun sequencing is the final step before genome sequences are delivered, the specification of 
sequencing process is determined based on targeted overall error rate. As previously discussed, 
fragment length must be optimized as a function of overall process since de Bruijn assembly 
prefers smaller fragments while shotgun prefers elongated fragments.   
7.3.2.1 Read Error Calculation  
 Read error rate, the probability that a given base in a fragment is incorrect, depends upon 
fragment length, accumulated error rate from sequencing step and de Bruijn assembly step. As 
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Figure 7.7 Lander-Waterman estimation of number of contigs vs. 
Coverage  8-10 coverage of reads is required to generate small number 
of contigs. 
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the fragment length increases, the probability that the fragment repeats in the entire genome 
sequence decreases (Equation 7.6).  
  (                         ) =   4    Equation 7.6 
Where G is genome length = 2.9 x 109 bases and nBp is fragment length.  For a given fragment 
length, 4nBp possible combinations of bases exist. Thus, it is less likely that the fragments are 
repeated as number of bases per fragment increases. This advantage of longer fragment allows 
shotgun sequencing to achieve specified error rate with lower coverage.  
In addition to the error rate expected as a result of fragment length, the accumulated rates 
from previous steps, sequencing and de Bruiji assembly, must be taken into account. Since the 
secondary reads are consisted of 50% acceptable but ambiguous graphs, the total error rate 
increased by 50%. Given such a high rate from de Bruijn assembly, the effect of pre-sequencing 
and sequencing error rates are considered negligible. Thus the probability that base in each 
position of the fragment is incorrect, Read Error, can be calculated (Equation 7.7): 
           =  =   4    × 1.5 Equation 7.7 
 This read error is further used to calculate the overall error rate upon completion of 
shotgun sequencing. 
7.3.2.2 Total Error Rate vs. Coverage 
Acceptable error rate for personal genome project is specified at 10-5. A trade-off 
between lower error rate and higher coverage exists because more information is required to 
determine the base at each position with higher accuracy. Unfortunately, higher coverage 
requires more fragments, more sequencing drops, and thus higher cost. In order to minimize cost 
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of the personal genome project, the coverage is selected such that the total error rate is slightly 
below the threshold, 10-5.  
 To understand the relationship between process error rate and shotgun sequencing 
requirements, coverage, a primary shotgun variable is studied. Coverage is the number of times 
fragments are expected to overlap or the amount of genome oversampling. The actual number of 
coverage is a Poisson distribution around expected number of coverage.  
  ( , µ ) =  µ       !  
 
Equation 7.8 
Where k = actual coverage, µc = expected number of 
coverage, P = probability of occurrence. For example, in 
Figure 7.8, Poisson distribution of actual coverage for 
expected coverage = 15 is presented. It can be observed 
that the probability of finding 15 coverages is the highest 
because it is equal to expected value. Probability of 
occurrence decreases as actual number of coverage moves 
away from the expected number of coverage.  
 
 
For each possible value of coverage, error rate from shotgun algorithm exists. This error 
rate is the result of Read Error and insufficient genome oversampling.  Shotgun algorithm 
implements the usage of overlapping fragments to determine the base at each position. In order 
for the position to be incorrectly determined, equal or greater than half of the base presented 
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Figure 7.8 Poisson Distribution of Actual 
Number of Coverage When the Coverage is 
stated, it is referred to Expected Coverage. For a 
particular Expected Coverage value, it is possible 
that more or less coverage exists. The probability 
of each coverage incident is presented in this 
figure. As the actual number moves away from 
expected value, the probability of occurrence 
decreases (Equation 7.8) 
168 | P a g e  
 
Micro$eq – Chomvong, King, Mahmoud 
must be incorrect. To illustrate the following shotgun error per base is calculated for actual 
coverage (Table 7.1). 
 
Actual Coverage Shotgun Error Rate 
1 =  Read Error = x 
2 =  Probability that fragment 1 or fragment 2 or fragment 1&2 are incorrect 
= 2x(1-x) + x2 
3 = Probability that frag 1&2 or frag 2&3 or frag 1&3 or frag 1&2&3 are incorrect 
= 3x2(1-x) + x3 
Table 7.1 Error Rate for Actual Coverage Calculation Error Rate can be calculated when read error is given 
for actual number of coverage. This calculation can be represented by mathematical formula presented in 
Equation 7.9. 
Mathematically, the error rate for a given number of actual coverage can be calculated: 
            ( ,  ) =    !( !)( −  )! ( ) (1 −  )        
 
Equation 7.9 
Where k = actual coverage, x = read error, σ = minimum number of incorrect base required to 
affect incorrect final base conclusion; σ ≥  k/2 while σ is an integer. From Equation 7.9, it can be 
observed that as number of actual coverage increases, error rate for a given number of actual 
coverage decreases. This can be explained by the oversampling of information which decreases 
the probability that majority of presenting bases are incorrect ( x << 1-x ). 
 Finally, total error rate of the project can be calculated from Equation 7.8 and Equation 
7.9. The total error rate of the process is the summation of all possible cases of number of actual 
coverage: 
           (µ , ) =             ( ,  ) ×  ( , µ )     
 
Equation 7.10 
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Total error rate is a function of read error and 
expected number of coverage. In Figure 7.9, a tradeoff 
between process accuracy and coverage required is 
demonstrated. To decrease total error rate, more coverage 
is required. As total error rate gets smaller, the cost of 
further decreasing such error rate accelerates since the 
curve is almost flat.  
The target error rate for personal genome project 
is set at 10-5. For a given read error, optimal coverage 
can be selected such that the total error rate is slightly 
less than 10-5.   
 
7.4 ASSEMBLY OPTIMIZATION 
Thus far, specification on fragment length has not been done. The ambiguous optimal 
fragment length is due to a trade-off between de Bruijn Assembly throughput and shotgun 
sequencing throughput. In addition, the final goal of the optimization is to minimize the required 
number of parent drops needed to be generated during sequencing step; thus, minimize the cost 
of the entire process. The following equation explores the relationship between fragment length 
and required number of parent drops (Equation 7.1Equation 7.3Equation 7.7Equation 7.10): 
                      =    ℎ2 × 1   = ( ×  )    ⁄ ℎ (2 ×    )⁄                                               = 2 ×  ×   ℎ   = 2 ×  { } ℎ {   } = 2 ×  {   } ℎ {   } 
 
Equation 7.11 
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coverage is presented. In this case, read error is 
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Where n is the number of fragment required for shotgun sequencing, Th is the throughput per 
droplet (bp), nBp is the expected fragment length, c is expected coverage, G is total genome 
length and x is read error which is the probability that a given base in a shotgun input fragment is 
incorrect. The assembled throughput per drop Th is divided by 2 in Equation 7.11 because the 
information gain from assembled base is redundant. The fragments inserted into a droplet are 
doubled strand DNA; thus for nFrag = 10, only 10/2 = 5 independent fragments exist. When 
these assembled secondary reads are used as input in shotgun sequencing, the redundant 
information of complementary fragments is not taken into account. Hence, when number of 
parent drops is calculated, only half of the assembled throughput is relevant for shotgun 
sequencing.  
From Equation 7.11, it can be observed that the 
number of parent drops required to sequence one 
genome depends on expected coverage and throughput 
per droplet. However, as fragment length increases, 
both coverage and de Bruijn throughput decrease. This 
results in inconclusive direction of fragment length. 
Thus, sensitivity analysis is conducted to explore 
relationship between number of parent drops required 
and variation of fragment length. 
 For a 6-mer oligo library with targeted error 
rate slightly below 10-5, expected number of parent 
drops required is calculated for different fragment 
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Figure 7.10 Number of Parent Drops Required 
vs. Expected Fragment Length The optimal 
length of fragment is selected such that the number 
of parent drop is minimized. The number of drops 
is the result of de Bruijn graph assembly and 
shotgun sequencing. From Equation 7.11, as
number of expected fragment length decreases, de 
Bruijn throughput increases while more coverage is 
required. This results in inconclusive direction of a 
preferred fragment length. However, the simulation 
is conducted to combine the effect of both steps for 
a given fragment length. The optimal fragment 
length which minimize number of parent drops is 
shown to be equal to 22 bases. 
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length (Figure 7.10). It is clear that when fragment length is short, the high read error rate (x) 
which resulted from possible repeat of in the entire genome (Equation 7.7) dominates the higher 
de Bruijn throughput. On the other hand, when the fragment length is long, the low de Bruijn 
throughput dominates the ease of shotgun assembly and results in higher number of parent drop 
required. Figure 7.10 shows that the optimal fragment length that requires minimal number of 
parent drops is 22 bp.  
Given that the fragment length is 22 bases, optimal number of fragments inserted into a 
droplet is 10 fragments which is equivalent to information obtained from 5 independent doubled 
strand DNA (Equation 7.3). With these values, de Bruijn assembly throughput is maximized at 
185 bases per droplet (see 7.3.2.2 Throughput Maximization). The read error rate for 22 base 
fragment is 2.47 x 10-4 (Equation 7.7). This specification results in minimum 11.55 coverage 
requirement for 9.98 x 10-6 total error rate (Equation 7.10). The number of fragment required is 
1.52 x 109 (Equation 7.1) and number of parent drops required to achieve the specification is 
3.63 x 108 drops (Equation 7.11).   
 
7.5 COMPUTING TIME, COMPUTATIONAL AND PERSONNEL 
DEMAND 
 The two main steps implemented to assemble initial reads to final sequence are de Bruijn 
assembly and shotgun sequencing. The two steps can be 6sualized in series; however, 
computationally, they can be parallelized since the assembled secondary reads from de Bruijn 
graph can be passed along to align with the reference sequence instantaneously, decreasing 
overall computing time for a given genome sequence. 
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7.5.1 De Bruijn Computing Time and Computational Demand 
The expected number of initial reads per drop came from de Bruijn graph estimation. 
Since the fragment length is 22 bases, the maximum number of initial reads that could be 
generated for a non-repeating fragment is 22 – 6 +1 = 17 reads, for kmer = 6 bases. However, 
from previous simulation, other possibilities of crossing exist for the combination of 22 bases of 
10 fragments per drop. Thus, the average number of initial reads per fragment is estimated to be 
15. Since there are 10 fragments in one drop, the estimated number of initial reads per drop is 
150. This number can be used to calculate de Bruijn computing time of one parent drop:  
                    =                                           ≈  150 = 22500       
Equation 7.12 
Because kmer-1 bases must match in order for de Bruijn nodes to be connected, 1352 
times of comparison must be looped in order to generate the graph (FLOPS stands for floating 
point operations per second). Upon completion of graph generation, de Bruijn assembly 
algorithm is estimated to be 2 fold of the graph generating time.  From this estimation, de Bruijn 
assembly computing time can be estimated: 
                  =  22500      1     × 3.63 × 10            1       × 3 × 1       2.4 × 10       = 2.83 ℎ /       
Equation 7.13 
In this case, the specification of a processor is 2.4 GHz which is translated to the ability 
to complete 2.4 x 109 FLOPS in one second.  
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7.5.2 Shotgun Computing Time and Computational Demand 
 To minimize shotgun computing time, which traditionally has been a bottleneck of 
genome sequencing process, the most efficient algorithm is selected. Bowtie, an open source 
memory efficient and short read aligner is suitable for personal genome project. It has been 
tested to achieve 25 million 35-bp reads alignment of human genome in one hour. In 
additionally, the run was conducted on standard PC with 2 GB RAM. Bowtie algorithm is 
capable of handling doubled strand DNA which is applicable to Micro$eq’s requirement  
(Langmead, Trapnell, Pop, & Salzberg, 2009). The estimation of Micro$eq runtime is estimated 
based on Bowtie algorithm: 
1.52 × 10          1       × 1 ℎ 25 × 10           = 60.9 ℎ /       
Equation 7.14 
For the same number of fragments, run time is expected 
to decrease when fragment length decreases since it is 
less resource intensive to check whether 22 bases match 
rather than whether 35 bases match. The experimental 
data from Bowtie test verifies the assumption (Figure 
7.11) (Langmead, Trapnell, Pop, & Salzberg, 2009). 
Since the decrease in CPU time decelerates as read 
length decreases, the computing time is estimated 
conservatively to be equal to that of 35 bp read length.  
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Figure 7.11 Bowtie CPU Time vs. Read Length
This relationship is derived from data from Table 
5 of (Langmead, Trapnell, Pop, & Salzberg, 
2009). In the experiment, server with a four-core 
2.4 GHz AMD Opteron processor and 32 BP of 
RAM is selected. The system aligned 2M 
untrimmed reads from 1,000 Genome project. It 
can be observed that as read length shortens, the 
CPU time decreases. 
174 | P a g e  
 
Micro$eq – Chomvong, King, Mahmoud 
 To achieve higher speed of the process, alignment can be parallelized by distributing 
reads among different threads for a multi-core server. The speed increases by 3.12 fold if the 
alignment is run on four threads instead of one on the four-core server (Langmead, Trapnell, 
Pop, & Salzberg, 2009). Thus, the estimated shotgun runtime improved to: 
 
60.9  1       × 1 3.19 = 19.1 ℎ /       Equation 7.15 
 
Thus, with four core server, 19.1 hour is required to shotgun human genome.  
7.5.3 Overall Computing Time and Personnel Demand 
 The overall computing time of assembly process depends on the bottleneck process, the 
aligning and merging shotgun sequencing. Since the output from de Bruijn assembly can be 
passed along to shotgun step instantaneously, the total assembly time only depends on shotgun 
sequencing step. For one genome, 19.1 hours of computing time is required to reassemble reads 
into original genome. 
 Personnel demand for genome assembly process is minimal. One technician is needed to 
maintain the servers and deliver final sequenced genome electronically to clients for a 
throughput of less than 72 genomes per day. Occasionally, the technician might have to modify 
assembly code to minimize assembling time according to newly launched algorithm.  
   
7.6 GENOME ASSEMBLY SUMMARY 
 Many genome sequencing variables are interrelated. Small change in one variable might 
cause dramatic fluctuation on others. The optimal values of fragment length, number of 
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fragments to be inserted in each parent droplet, and number of coverage are determined in this 
chapter using sensitivity analysis. It is concluded that the optimal fragment length which 
minimize number of parent drops required is 22 bases. With specified fragment length, number 
of fragments to be inserted to each droplet is optimized so that de Bruijn throughput reaches its 
maximum—in this case, 10 fragments from 5 doubled strand DNA, each with 22 base in length 
yields assembled throughput of 185 bases/parent drop. Fragment length also affects the read 
error—probability in which a given base on fragments prior to shotgun sequencing is incorrect. 
The read error is then to calculate coverage required to shotgun the entire genome at acceptable 
error rate. In this case, 11.55 expected number of coverage is required to achieve 9.98x10-6 error 
rate. The number of coverage is further applied to calculate number of fragment required to 
accomplish shotgun sequencing (1.52x109 fragments), which implies number parent drops 
needed to be generated (3.63x108 drops). The computing time expected per genome is 19.1 
hours. Specification that minimum of 12 genomes must be sequenced per day can be 
accomplished by using 10 servers of four core 2.4 GHz AMD Opteron processor and 32 GB of 
RAM. 
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CHAPTER 8  
 
Cost Estimation Breakdown 
 
While the technical aspects of Micro$eq’s entire process have now been outlined, the 
financial costs of each of the processes has not been discussed. As one of Micro$eq’s primary 
objectives is to generate a relatively low-cost, sequenced genome product, it is necessary to 
verify that its proposed process is feasible in a low-cost operating environment. While a financial 
analysis will be done on the whole-company level in Chapter 9 of this report, this chapter aims to 
outline in detail the reagent, microfluidic platform, and equipment costs associated with each 
step in the process.  
 
 
177 | P a g e  
 
Micro$eq – Chomvong, King, Mahmoud 
8.1 REAGENT COSTS 
 Annual reagent costs will be directly related to annual genome throughput as reagents are 
non-recyclable and thus a certain quantity most be allotted to each sequenced genome. This 
section outlines the reagents required for the pre-sequencing and sequencing steps of the process. 
As no physical sample handling takes place in the reassembly step of the process, it requires no 
reagents. 
8.1.1 Presequencing Reagents 
 All reagents required for the presequencing steps outlined in Chapter 5 of this report have 
been summarized in Error! Reference source not found.. Most of the presequencing step 
reagents are obtained in the form of kits, which include all the necessary reagents (buffers, salts, 
enzymes, etc) for that particular reaction. However, while standard kits were available for most 
of the presequencing reactions, a few custom oligonucleotides (adaptors, primers, quenched 
primers) had to be synthesized which add additional costs. 
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Initial DNA Extraction and Purification 
 Unit price Genomes per unit Cost per Genome 
OrageneSaliva kit (Genotek) $778  960 $0.81  
Preliminary DNA Fragmentation 
Quick purification kit 
(Qiagen)  $471  500 $0.94  
Adenosine Tail Addition 
A-ligaiton kit (Qiagen) $1,000  1124 $0.89  
Internal Adaptor Insert 
Basic Ligation kit (Qiagen) $1,000  1124 $0.89  
Internal Adaptors (IDT) $17.50  4000 $0.00  
Exonucleolysis 
Exonuclease Kit (NEB) $244  1500 $0.16  
MmeI Digestion 
MmeI Digestion Kit (NEB) $244  1000 $0.24  
Quick purification kit 
(Qiagen)  $471  500 $0.94  
End-it DNA repair kit 
(Epicenter Biotech) 200 500 $0.40  
Terminal Adaptor Ligation 
Basic Ligation kit (Qiagen) $1,000  1124 $0.89  
Internal Adaptors(IDT) $1.75  4 $0.44  
PCR Amplificaiton1 
PCR basic kit (Qiagen) $1,000  1124 $0.89  
Custom primers (IDT) $0.63  100 $0.01  
PCR Amplification 2 
PCR basic kit (Qiagen) $1,000  1124 $0.89  
Custom primers (IDT) $0.63  10 $0.06  
Primer Quenchers (IDT) $0.25  10 $0.03  
  Total per genome $8.49  
Table 8.8.1 Presequencing Reagent Cost estimates(amounts in US$) 
As seen in Table 8.8.1, no single reaction is particularly costly on the per genome level. 
Because all purchased kits may be stored for at least a year-long time period, and no kit purchase 
exceeds Micro$eq’s annual throughput, the prices cited for each unit are for the company’s 
largest available bulk price, making it the cheapest cost per individual kit.  
Because the genomes are processed on a small scale, the amount of reagents required per 
genome is relatively small. The amount of genomes per unit of reagents/kits were calculated by 
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adjusting the processing volume or DNA weight per each kit by the volume or weight of DNA 
being processed per genome at each particular step.  
The custom-made adaptors were priced on a per base pair level, with an economies of 
scale pricing scheme as the number of bases increased.  This is the reason for the discrepancy 
between the two sets of adaptors: the 250bp adaptor costs approximately ten times as much as 
the 25bp adaptor. 
The custom primers are required in smaller amounts than custom adaptors. However, as 
primers are used in every copy of DNA generated, each unit of primers served a much smaller 
number of genomes. Similarly, the primers required for the first amplification served more 
genomes than the primers required for the second amplification as the second amplification 
produced more copies of DNA.  
As seen in Table 8.8.1 the total presequencing reagent cost of one genome is $8.49, 
which is very reasonable in terms of the current competitive market. The main reason this 
reagent cost is low is that the microfluidic platform used both requires the processing of a very 
small amounts of DNA and capitalizes on the droplet microreactors yielding high-efficiency 
reactions. 
8.1.2 Sequencing Reagents 
The sequencing reagents are the fluorescent 6-bp oligomers and 6-bp dark quenchers for 
fluorophore –dark quencher hybridization system (Section 4.3.2.2.2).  The concentration of the 
oligomers was chosen based on signal to noise analysis (Section 6.8).  This concentration was 
chosen to be 1µM for the both the fluorophore and quencher.   
The fluorophores and dark quenchers are purchased from Integrated DNA Technologies 
(IDT).  To calculate the cost associated with sequencing the human genome, one first has to 
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calculate the total number of moles of 6-mers required to sequence the human genome.  The 6-
mer concentration in each 5 pL drop is 1 µM.  The total number of drops required is given by the 
size of the oligos library, the number of fragments in each droplet, and the depth.  Optimization 
of throughput determined that 1.83x1011 droplets are required to sequence a human genome.  
Multiplying the number of drops by the number of moles of oligomers in each drop gives the 
total number of moles of 6-bp oligomer required to sequence the human genome. A summary of 
these calculations can be seen in Table 8.2 
 
Table 8.2 Sequencing Reagents Cost: The oligos library is custom synthesized by Integrated DNA technologies (amounts 
in US$) 
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For the calculations in Table 8.2, it was assumed that the oligomers are purchases on a 10 
µM synthesis scale.  Modifications are assumed to be purchased on a 10 micromole scale for the 
fluorophores and a 1 micromolar scale for the quencher.  Multiplying the total number of moles 
by the modification cost and adding both modified strands gives the total cost of the prepared 
quencher-fluorophore system to sequence a human genome of $19.22.    
 
8.2 MICROFLUIDIC PLATFORM COSTS 
 The cost estimates for the microfluidic platforms for this process are important. As 
microfludic technology is a relatively new field, equipment costing is still relatively expensive, 
thus these microfluidic platforms present the potential for being a financially-limiting factor in 
the overall process.  
 Each microfluidic platform must have a microfluidic syringe pump which provides the 
driving force for droplet flow, as well as a custom-made microfluidic chip containing the flow 
channels for the droplets. The syringe pump to be used in this process can feed up to 10 different 
channels simultaneously (Dolomite). The custom-made chips may be recycled via washing, but 
must be disposed of every 10 days (for daily base output of 12 genomes per day). Thus while the 
syringe pumps are a fixed cost and will be lumped with equipment costing in the final cost 
estimates spreadsheet, the required microfluidic chips will be a scalable cost dependent on the 
company’s throughput and will be lumped with inventory.  
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8.2.1 Presequencing Microfluidic Platforms 
 The presequencing process involves two microfluidic apparatuses. The first is initial 
parent droplet generation and merging with PCR reagent droplets prior to amplification. As 
discussed in chapter 5, this process will be run for 12 samples simultaneously, with each sample 
being split into 10 parallel channels. The required flow rate of the microfluidic chip is 
100µL/min. The Syringe pump is capable of 1mL/min of flow, thus 10 parallel channels at 
100µL/min each can be powered by one syringe pump. This implies that a syringe pump is 
required for each genome for this droplet generation step. The syringe pump has a base unit price 
of $6,250, with a required supplementary syringe attachment, which costs $165 per unit, yielding 
a total unit cost the syringe pump station of $6,415. 
Additionally, the size of the microfluidic chip can be estimated based on the size of the 
droplets. The channel width are estimated based on microfluidics as discussed in Chapter 6 of 
this report, and will for estimated using the merged droplet size, as this will limit the flow 
channel size. For the 1nL merged parent droplets, the required diameter size of the channel will 
be 0.15mm. The distance between the channels will be assumed to be the same as channel width. 
Thus the total width of each channel is calculated as shown below: 
( )120 120 0.15 36Channels Spacers mm mm´ + ´ × =  
The length required for the merging process is 25mm, thus the total area of the chip is calculated 
as shown below: 
36mm ´ 25mm ´ 0.00155in
2
mm2
=1.4in2  
It is important to note that a residence volume for all drops on the chip need not be 
calculated as the merged droplet will be directed off the chip and into the tubes for PCR 
amplification, thus not all droplets need reside on the chip at a single time, which decreases the 
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length of chip required as the only plumbing that must exist on the chip is that which is required 
for the merge operation. 
At an estimated market price of $100 per square inch of custom-made microfluidic chip 
(Dolomite), the total microfluidic chip price for this first step is $140. Again, as each chip may 
be used for 120 genomes, this is a inventory microfluidic price of $1.17 per genome. 
 The second step in requiring microfluidic platform in the presequencing process is the 
parent droplet split. As the number of droplet has not changed from the previous microfluidic 
process, the number of droplet injectors will remain the same (1 per genome). Additionally, the 
number of required channels will initially be the same. As the parent droplets are split the 
number of required channels increases, but the channel width decreases proportionally, so the 
total width of this chip will still be 36mm.  The required length for the split process is again 
estimated as 25mm, therefore the total chip area will also be 1.4in2, and thus cost out to $140, or 
$1.17 per genome.  
A summary of the presequencing Microfludic platform costs can be found below in Table 
8.8.3: 
DNA-PCR Reagent Droplet merge 
 Unit Cost Genomes per Unit Cost per Genome 
Mitos-XS Pump Basic (Dolomite) $6,250 1 $6250 
Custom Microfluidic Chip 
(Dolomite) 
$140 120 $1.17 
Parent Droplet Split 
Mitos-XS Pump Basic & 
Accompanying Syringe 
(Dolomite) 
$6,415 1 $6415 
Custom Microfluidic Chip 
(Dolomite) 
$140 120 $1.17 
  Total per 
Genome 
$12,502.34 
Table 8.8.3 Presequencing MicroFluidic Platform Cost Estimates (amounts in US$) 
As can be seen from Table 8.8.3, the estimated cost per genome for the presequencing 
microfluidics platforms are ~$12.5 thousand. While this may seem unrealistically high for a per 
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genome market price point aimed at $1000, it is important to keep in mind that only $2.34 of the 
microfluidics costs are disposable inventory, and the remaining $12,500 are fixed equipment 
costs.  
8.2.2 Sequencing Microfluidic Platforms 
The sequencing process involves only one microfluidic setup. However, this process is 
slightly more complex as it involves the merging of the 6mer oligonucleotides library droplets 
with the sets of daughter droplets generated by the presequencing steps. This microfluidic setup 
will require the same type of pump and syringe setup as the presequencing step. The required 
generated flow rate for the downstream sequencing process is 35 µL/min.  Thus one syringe 
pump at 1mL/min will suffice for the generation of the oligos library required for one station, 
again costing $6,415 per syringe pump unit. As ~2.63 stations are required for each genome, this 
means a total of 2.63 syringe pump setups are required per genome.  
The dimensions associated with the sequencing microfluidic platform are mainly 
determined by the dimensions of the semi-permeable electrode gated barrier used to align the 
drops for scanning by the CCD camera.  The diameter of 5 pL droplet is 22 micrometers.  In 
order to array 505 droplets in a line, while leaving a gap whose dimension is equal to the 
dimension of a droplet for the electrode (Figure 6.11.14) the microfluidic chip’s dimension must 
be at least: 0.000022 ∗ 505      ∗ 2 = 0.022     2.2               
In addition to possessing a dimension larger than the dimension of the electrode gated 
barrier needed to array the droplet, room must be given for the tree root design (Figure 6.11).  25 
mm are allocated to the tree root system.   
 Thus the area of the chip is calculated as shown below: 
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(25  ) ×  0.03937      = 0.9687    
So, for a 0.9867in2 chip at $100 per square inch, each chip will cost $96.87. As with the 
sequencing chips, the chips will be replaced every 10 days for a base of 12 genomes per day, 
thus this cost will be divided by 120 to get a per genome microfluidic chip cost of ~$0.81. 
A summary of the costs associated with the microfluidics platforms in the sequencing step is 
shown below in Table 8.8.4 
Parent Droplet Split 
Mitos-XS Pump Basic & 
Accompanying Syringe 
(Dolomite) 
$6,415 2.63 $16,871.45 
Custom Microfluidic Chip 
(Dolomite) 
$96.97 120 $0.81 
  Total per 
Genome 
$16,872.26 
Table 8.8.4 Sequencing MicroFluidic Platform Cost Estimates (amounts in US$) 
As can be seen from Table 8.8.4, the estimated cost per genome for the presequencing 
microfluidics platforms are ~$16.9 thousand. While, similarly to the presequencing microfluidic 
platform costs, this may seem unrealistically high for a per genome market price point aimed at 
$1000, it is important to keep in mind that only $0.81 of the microfluidics costs are disposable 
inventory, and the remaining $16.9 thousand are fixed equipment costs.  
 
8.3 EQUIPMENT COSTS 
 This section will provide a detailed breakdown of the equipment costs on the per genome 
or per 12 genome unit basis. In this analysis, it is important to remember that while the reagents 
are inventory costs, equipment is fixed costs and while dependent on Micro$eq’s targeted 
throughput, will be a one-time purchase at the beginning of the sales phase. As will be discussed 
in this section, some of the required equipment or equipment station setups will be multiplied in 
order to increase process throughput to achieve a one-day genome sequencing process.  
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8.3.1 Presequencing Equipment 
All required equipment for the presequencing process were explicitly stated in the 
presequencing process chapter (Chapter 5) of this report, with the exception of the conventional 
laboratory centrifuging and vortexing machines, were are necessary in many of the DNA 
preparation protocols.  
A summary of all the required presequencing equipment is shown below in  
Equipment Cost per unit units per base process total cost 
Vortex mixer (VELP) 179.99 1 179.99 
Lab Centrifuge (UNICO) 679.68 0.5 339.84 
Magtration 12GC (Pss 
Bioinstruments) $1,000  1 $1,000  
s2 Shearer (Covaris) $500  1 $500  
ThermalCycler (Biometra) $4,000  4 $4,000  
  Total $18,019.83 
Table 8.8.5 Presequencing Equipment Costing Estimates for base process of 12 genome simultaneous processing (amounts 
in US$) 
 
It should be noted that the “base process” referred to in Table 8.8.5 refers to the 
simultaneous processing of 12 genomes. For this reason, the centrifuge, which can handle 24 
samples at once, it marked as only having 0.5 units required. For the overall process cost 
estimates found in chapter 9 of this report, the number of centrigues required will be rounded up 
if the total process integer multiples of the 12 genomes base process is not even (thus divisible 
by 24).  
Similarly, the Thermal Cycler can handle 3 genomes at once, thus a total of 4, for the base 
process of 12 genomes, is required.  
The sum total of presequencing equipment, as seen in Table 8.8.5, is ~$18,000, a very 
reasonable price when compared to the equipment required of the sequencing and genome 
reassembly equipment costs, and thus will not be the cost-determining portion of the process.  
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8.3.2 Sequencing Equipment 
Sequencing equipment is required for the optical system and for the microfluidic system.  
For the optical system, a prism is required to refract fluorescence emitted from the droplets onto 
the line scanning CCD camera (Figure 5.12.15).  Furthermore, two lenses of 1X magnification 
are required to transmit fluorescence.  A Nikon 60 mm Micfo-Nikkor Lens was selected which 
possesses a lens diameter of 2.9 inches.  Also a Hamamatsu back thinned CCD image sensor is 
required to scan the microdroplets.  A CCD chip was found the specifications required.  
Hamamatsu was contacted, and a representative can be quotes a price of a fully equipped CCD 
camera with power sources to be on the order of $25,000.  A laser is also required  to excite the 
fluorphores.  The required laser power is roughly10 mW (Section 6.8).  A summary of the costs 
associated with one optical setup station can be seen below in Table 8.8.6. As shown, the total 
optical setup cost per station is ~$27 thousand. 
Item Price ($) 
Tedco Prism $6 
Nikon Micro-Nikkor Lensx2 $945.98 
Hamamatsu back thinned CCD image sensor $25,000 
Laser $6.74 
Hp Compaq 8200 Small Form Factor Desktop PC with Screen $989 
Total Cost per optical setup station $26,947.72 
Table 8.8.6 Sequencing Equipment Associated with the Optical System: The optical system consists of a prism, two lens, a 
fully equipped CCD image sensor, a laser, and a computer. (amounts in us$) 
 
 As 2.63 stations per genome are required to achieve a throughput time of 24hrs per unit 
of genomes, the total optical equipment cost per genome will 2.63 times the optical setup station, 
thus $70.9 thousand per genome. While this number may seem alarming, it is important to note 
that it is a fixed equipment cost based on the annual throughput. At a throughput of ~25,000 
genomes per year, this is less than $3 per genome per optical setup for only a year of operations, 
much less for the three years of full operations and one year of 50% operations. 
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In addition to the optical setup, a computer is translate the signal information to the 
bioinformatic computation system.  The Hamamatsu CCD chip has a pixel dimension of 1024 by 
16 pixels and scans at a frame rate of 1777 frames per second.  Thus, the total amount of pixels 
transferred per second is: 
                             = 1024       ∗ 16       ∗ 1777         = 29 ∗ 10          = 29          /    
If one images in a 24 bit format, a typical screen resolution of 1024 x 768 pixels take up 
2,359,296 bytes.   
The number of bytes in a pixel is: 2,359,296     1024 ∗ 768       = 3      /      
Translating the Megapixels/sec transferred into bytes per seconds.  29 ∗ 10          ∗  3           = 8.7 ∗ 10      /    
Using the fact that 1 byte=8bits 
 . ∗           ∗          ∗    /     = 696  / ec 
A typical 2010 computer with an RPM of 7,200 has a data streaming rate of 1030 
MB/sec.  Thus one computer can be used to stream data from 1.48 stations. For this process, the 
Core IF-2400 processor from Intel will be used, with a price of $889 per computer, which 
translates into a price of $1,315.72 per station and thus $3460.31 per genome. A summary of all 
sequencing equipment costs is shown below in . 
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Equipment Cost per unit units per genome total cost 
Tedco Prism $6 2.63 $15.78 
Nikon Micro-Nikkor Lensx2 $945.98 2.63 $2,487.93 
Hamamatsu back thinned CCD 
image sensor 
$25,000 2.63 $65,750.00 
Laser $6.74 2.63 $17.73 
Hp Compaq 8200 Small Form 
Factor Desktop PC with Screen 
$989 2.63 $2,601.07 
Intel Core IF-2400 processor $889 3.89 $3,460.30 
  Total $74,332.80 
Table 8.8.7 Sequencing Equipment Costing Estimates per genome (amounts in US$) 
  
Again, as the sum of ~$74 thousand per genome seems extraordinarily high, it is 
important to remember that these are all fixed equipment costs and will therefore be virtually 
negligible on the per genome basis.  
 
8.3.3 Genome Reassembly Equipment 
In addition to the existing computer system discussed in 8.3.2, supplementary servers are 
required to complete genome assembly step. As previously discussed in Section 7.5 
computational equipment required for genome assembly process is based off of assembly 
algorithm. To assemble one genome, raw sequencing data has to be processed through de Bruijn 
assembly and shot gun sequencing. The bottleneck of assembling process is the later one where 
19.1 hours is required to assemble one genome on a four core 2.4 GHz AMD Opteron Processor 
with 32 GB of RAM (Equation 7.16). Computational demand specification is based off of an 
open source assembly algorithm, Bowtie, where Red Hat Enterprise Linux AS release 4 was 
selected as operating system (Langmead, Trapnell, Pop, & Salzberg, 2009).  
For Micro$eq’s assembly process, Quad-Core AMD Opteron Processor 8356 is selected 
because it is applicable to Linux operating system and satisfies 2.4GHz and 32 GB RAM 
requirement (Geekbench Result Browser, 2008).  
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 The specification of personal genome project is to assemble 12 genomes per day. In order 
to do so, more than one server is required since 1 server takes 19.1 hours to assemble 1 genome. 
Number of servers required can be calculated: 
12                1    × 19.1 ℎℎ 1       × 1    24 ℎℎℎ = 9.55 = 10         
If 10 servers of defined specification are run in parallel, 12 individual genomes can be 
assembled per day. Then the relationship between number of genome assembled and 
computational demand is further explored,  
 9.55       12         ⁄ ×                                 =                   
 
Equation 8.1  
 
                     = 0.796 ×                                                                                           = 2.41 × 10  ×                                    
 
 
Equation 8.2 
The relationship between number of specified server and target number of genome to be 
assembled per day is illustrated in Equation 8.2. The estimation was also illustrated for number of 
targeted assembled genome annually, assuming 330 operating days. The calculated number of servers 
must be rounded up to satisfy the capacity required. From Equation 8.2, as number of target genome to be 
assembled increases, number of server requires to accomplish genome assembly increases linearly. The 
cost of each server is approximately $1650 including associated hardware and Red Hat Linux software 
(AMD). Based on relationship in Equation 8.2, the cost of computational equipments required for genome 
assembly process can be estimated as a function of targeted number of genome product:  
             =  0.796 ×                                × $1650           =  1313 ×                                               =  3.979 ×                                  
     Equation 8.3 
 As illustrated in      Equation 8.3, the cost of servers and their associated software and hardware 
can be estimated as a function of targeted number of genomes Micro$eq wishes to accomplishes. With the 
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initial target of 12 genome per day for Series A investor, the server cost associated with genome assembly 
is $15,756. After Series B funding, the targeted genome increases to 10,000 genomes per year with 
associated assembly server cost equals to $39,792.  
 
8.4 COST ESTIMATE BREAKDOWN SUMMARY  
 This chapter provided a detailed breakdown of the required reagents, microfluidics platforms, and 
equipment for all three stages of Micro$eq’s genome sequencing process. This breakdown will be applied 
in the next chapter, and thus a full process summary will not be provided here, as it can be found in 
section 9.2 of Chapter 9 in this report. A full analysis of the cost estimates, within the context of the entire 
company’s financial analysis will be provided there. However, it is interesting to note that from the above 
summarized, the most expensive equipment and microfluidics sector is the DNA scanning, whereas the 
most expensive reagents sector is the presequencing preparation steps. The genome reassembly is not 
financially limiting in any sector of the discussed cost breakdown.  
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CHAPTER 9  
 
Financial Analysis 
 
While the previous sections have discussed the technical aspects of Micro$eq, it is 
necessary to analyze the financial feasibility of such a company. As a major objective of this 
project was to minimize the cost of sequencing a whole human genome, the actual market price 
of Micro$eq’s production that would allow it to remain profitable must be explored. The goal is 
to achieve a market price at least an order of magnitude less than the current market price, and 
have the capability of a throughput that will match the currently growing market demand. In 
order to achieve the necessary low price per genome, but still maximize the investors’ margins, a 
balance between a low market price and a financially profitable company must be found. 
193 | P a g e  
 
Micro$eq – Chomvong, King, Mahmoud 
While the project specification was originally set at 12 genomes per day and priced at 
$100 per genome, the financial analysis shows that this is unfeasible. However, the financial 
analysis will show that at an increased throughput, a market price of $999 per genome– a full 
order of magnitude  below the current market standard of $10,000 per genome – may be 
achieved while still operating well above Micro$eq’s breakeven point. It is important to note that 
this financial analysis includes several assumptions and a few simplifications. Thus, these 
numbers may not be exact, but are sufficient estimates to show the potential feasibility of the 
project. 
 The analysis begins with revenue projections that are based on the annual genome 
throughput and market price. As the project’s financial feasibility is highly dependent on the 
product price, a separate sensitivity analysis will be done on the market price after a throughput 
number has been determined. Next, the total costs and depreciation values are explored. Costs 
are pseudo-dependent on genomic throughput, as rental space, personnel, and equipment often 
need to be adjusted when throughput is increased. The cost and depreciation values are then 
combined with the projected revenues to create an income statement. However, as the income 
statement is concerned only with earnings, free cash is the real figure that needs to be examined. 
The income statement is then combined with financial investments, working capital, and other 
cash affecting items to get the free cash flows. 
Once free cash flow projections have been decided, the company can then be valued by a 
combination of the terminal value analysis and the discounted cash flow analysis. This company 
value is then translated into a rate of return analysis for investors. This analysis is key in 
convincing investors to fund the project, as they need to know their potential gain by becoming 
financially involved.  
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The scheme of investors for this project is slightly more complicated than a simple start-
up venture capital model. For this project, two distinct series of investors (series A and series B) 
will be involved, the series A investors investing from day one and the series B investors getting 
involved later on in the company life. To simplify the calculations involved in investor return, an 
equity stake analysis is performed. The results of all the calculations are summarized in a 
complete financial statement for the company, at the determined optimal annual throughput and 
market price. 
Once this preliminary analysis has been performed, a what-if analysis which tests some 
of the assumptions made will be performed to explore how these assumptions affect Micro$eq’s 
bottom line and to confirm the final throughput and market price that were chosen. Additionally, 
while the base financial calculations model a small-scale company with ~25,000 genomes 
produced annually, a company expansion is modeled to evaluate the feasibility of achieving a 
monopoly on the Pharmaceuticals and Healthcare markets, as previously discussed in the Market 
Analysis, section 1.1, of this report.  
 
9.1 MARKET AND REVENUE PROJECTIONS 
The genome sequencing market is a relatively new and volatile market. For this reason, 
the standard market price of whole genome sequencing is somewhat unknown. Until five years 
ago, whole genome sequencing was limited to basic science research, as its price was enormous 
(>$10,000,000 per genome). In 2006, the X Prize Foundation, along with the J. Craig Vetner 
Science Foundation launched the Archone X Prize for Genomics, which was to be awarded to 
the first team that can build a device that has the capability of sequencing 100 human genomes in 
10 days or less, with an error rate of 1 in 100,000 bases at the cost of $10,000 per genome 
(Archon Genomics X Prize Overview). Since the launch of this challenge, a race to the 
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commercialization of whole genome sequencing has shown the potential of the market shift for 
this industry. As the price has decreased by orders of magnitude from the original cost of whole 
genome sequencing, the proposed market is now high wealth individuals who wish to have as 
much information about their personal biology as possible. At a price of $10,000 or more per 
genome, having this diagnostic test is still not feasible as a routine medical requirement or as a 
means of research for drug companies. Since 2006, several companies such as IBM, Pacific 
Biosciences, Complete Genomics, Knome, and Illumina  have claimed  that they will soon be 
able to achieve costs of $1000 or less per genome (Carlson). However, as of April 2011 the 
Archone X prize is still unclaimed and the lowest found market price (for non-medically required 
whole genome sequencing) is $10,000 per human genome from Complete Genomics, as of June 
2010 (Complete Human Genome Sequencing Technology Overview, 2009). 
 For the purpose of this discussion, the market price of our genome was chosen to be $999 
per genome. The determination of this price will be discussed later in the section. Additionally, 
at 100% design capacity, Micro$eq sells 72 genomes per day, or 23,760 genomes per year (at 
330 operating days per annum). Thus at full operating capacity, Micro$eq should gross ~$24 
Million per year.  
 The growth and development of the company can be divided into four stages: the 
research stage, the scale up stage, the sales stage, and the terminal stage. During the research 
stage, scientists are developing a working prototype and there is no revenue. All needed capital 
for the research stage is provided by the series A investor. Immediately after the working 
prototype is fully developed, series B investors are brought into the picture. This second set of 
investors provides the necessary capital to being the scale up stage of company development. 
Scale up involves the addition of new equipment, new staff, physical company expansion, and 
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the first intake of revenue. Ideally, the scale up stage will operate at an average of 50% of 
nominal design capacity. After full scale up, the sales stage begins during which the company 
operates ideally at 100% design capacity.  During the sales stage, the company takes in its 
maximum revenue and must turn a profit in order for the entire company to be financially 
feasible. Finally, the terminal stage is the means by which the company will liquidate. This step 
is very important for biotech companies such as Micro$eq, as the market is so dynamic and one 
technology will become obsolete very quickly. A terminal value for the company will be 
calculated based on the free cash flow projections. The idea of the terminal value will be 
discussed in more detail in a later section.  
 Ideally, the research stage takes on year, the scale up stage takes another year, and by the 
beginning of the third year, the company is fully developed and has entered the sales stage. For 
this company, the total company life is modeled as five years. Thus, the sales stage will be 
projected as lasting three years, at the conclusion of which, the terminal value will be determined 
and the company will liquidate. 
 Using this timeline and the above discussed genomic throughput and market price, the 
results of the revenue projections are summarized below in Table 9.8.  
Revenue Projections           
Year 2012 2013 2014 2015 2016 2017
Stage Research Scale-up Sales Sales Sales Terminal 
Design Capacity 0% 50% 100% 100% 100% 100%
Revenue $0.00 $11,879,881.20 $23,759,762.40 $23,759,762.40 $23,759,762.40 Terminal Value 
Table 9.8 Micro$eq’s Revenue Projections for a 5-year company lifetime (amounts in US$) 
 It should be noted that for the purpose of all financial analysis, inflation is ignored. The 
inflation calculated over such a short lifetime is unnecessary and are only relevant in the event of 
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hyperinflation. In 1986, the Financial Accounting Standards Board determined that inflations 
account is unnecessary for financial statements, and thus will be ignored here in the discussion of 
Micro$eq’s financial feasibility. 
 As seen in Table 9.8, for the proposed annual throughput and market price, Micro$eq’s 
gross revenue at full operating capacity is ~$24 million. How this translates into Micro$eq’s 
overall profitability will be discussed in the remained of this chapter. 
 
9.2 COSTS, PPE AND DEPRECIATION 
There costs associated with a start-up such as Micro$eq can be divided into equipment 
purchase and annual cost. Each of these categories contains a research and a sales sector. The 
research equipment consists of what’s required to develop a working prototype. The sales 
equipment will be an expansion of the equipment required for the research phase and will be 
purchased after a working prototype has been secured, to the amount required for Micro$eq to 
operate at fully scaled-up conditions. Annual costs during the research stage will be primarily lab 
space rent and personnel salary. Once a working prototype has been developed, annual costs 
during full operation will also include inventory, research and development, and sales.  
9.2.1 Preliminary Investment 
Two series of investors will be brought into the picture. The series A investors will be 
involved from day one – supplying money for research equipment purchase, and one year’s 
value of research annual cost. Because preliminary funding occurs before a working prototype 
has been confirmed, these investors are generally wealthy “angel” investors that are willing to 
invest in a risky new technology. Consequentially, series A investors will receive the highest 
return on investment as they are undertaking the greatest risk. The details of this financial 
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arrangement will be discussed later on in the Equity Shares section of this chapter. Additionally, 
at scale up time, the series A investors will have the first right of refusal. This allows them to 
invest further (thus making them a series B investor as well) before any other investors are 
petitioned. For the purpose of this discussion the series A and series B investors will be treated as 
separate entities. However it is important to keep in mind that there will most likely be an 
overlap between the two groups of investors. The funding required of series A investors is 
determined in the Cost Estimates spreadsheet (which can be found at the end of this section – 
Table 9.2) and is $600,000.   
The second series of investors – series B investors – provide funding after a working 
prototype has been developed, thus seriously reducing their risk of investing from that of the 
series A group. Series B funding occurs, ideally, one year after series A investment. It is assumed 
that a working prototype may be developed within this time frame. The Series B investors 
provide funding for production scale-up. Their investment is used for the required additional 
equipment purchase, and three months of space rent, personnel salary, and inventory purchases, 
with the assumption that the company will achieve 50% of design capacity by the end of this 
time period. After this period, it is assumed that all remaining costs can be funding by company 
revenue. The required series B investment for this project is $7,000,000.   
The manner in which these monetary investments will be converted to company 
ownership will also be discussed in detail later on in the Equity Shares section of this chapter. 
9.2.2 Personnel Costs 
During the research stage, personnel will be minimized in order to have the lost possible 
operating costs. Staff will include a single secretary and four senior scientists. Of these scientists, 
one will serve as chief technical officer (CTO). Additionally, until a working prototype is 
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confirmed, all scientists will earn two-thirds of their scale up salary. As compensation for this 
sacrifice, the four scientists will own 10% of the original company (2.5% each). It is typical for 
series A investor of this type – particularly when the company employs personnel with very little 
or no entrepreneurial experience (i.e. senior scientists) -   to own 85% of the start-up company. 
However, because this is a biotechnology company, and the market is so volatile, this company 
carries more inherent risk than most ventures. Hence, the series A investors in this case will own 
an additional 5% of the company – 90% - to help compensate for the additional risk they are 
undertaking.  It assumed that one of the primary investors will also serve as the company’s CEO 
from day one, and will be involved in financial planning for the second series of investors and 
company scale up, even during the research stage. However, he will not receive a salary until the 
scale up stage.  
Once a prototype has been confirmed and the company scales up, the initial four senior 
scientists will receive their full salaries. Additional personnel at this point will be added, such as 
junior scientists, sales personnel, and an IT specialist.  
As was discussed in each of the process stage chapters (Chapters 5,6, and 7 of this 
report), the number of technicians required depends somewhat on process throughput. A Gant 
chart of the total processing of a base unit output of 12 genome per day, as shown below in 
Figure 9.75 is used to determine the number of technicians required.  
 
 
 
22:00 2:00 6:00 10:00 14:00 18:00 22:00 2:00 6:00
DNA Preseq Prep(12.5 hrs)
DNA Sequencing (24)
Genome Reassembly (19.1 hrs) Genome Reassembly (19.1 hrs)
Time(hr): 6:00 10:00 14:00 18:00 22:00 2:00 6:00 10:00 14:00 18:00 22:00 2:00 6:00 10:00 14:00 18:00
DNA Preseq Pre p(12.5 hrs) DNA Preseq Pre p(12.5 hrs) DNA Pre seq Prep(12.5 hrs)
DNA Sequencing (24) DNA Sequencing (24)
Genome Reassembly (19.1 hrs)
Figure 9.75 Gant Chart of Micro$eq's overall process 
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As seen in Figure 9.75, the very first process will begin with a 31.6 hr delay (it will take 
the standard 24 hrs plus an additional 31.6 hours to produce the first batch of genomes). 
However, once the process has begun, it can be seen that a whole unit output is produced every 
24 hours, which the DNA sequencing step being the process bottleneck, in taking 24 hours.  
The most important steps in this process are the initial genomic DNA preparation and 
amplification, as well as the 6mer library generation and preparation. It was found that the DNA 
preparation requires two lab technicians for every unit output of 24 genomes per day. Similarly, 
the DNA sequencing process was found to require one lab technician for every unit output of 12 
genomes per day. The DNA reassembly process was found to require only one IT personnel for 
up to a unit output of 72 genomes per day. However, as the computational part of this process 
requires a very different set of skills than the more molecular biology based-sequencing and 
presequencing steps, and a backup IT is required as the other more molecular-biology oriented 
technicians may not necessarily have the skills to fill in for the IT position. 
As the throughput is 72 genomes per day, a total of 12 lab technicians and 2 IT personnel 
are required.  It is feasible that with so many lab technicians on hand, with two shifts of 
technicians, one might be able to substitute for another in the event of an emergency or 
complication.  Additionally, four senior scientists are on staff that my substitute for a lab 
technician in an absolute emergency. This allows the required throughput to be attainable even in 
the occurrence of some inefficiencies regarding personnel.  
9.2.3 Inventory Costs 
The inventory costs for this process included the required bioprocess kits and 
accompanying reagents, additional reagents for processes such as the 6mer library, and genomic 
DNA amplification process, and the microfluidic chips. A detailed breakdown of the inventory 
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costs for each stage in the process was previously given in section 8.1 of Chapter 8 of this report. 
These costs were estimated on a per genome basis and are multiplied by the total annual genome 
throughput to adjust the inventory costs to an annual sum. Additionally, the total inventory costs 
depend on the design capacity. During the research stage, it is assumed that inventory costs are 
negligible, as the only production is prototype development. At the initial 50% scale up 
operation, inventory costs total ~$360,000 At the second scale up, to 100% design capacity, 
inventory costs are double this and total ~$720,000. 
9.2.4 Operating Costs 
Operating costs include further research and development costs. This component of the 
company is necessary in order for the company to remain competitive. The biotechnology 
market, as previously discussed, is extremely dynamic. It is assumed that the original working 
prototype will become obsolete very quickly. In order for the company to have enough value to 
sell at the end of the prescribed five-year period, its intellectual property and patent ownership 
must remain competitive.  
Operating costs also include sales cost and have been estimated as a percentage of 
revenue.  
9.2.5 Rental Costs 
The location of the company is assumed to be Arizona, USA. This location was chosen as 
it is not too rural to exclude the recruitment of well-qualified personnel and investors. 
Additionally, shipping costs of both inventory and patient samples is minimized by being inside 
the continental united sates. The annual rental price is estimated from the current market price of 
laboratory and office space in this location, as of April 2011 (Arizona Real Estate). Rental costs 
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are minimized during the research stage, but scale-up operation requires a large increase in 
required space. The plant is assumed to be expanded after the first year to full capacity, and thus 
rental costs will be at 100% even when design capacity is only at 50%. Required rental space 
included laboratory space, sequencing space, and office space.  
These cost estimates are summarized on the next two pages in Figure 9.76. As seen from 
this summary, the total annual cost estimates for the Research stage are ~$566 thousand, thus the 
initial investment required of Series A investors will be set at $600 thousand. The total scale-up 
annual costs are ~$9 million. However, this entire sum is not required from the Series B 
investors, as this phase will also generate income. Instead, the required Series B investment is set 
as slightly greater than the Series B equipment purchase (~$6.7 million) at $7 million. 
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Figure 9.76 Summary of Cost Estimates for Micro$eq's Operations (Amounts in US$) 
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9.2.6 Depreciation 
Depreciation of equipment will be estimated using a 5-year MACRs depreciation 
schedule. An alternative model to the MACRS is the Accelerated Tax Schedule, but this does not 
provide the company with tax savings. While depreciation is a non-cash expense, it still affects 
pre-tax income, from which taxes are deducted. If the pre-tax income decrease, the money lost to 
taxes will also decreases.  Tax, unlike depreciation, is a cash expense. An accelerated 
depreciation schedule for short lived projects such as this one will have a significant import on 
the NPV and MIRR analysis. The depreciation percentages for a 5-year MARCS schedule are, in 
chronological order, 20%, 32%, 19.2%, 11.52%, 5.76%. The effects of this estimated 
depreciation are displayed in Table 9.9 Depreciation Schedule using the 5 year MACRs schedule 
(amounts in US$). 
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Depreciation Schedule         
MACR Tax Schdule: 20.00% 32.00% 19.20% 11.52% 11.52% 
Year 2012 2013 2014 2015 2016 
Series A equipment $54,093.67         
Depreciation ($108.19) ($173.45) ($104.40) ($62.76) 
Series B Equipment   $6,793,176.42       
Depreciation ($21,738.16) ($13,084.64) ($7,865.86) 
Begininning Net PPE           
PPE Purchase/(Sold) $54,093.67 $6,793,176.42 
Less: Total Depreciation ($108.19) ($21,911.61) ($13,189.04) ($7,928.62) 
Ending Net PPE $54,093.67 $6,847,161.90 $6,825,250.29 $6,812,061.26 $6,804,132.64 
Table 9.9 Depreciation Schedule using the 5 year MACRs schedule (amounts in US$) 
 
Equipment denoted as series A is that purchased in the research phase. Equipment 
denoted as series B is that purchased for the operation scale-up. The ending net PPE figures are 
balance sheet items and represent how much property and equipment the company owns post-
depreciation. The total depreciation is what appears on the income statement and will decrease 
pre-tax income. Note: these calculations assume that the research stage takes exactly one year. 
As science is very volatile, it is possible that it will be a full two years before a working 
prototype as been confirmed. If this is the case, the depreciation schedule percentages would 
remain unchanged, simply the series B equipment would be shifted to year three instead of year 
2. This would additionally affect total depreciation and Ending Net PPE. This scenario will be 
further discussed in a later section.   
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9.3 INCOME STATEMENT 
Total costs are divided into costs of sales and operating and selling, general, and 
administrative services (SG&A) expenses. The cost of sales (alternatively referred to as the costs 
of goods sold, COGS) is the sum of fixed costs and variable costs and includes costs that are 
directly involved in the making of the goods. Fixed costs include rent and overhead, because 
these are assumed to be constant during each of the two stages (research and full operation). 
Variable costs include inventory costs, which is virtually a direct function of the sample 
throughput. The gross profit is calculated by subtracting the cost of sales from the revenue. The 
gross margin is a percentage showing how much money is left from the revenue after the cost of 
sales is subtracted. Operating and SG&A expenses are costs associated with business 
management. These include salary, as well as research and development, and sales cost. 
Subtracting these new expenses and the depreciation, as previously discussed, yields the pre-tax 
income. The summary of these results are displayed in Table 9.10. 
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Income Statement           
Year 2012 2013 2014 2015 2016
Revenue $0.00 $11,879,881.20 $23,759,762.40 $23,759,762.40 $23,759,762.40 
Cost of Sales $172,000.00 $380,603.80 $382,207.60 $382,207.60 $382,207.60 
Gross Profit ($172,000.00) $11,499,277.40 $23,377,554.80 $23,377,554.80 $23,377,554.80 
Operating, SG&A expenses $340,000.00 $1,550,691.89 $1,561,383.79 $1,561,383.79 $1,561,383.79 
Pre-tax Income ($512,000.00) $9,948,585.51 $21,816,171.01 $21,816,171.01 $21,816,171.01 
40% tax rate ($204,800.00) $3,979,434.20 $8,726,468.41 $8,726,468.41 $8,726,468.41 
Net Income ($307,200.00) $5,969,151.30 $13,089,702.61 $13,089,702.61 $13,089,702.61 
Design Capacity % 0 50 100 100 100
Margins           
Gross Margin % 0.00% 96.80% 98.39% 98.39% 98.39%
Profit Margin % 0.00% 50.25% 55.09% 55.09% 55.09%
Table 9.10 Income statement showing gross and profit margins (amounts in US$) 
The tax rate is calculated via the addition of both Federal and State tax. Federal tax is 
assumed to be ~35%, with State tax assume to be 5%. As seen from the income seen in the 
income sheet in Table 9.10 Income statement showing gross and profit margins (amounts in US$), the 
company loses money in the first year. Tax shields (alternatively called negative taxes) apply to 
many start-up companies, and it will be assumed that this is the case for Micro$eq. When a tax 
shield is in place, a company that loses money in its first year actually receives funds from the 
government. This is reflected by the positive tax figure for year one.  
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9.4 WORKING CAPITAL 
While the income statement allows calculation of net income, net income is the the 
equivalent of cash flows. In order to obtain true cash estimates, and thus subsequent NPV and 
IRR analyses, the net income must be adjusted for cash items, such as change in working capital.  
Working capital is the amount of capital required for normal company operation. A 
portion of net income must be allocated daily operations before a profit is calculated. Working 
capital can be thought of as the difference between current assets and current liabilities. Current 
assets may be easily and almost immediately converted to cash, whereas current liabilities are 
bills and debts the company has to pay almost immediately. Working capital is therefore the cash 
leftover after the company has paid its imminent bills.  
Working capital can be broken into four main items: accounts receivables, accounts 
payable, inventory, and cash reserve. Accounts receivables are earnings that have been recorded 
but have yet to receive cash payment.  The time gap between recording and receiving of these 
earnings is generally between 30-60 days. For the purpose of this discussion, it will be assumed 
that the client pays within 30 days. Because all accounts receivables convert into revenue 
eventually, accounts receivable (AR) can be expressed as: 
   =         ($)    ×               ×         
 
Accounts payable is the inverse of accounts receivable. Accounts payable are bills the 
company has recorded as paid, and subtracted from the revenue, but has not actually paid in cash 
yet. It will be assumed that bills are paid on a monthly basis (assume to be a 30 day period). It is 
traditional that accounts payable(AP) is expressed as : 
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   =                ($)    ×               ×         
 
Where cost of sales contains rent, operating costs, and inventory costs. For the purpose of 
this project, we have separated out inventory sales, and cost of sales consists almost exclusively 
of rent and operating costs. Thus AP may be more specifically expressed as: 
 
   =  (     +                )($)    ×               ×         
 
Similarly, to accounts payable and receivable inventory – what the company requires in 
order to produce its goods – will be bought on a monthly basis (assume to be a 30 day period), so 
that inventory (Inv) may be defined as: 
 
   =         ($)    ×               ×         
 
Cash reserve is defined as the cash available on hand to pay future salaries. For the 
purpose of this discussion, it will be assumed that 3 months worth of salaries will be reserved, so 
that cash reserve(CR) may be defined as: 
 
   =         ($)    ×              ×           
 
The results of these calculations are displayed in Table 9.11. 
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Working Capital           
Year 2012 2013 2014 2015 2016 
Working Capital Item Estimates           
Acounts Receivable ((AR) $0.00 $976,428.59 $1,952,857.18 $1,952,857.18 $1,952,857.18 
Accounts Payable (AP) $14,136.99 $32,029.47 $32,908.26 $32,908.26 $32,908.26 
Inventory (Inv) $0.00 $131.82 $263.64 $263.64 $263.64 
Cash Reserve (CR) $85,000.00 $385,000.00 $385,000.00 $385,000.00 $385,000.00 
Changes in Working capital           
Changes in AR $0.00 ($976,428.59) ($976,428.59) $0.00 $0.00 
Changes inAP $14,136.99 $17,892.48 $878.79 $0.00 $0.00 
Changes in Inv $0.00 $131.82 $131.82 $0.00 $0.00 
Changes in CR ($85,000.00) ($300,000.00) $0.00 $0.00 $0.00 
Total Change in Working Capital ($70,863.01) ($1,258,404.29) ($975,417.99) $0.00 $0.00 
Table 9.11 Working Capital and Changes in Working Capital (amounts in US$) 
As seen in Table 9.11, it is important to consider to effects of changes in each of the four 
sectors of working capital. Any increase in assets decreases total cash. Conversely, a decrease in 
assets increases total cash. Increased liability increases cash temporarily, as the company has that 
liability on hand to spend before it must be repaid. A decrease in liability implies that the 
company has spent money to repay that liability and thus implies a decrease in cash. 
Increase in accounts receivable since the previous fiscal year decrease cash because net 
income has taken this amount into account, but the company has yet to actually receive the 
money. The following fiscal year, however, the account will have been paid, which is reflected 
by a decrease in account receivable (assuming no additional chances in accounts receivable).  
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Increase in accounts payable increase cash because net income is revenue less accounts 
payable, and the company has yet to actual let go of the cash. 
Increases in inventory decrease cash, as cash spending is required for the purchase of 
additional inventory.  
Increases in cash reserve decrease cash, as cash has to be set aside to pay for future 
salaries, and thus cannot be used to pay company owners. 
It is also important to note that two other cash items have yet to be discussed: PPE and common 
stock. Purchasing PPE (plan, property, and equipment) decrease cash almost immediately. 
However, a PPE purchased does not show up on the income statement and instead is slowly 
amortized. This is because the income statement reflects the company’s operational efficiency, 
which doesn’t necessarily include one-time cash expenses. Selling of equipment is the same 
principle, simply inverted. Selling of equipment generated immediate cash, but is not included as 
part of the revenue as revenue only reflects the company’s normal operations and selling 
unused/unwanted equipment is a one-time event. 
Similarly, the issuance of common stock is not included in part of the revenue. The 
selling of stock to investors – either series A or B – does generate immediate cash, but is a one-
time event. Repurchasing of existing shares from investors similarly decrease cash, but will not 
be reflected on the income statement. Instead, all the cash items will be found in the cash flow 
statement. 
 
9.5 FREE CASH FLOW AND TERMINAL VALUE 
As mentioned in the previous section, net income does not directly imply net cash. Net 
income must be adjusted by cash from operation activity (which includes depreciation, changes 
in working capital, accounts receivable, accounts payable, inventory, and cash reserve), cash 
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from investing activities such as purchasing/selling equipment, and cash from financing 
activities. The summation of these four sectors yields free cash flow, the complete projections of 
which are displayed in  
Free Cash Flow           
Year 2012 2013 2014 2015 2016
Net Income (307,200.00) 5,969,151.30 13,089,702.61 13,089,702.61 13,089,702.61 
Cash Flow Operating Activites           
Plus:Depreciation 0.00 (108.19) (21,911.61) (13,189.04) (7,928.62)
Changes in Working Capital 0.00 0.00 
Changes in AR 0.00 (976,428.59) (976,428.59) 0.00 0.00 
Changes in AP 14,136.99 17,892.48 878.79 0.00 0.00 
Changes in Inv 0.00 131.82 131.82 0.00 0.00 
Changes in CR (85,000.00) (300,000.00) 0.00 0.00 0.00 
Total Change in Working Capital (70,863.01) (1,258,404.29) (975,417.99) 0.00 0.00 
Cash From Investing Activities           
Purchasing/Selling of Equipment (54,093.67) (6,793,176.42) 
Cash from Financing Activites           
Issuance of Common Stock 600,000.00 7,000,000.00 
Total Free Cash Flow 96,980.30 3,659,058.12 11,116,955.02 13,076,513.57 13,081,773.99 
Table 9.12: 
Free Cash Flow           
Year 2012 2013 2014 2015 2016
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Net Income (307,200.00) 5,969,151.30 13,089,702.61 13,089,702.61 13,089,702.61 
Cash Flow Operating Activites           
Plus:Depreciation 0.00 (108.19) (21,911.61) (13,189.04) (7,928.62)
Changes in Working Capital 0.00 0.00 
Changes in AR 0.00 (976,428.59) (976,428.59) 0.00 0.00 
Changes in AP 14,136.99 17,892.48 878.79 0.00 0.00 
Changes in Inv 0.00 131.82 131.82 0.00 0.00 
Changes in CR (85,000.00) (300,000.00) 0.00 0.00 0.00 
Total Change in Working Capital (70,863.01) (1,258,404.29) (975,417.99) 0.00 0.00 
Cash From Investing Activities           
Purchasing/Selling of Equipment (54,093.67) (6,793,176.42) 
Cash from Financing Activites           
Issuance of Common Stock 600,000.00 7,000,000.00 
Total Free Cash Flow 96,980.30 3,659,058.12 11,116,955.02 13,076,513.57 13,081,773.99 
Table 9.12 Free Cash Flow from Net Income (amounts in US$) 
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 These free cash flow will be used to calculate net present value (NPV) and internal rate 
of return (IRR), which represent real cash received by the company shareholders. However, 
before these analyses, the terminal value of the company needs to be determined. This value is 
the present value off the continuing future cash flows, which assumes that all future cash flows 
are entirely predictable.  Terminal values may be estimated using the perpetuity growth model as 
seen below:                =            ×  (   )(   )  
  
Where the cash flow is the last free cash flow, g 
is the growth rate of cash flow and the company, and r is 
the discount rate. Using this value, the terminal value is 
predicted for for growth rates varying between 25 and -
25%, as seen in Table 9.13.  
Note: when the growth rate is zero, the terminal value 
simplifies to being = cash flow/r, which is defined as the 
basic perpetuity model. 
 For this majority of this discussion the growth 
will be assumed to be zero, with alternative possibilities 
discussed as possible cases toward the end of this 
chapter. 
 
 
 
Terminal Value   
Last Free Cash Flow $13,081,773.99 
Discount Rate 25.00% 
Growth Rate Terminal Value 
-20.00% $23,256,487.10 
-15.00% $27,798,769.73 
-10.00% $33,638,847.41 
-5.00% $41,425,617.64 
0.00% $52,327,095.97 
5.00% $68,679,313.46 
10.00% $95,933,009.28 
15.00% $150,440,400.91 
20.00% $313,962,575.82 
Table 9.13 Terminal Values for Varying Growth Rates  
(amounts in US$) 
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9.6 NPV VALUATION 
The net present value (NPV) is a mathematical model that describes the financial gain 
possible for an investor. At the point where the NPV is zero, the company has broken even. 
Above a NPV of zero, the company is operating above their bottom line. The NPV is the sum of 
all present values of every cash flow, and is highly dependent on the discount rate. In this case, 
every cash flow includes only free cash flow and terminal value. The discount rate is dependent 
on the risk-level involved in the model industry. A high-risk industry such as the Biotech 
industry used for this model company will have a relatively high discount rate. For the purpose 
of this discussion, the discount rate will be approximated as 25%. However, the discount rate 
during the research stage is significantly higher, as the company’s risk is much greater when a 
working prototype has yet to be confirmed. It will be assumed that during the research phase, the 
discount rate is 50%.  
In order to calculate the NPV’s, all projected free cash flows and terminal values are 
discounted back into present values. The present values are then summed, and the present values 
of the cost of the project (initial investments) must be subtracted. This calculation is complicated 
by the fact that two different investment times from two different investors. The initial 
investment – series A – has a present value equal to the actual investment amount ($600,000) 
and will not be discounted. This is because the initial investment is not a future cash flow, but 
rather occurs at time equals zero. However, the second investment – series B – is a future cash 
flow which occurs after a working prototype has been confirmed. Thus, the series B investment 
must be discounted at the 25% discount rate as previously discussed. 
It is also important to note that the terminal value of the company is terminal value of the 
company, because it is a future projected values, is discounted to the present. For the purpose of 
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this discussion it is assumed that the growth rate is 0%. The possibility that growth is in fact 
greater than 0% will be discussed in a later section. The net present value, therefore, is the sum 
of all present values, which includes all positive future cash flows with present negative 
investments subtracted.  The summary of these analyses is displayed in Table 9.14.  
NPV Calculations @ 25% Discount Rate         
Year 2012 2013 2014 2015 2016 2017 Terminal Value 
Year of Operation 0 1 2 3 4 5 6 
Free Cash Flow $0.00 $96,980.30 $3,659,058.12 $11,116,955.02 $13,076,513.57 $13,081,773.99 $41,031,281.01 
Discount Rate 0.00% 50.00% 25.00% 25.00% 25.00% 25.00% 25.00% 
Present Value $0.00 $64,653.54 $2,341,797.20 $5,691,880.97 $5,356,139.96 $4,286,635.70 $10,756,104.13 
Investments (600,000) (7,000,000) 
Discount Rate 0.00% 25.00% 
Present Value (600,000.00) (5,600,000.00) 
Sum of All Present Vales (NPV)   $4,556,104 
Table 9.14 Net Present Value Calcuations using a 25% Discount Rate (all amount in US$) 
 
As seen in Table 9.14, the NPV under the above assumed conditions, is estimated to be 
~$4.5 million, which indicates that Micro$eq is operating well above its bottom line and predicts 
that all combined investors will earn approximately an additional $4.5 million for their initial 
investment .  
 
9.7 EQUITY SHARES 
Of course, this total cash gain by the investors is not divided equally between all 
investors. As previously discussed, the series A investors own 90% of the original company, 
during the research phase. However, once the series B investors become involved, the percentage 
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of the total company that series A investors own will significantly decrease. The amounts that 
each investors’ series contributed are considered and their relative company percent ownership is 
calculated. It is important to note that in order to directly compare the two monetary investments, 
the series A investment must be discounted for the first year by 50% (as previously discussed, 
this was the discount rate during the research phase).  The results of these calculations are shown 
in Table 9.15. 
Percentage of Investments     
Investment FV Investment Share Fraction 
Series A Investors $600,000.00 $750,000.00 9.68% 
Serirs B Investors $7,000,000.00 $7,000,000.00 90.32% 
Total $7,600,000.00 $7,750,000.00 100.00% 
Table 9.15 Percentage of Investments for the two Series (amounts in US$) 
It should be noted that, as previously discussed, the series A investors took on a higher 
level of risk by investing before a working prototype was confirmed. As incentive to undertake 
this increased risk level, the series A investors were promised a larger company ownership 
percentage than later investors. While it is illegal to arbitrarily give the series A investors an 
additional monetary (chare) compensation for their increased risk, it can be seen from Table 9.15 
that the series A investors “purchased” their shares at a lower “price” that the series B, due to the 
time difference between the two investments.  Additionally, it was discussed that the original 
four senior scientists would collectively own 10% of the original company, which translates into 
10% of the 9.68% of the fully scaled-up company owned by the original investors.  
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Using the previously-calculated NPV values, these adjusted shares and each owner’s 
share values for each year of the projected company existence can be calculated. The results of 
these calculations are shown in Table 9.16. 
Equity Percentage           
Year 2012 2013 2014 2015 2016 2017 
Scientists 10.00% 0.97% 0.97% 0.97% 0.97% 0.97% 
Series A Investors 90.00% 8.71% 8.71% 8.71% 8.71% 8.71% 
Series B Investors 0.00% 90.32% 90.32% 90.32% 90.32% 90.32% 
Total 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 
NPV @ 25% ($27,799,310.17) ($27,134,656.63) ($15,842,775.66) ($10,486,635.70) ($6,200,000.00) $4,556,104.13 
Shares Values v. Time           
Scientists $0.00 $0.00 ($153,317.18) ($101,483.57) ($60,000.00) $44,091.33 
Series A Investors $0.00 $0.00 ($1,379,854.65) ($913,352.14) ($540,000.00) $396,821.97 
Series B Investors $0.00 $0.00 ($14,309,603.82) ($9,471,799.99) ($5,600,000.00) $4,115,190.83 
Total $0.00 $0.00 ($15,842,775.66) ($10,486,635.70) ($6,200,000.00) $4,556,104.13 
Table 9.16 Equity Percentage and Share Values of Owners (amounts in US$) 
 
It is important to note that the total share value at the completion of the 5-year company 
projection is the same total NPV calculated in the previous section. This agreement confirms the 
idea that the NPV is the total amount of investment return to be received collectively by all 
investors.    
 
9.8 RATE OF RETURN ANALYSIS 
Rate of return analysis is traditionally done using the internal rate of return model (IRR). 
However, the IRR model assumes that free cash flows are reinvested at the rate they are 
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calculated at. This assumption does not hold for this company model, as there are only two 
rounds of investments and none of the free cash flows are ever reinvested, much less continually 
reinvested. Thus, for the purpose of this discussion, the IRR model will not be used. 
Instead, the modified internal rate of return (MIRR) model will be used. This model requires 
specification of the finance and reinvestment rates. The finance rate is the annual percentage rate 
(APR) the company must pay to debt lenders if any negative cash flows exist. The APR will be 
chosen to be 3.95, as is estimated as the Term Loan Rate by the US treasury as of April 2011 
(Bankrate). The reinvestment rate is the rate at which the owners receive payment on positive 
cash flows. For the purpose of this discussion, a 4.84% reinvestment rate will be assumed. This 
number is derived from the current (as of April 2011) yield on a 1 year US Treasury bills 
(Bankrate), which can be used to define a risk free rate in the current economy. It is possible that 
a higher reinvestment rate could be chosen, as the investors are assumed to be experienced 
enough in the financial world to be able to earn more than the risk free rate. However, in order to 
maintain a conservative profitability analysis, the risk free rate will be used in these calculations.  
This adjusted model involved two relatively simple steps. First, the investment is defined. 
Then, all free cash flows the investor would receive are divided into the equity percentages as 
defined in the previous section. The results of these calculations are shown in Table 9.17. 
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MIRR Analysis            
       Year 2012 2013 2014 2015 2016 2017 
Free Cash Flows $96,980.30 $3,659,058.12 $11,116,955.02 $13,076,513.57 $13,081,773.99 $41,031,281.01 
Equity Percentages           
Series A 90.00% 8.71% 8.71% 8.71% 8.71% 8.71% 
Series B 0.00% 90.32% 90.32% 90.32% 90.32% 90.32% 
Cash Flows Investment         
Series A 600,000 
Series B 7,000,000 
Divided Free Cash Flows 
$87,282.27 $318,692.16 $968,250.92 $1,138,922.15 $1,139,380.32 $3,652,527.82 
$0.00 $3,304,955.72 $10,041,120.67 $11,811,044.52 $11,815,795.86 $36,972,916.77 
Future Value of Positive Cash Flows @4.84 Reinvestment Rate     
Series A $410,198.89 $1,398,303.44 $2,604,903.48 $3,870,361.12 $4,057,686.60 
Series B $3,304,955.72 $13,506,036.25 $25,970,772.92 $39,043,554.19 
Series A MIRR % 89.11% 
Series B MIRR % 77.34% 
Table 9.17 MIRR Calculations at APR rate of 3.95% and Reinvest rate of 4.84% (amounts in US$) 
From Table 9.17, it can be seen the series A investors can expect ~89% returns and the 
series B investors can expect ~77% returns, both of these values being very competitive in the 
current Biotech start-up industry (BCC Research). It is important to note that without the 
adjusted finance and reinvestment rates, the original IRR model would yield about 130% returns, 
which can be seen to be a gross overestimation of the actually found numbers using the MIRR 
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model. It is also important to note the series B investors are not included in the first year’s 
earnings, as they were not involved in the company at this stage. Additionally, as previously 
discussed, the series A investors receive a higher return on investment than the series B 
investors, as they undertook the higher risk upon their initial investment and thus were promised 
higher return as an incentive to undertake that risk. 
 
9.9 PRELIMINARY FINANCIAL SUMMARY 
To this point, a preliminary financial analysis has been performed. This includes the 
creation of a pro forma income statement, which was subsequently adjusted to get free cash 
flows. From the calculated cash flows, the NPV and MIRR analyses were performed, using a 
modeled equity share scheme. The results of this preliminary financial analysis are summarized 
in Table 9.18.  It can be seen that the projected NPV is ~$6.5 million with MIRR for series A and 
series B investors at 89.1% and 77.3% respectively, indication that both the company is 
operating well above the bottom line and that both series of investors will receive a significant 
returns on investment.   
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Table 9.18 Preliminary Financial Summary for 72 genomes per day output @ $999/genome (amounts in US$) 
  
Growth Case Financial Summary - 72 genomes/day @$999/genome & 25% annual growth
Year 2012 2013 2014 2015 2016 2017
Stage Research Scale Up Sales Sales Sales Terminal
% of Design Capacity 0.00% 50.00% 100.00% 100.00% 100.00% 100.00%
Income Statement
Revenue $0.00 $11,879,881.20 $23,759,762.40 $23,759,762.40 $23,759,762.40
Cost  of sales $172,000.00 $380,603.80 $382,207.60 $382,207.60 $382,207.60
Operateing, SG&A expenses $340,000.00 $1,550,691.89 $1,561,383.79 $1,561,383.79 $1,561,383.79
Depreciation $0.00 ($108.19) ($21,911.61) ($13,189.04) ($7,928.62)
Pre-tax income ($512,000.00) $9,948,585.51 $21,816,171.01 $21,816,171.01 $21,816,171.01
Tax @ 40% ($204,800.00) $3,979,434.20 $8,726,468.41 $8,726,468.41 $8,726,468.41
Net income ($307,200.00) $5,969,151.30 $13,089,702.61 $13,089,702.61 $13,089,702.61
Cash Flow Statement
Cash from Operating Activities
Plus:Depreciation $0.00 ($108.19) ($21,911.61) ($13,189.04) ($7,928.62)
Changes in Working Capital
Changes in AR $0.00 ($976,428.59) ($976,428.59) $0.00 $0.00
Changes in AP $14,136.99 $17,892.48 $878.79 $0.00 $0.00
Changes in Inv $0.00 $131.82 $131.82 $0.00 $0.00
Changes in CR ($85,000.00) ($300,000.00) $0.00 $0.00 $0.00
Total Change in Working capital ($70,863.01) ($1,258,404.29) ($975,417.99) $0.00 $0.00
Cash from Investing Activities
Purchase/Sale of Equipment ($54,093.67) ($6,793,176.42)
Cash from Financing Activities
Issuance of Common Stock $600,000.00 $7,000,000.00
Free Cash Flow $96,980.30 $3,659,058.12 $11,116,955.02 $13,076,513.57 $13,081,773.99 $41,031,281.01
NPV@25% Discount Rate $4,556,104.13
Equity Shares Investment
Series A Equity 600,000
Series B Equity 7,000,000
Divided Free Cash Flows
$87,282.27 $318,692.16 $968,250.92 $1,138,922.15 $1,139,380.32 $3,652,527.82
$0.00 $3,304,955.72 $10,041,120.67 $11,811,044.52 $11,815,795.86 $36,972,916.77
Series A MIRR 89.11%
Series B MIRR 77.34%
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9.10 PRICE AND THROUGHPUT DETERMINATION 
 Thus far, the preliminary financial analysis has been with the determined optimal market 
price and annual throughput. However, before these numbers were determined, alternative 
scenarios were explored.  
9.10.1 Original Project Specifications 
 As previously discussed, the original project statement was to achieve a throughput of 12 
genomes per day (3460 per year @ 330 operation days per year) at a market price of $100 per 
genome. By adjusting the required inventory, personnel, and equipment to this throughput, the 
financial analysis was first run at this market price. The summary of the results of this analysis 
are displayed in Table Table 9.19 on the next page. As seen in this table, the found NPV is ~ - 
$3.2 Million, with MIRR’s for the series A and series B investors being -148% and -163%, 
respectively. It is evident that this throughput and market price, for the process as designed, 
Micro$eq would be financially infeasible.  
 Next, with the project specified throughput of 12 genomes per day, the minimum price 
for Micro$eq to break even (NPV value =~0) was found. The summary of the results from this 
calculation are found in Table 9.20, adjacent to Table 9.19. As seen in this table, the NPV is 
found to be $0 indicating the company is exactly the breakeven level of operation, for market 
price of $1,710 per genome. For this MIRR’s for the series A and series B investors being 58.6% 
and 47.8%, respectively. While these are low, but plausible values, investors, particularly in such 
a high-risk industry, generally expect projected margins to be at minimum, 50%. This breakeven 
market price is almost a full order of magnitude lower than the lowest current market price 
($10,500, Complete genome) but still more than an order of magnitude greater than the project’s 
original target price of $100 per genome. 
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Table 9.19 Financial Summary for 12 genomes per day @ $100 per genome (all amounts in US$) 
  
Preliminary Financial Summary - 12 genomes/day @ $100/genome
Year 2012 2013 2014 2015 2016 2017
Stage Research Scale Up Sales Sales Sales Terminal
% of Design Capacity 0.00% 50.00% 100.00% 100.00% 100.00% 100.00%
Income Statement
Revenue $0.00 $198,000.00 $396,000.00 $396,000.00 $396,000.00
Cost of sales $172,000.00 $380,603.80 $382,207.60 $382,207.60 $382,207.60
Operateing, SG&A expenses $340,000.00 $1,000,178.20 $1,000,356.40 $1,000,356.40 $1,000,356.40
Depreciation $0.00 ($108.19) ($3,796.47) ($2,285.17) ($1,373.74)
Pre-tax income ($512,000.00) ($1,182,782.00) ($986,564.00) ($986,564.00) ($986,564.00)
Tax @ 40% ($204,800.00) ($473,112.80) ($394,625.60) ($394,625.60) ($394,625.60)
Net income ($307,200.00) ($709,669.20) ($591,938.40) ($591,938.40) ($591,938.40)
Cash Flow Statement
Cash from Operating Activities
Plus:Depreciation $0.00 ($108.19) ($3,796.47) ($2,285.17) ($1,373.74)
Changes in Working Capital
Changes in AR $0.00 ($16,273.97) ($16,273.97) $0.00 $0.00
Changes in AP $14,136.99 $17,028.35 $14.65 $0.00 $0.00
Changes in Inv $0.00 $131.82 $131.82 $0.00 $0.00
Changes in CR ($85,000.00) ($165,000.00) $0.00 $0.00 $0.00
Total Change in Working capital ($70,863.01) ($164,113.81) ($16,127.51) $0.00 $0.00
Cash from Investing Activities
Purchase/Sale of Equipment ($54,093.67) ($1,132,196.07)
Cash from Financing Activities
Issuance of Common Stock $600,000.00 $3,000,000.00
Free Cash Flow $96,980.30 $829,798.93 ($627,989.89) ($594,223.57) ($593,312.14) ($888,746.37)
NPV@25% Discoun t Rate ($3,232,979.53)
Equity Shares Investment
Series A Equity 600,000
Series B Equity 3,000,000
Divided Free Cash Flows
$87,282.27 $149,363.81 ($113,038.18) ($106,960.24) ($106,796.18) ($90,148.53)
$0.00 $663,839.14 ($502,391.91) ($475,378.86) ($474,649.71) ($788,581.34)
S erie s A MIRR -148.58%
S erie s B  MIRR -163.28%
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Table 9.20 Preliminary Financial Summary for 12 genomes per day @ $1,710 per genome (all amounts in US$) 
 
 
  
Preliminary Financial Summary - 12 genomes/day @$1,710/genome
Year 2012 2013 2014 2015 2016 2017
Stage Research Scale Up Sales Sales Sales Terminal
% of Design Capacity 0.00% 50.00% 100.00% 100.00% 100.00% 100.00%
Income Statement
Revenue $0.00 $3,386,634.76 $6,773,269.52 $6,773,269.52 $6,773,269.52
Cost of sales $172,000.00 $380,603.80 $382,207.60 $382,207.60 $382,207.60
Operateing, SG&A expenses $340,000.00 $1,003,047.97 $1,006,095.94 $1,006,095.94 $1,006,095.94
Depreciation $0.00 ($108.19) ($3,796.47) ($2,285.17) ($1,373.74)
Pre-tax income ($512,000.00) $2,002,982.99 $5,384,965.98 $5,384,965.98 $5,384,965.98
Tax @ 40% ($204,800.00) $801,193.20 $2,153,986.39 $2,153,986.39 $2,153,986.39
Net  income ($307,200.00) $1,201,789.79 $3,230,979.59 $3,230,979.59 $3,230,979.59
Cash Flow Statement
Cash from Operating Activities
Plus:Depreciat ion $0.00 ($108.19) ($3,796.47) ($2,285.17) ($1,373.74)
Changes in Working Capital
Changes in AR $0.00 ($278,353.54) ($278,353.54) $0.00 $0.00
Changes in AP $14,136.99 $17,264.22 $250.52 $0.00 $0.00
Changes in Inv $0.00 $131.82 $131.82 $0.00 $0.00
Changes in CR ($85,000.00) ($165,000.00) $0.00 $0.00 $0.00
Total Change in Working capital ($70,863.01) ($425,957.51) ($277,971.20) $0.00 $0.00
Cash from Investing Activities
Purchase/Sale of Equipment ($54,093.67) ($1,132,196.07)
Cash from Financing Activities
Issuance of Common Stock $600,000.00 $3,000,000.00
Free Cash Flow $96,980.30 $2,217,570.52 $2,671,240.70 $3,228,694.41 $3,229,605.85 $11,444,091.80
NPV@25% Discount Rate $0.00
Equity Shares Investment
Series A Equity 600,000
Series B Equity 3,000,000
Divided Free Cash Flows
$87,282.27 $399,162.69 $480,823.33 $581,164.99 $581,329.05 $2,129,762.34
$0.00 $1,774,056.42 $2,136,992.56 $2,582,955.53 $2,583,684.68 $9,077,689.20
Series A MIRR 58.63%
Series B MIRR 47.79%
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9.10.2 Modified Throughput and Price Sensitivity 
 In order to achieve a market price lower than one order of magnitude greater than the 
original project goal, increasing the throughput of the process was explored. It was determined 
that a throughput of 72 genomes per day (23,760 genomes per year at 330 operating days per 
year) was the optimal throughput with respect to economies of scale for personnel, lab space, and 
equipment requirements (financial summaries for alternative throughput scenarios with 
corresponding breakeven operations can be found in Appendix D). At this throughput, the 
breakeven market price was found to be $466 per genome – almost a quarter of the required 
price at a throughput of 12 genomes per day. The results of this calculation are displayed in 
Table Table 9.21 on the next page.  
The set market price was then increased above this breakeven price to generate larger 
company profit and larger MIRR’s for the investors. As previously discussed the final price was 
set at $999 per genome. This price was chosen partially for its marketing benefit of still being 
under the $1000 per genome benchmark. This benchmark is a significant milestone in the 
genome market as it is a ten-fold decrease from the current minimum market price. As 
previously stated, for this final determined throughput, the projected NPV is ~$4.5 million with 
MIRR for series A and series B investors at 89.1% and 77.3% respectively, which is a significant 
increase in return for investors from the $466 per genome breakeven market price. For the 
purpose of comparison, the full financial analysis of Micro$eq’s final market price and output 
can be found in figure Table 9.18 in section 9.9 of this chapter.   
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Table 9.21 Financial Summary for 72 genomes per day @ $466 per genome (all amounts in US$) 
  
Preliminary Financial Summary - 72 genomes/day @$466/genome
Year 2012 2013 2014 2015 2016 2017
Stage Research Scale Up Sales Sales Sales Terminal
% of Design Capacity 0.00% 5000.00% 10000.00% 10000.00% 10000.00% 10000.00%
Income Statement
Revenue $0.00 $5,534,280.52 $11,068,561.04 $11,068,561.04 $11,068,561.04
Cost  of sales $172,000.00 $380,603.80 $382,207.60 $382,207.60 $382,207.60
Operateing, SG&A expenses $340,000.00 $1,904,980.85 $1,909,961.70 $1,909,961.70 $1,909,961.70
Depreciation $0.00 ($108.19) ($21,911.61) ($13,189.04) ($7,928.62)
Pre-tax income ($512,000.00) $3,248,695.87 $8,776,391.73 $8,776,391.73 $8,776,391.73
Tax @ 40% ($204,800.00) $1,299,478.35 $3,510,556.69 $3,510,556.69 $3,510,556.69
Net income ($307,200.00) $1,949,217.52 $5,265,835.04 $5,265,835.04 $5,265,835.04
Cash Flow Statement
Cash from Operating Activities
Plus:Depreciat ion $0.00 ($108.19) ($21,911.61) ($13,189.04) ($7,928.62)
Changes in Working Capital
Changes in AR $0.00 ($454,872.37) ($454,872.37) $0.00 $0.00
Changes in AP $14,136.99 $17,423.08 $409.39 $0.00 $0.00
Changes in Inv $0.00 $131.82 $131.82 $0.00 $0.00
Changes in CR ($85,000.00) ($390,000.00) $0.00 $0.00 $0.00
Total Change in Working capital ($70,863.01) ($827,317.47) ($454,331.17) $0.00 $0.00
Cash from Investing Activities
Purchase/Sale of Equipment ($54,093.67) ($6,793,176.42)
Cash from Financing Activities
Issuance of Common Stock $600,000.00 $3,000,000.00
Free Cash Flow $96,980.30 ($3,498,702.02) $4,335,261.09 $5,252,646.00 $5,257,906.42 $11,444,091.80
NPV@25% Discount Rate ($0.00)
Equity Shares Investment
Series A Equity 600,000
Series B Equity 3,000,000
Divided Free Cash Flows
$87,282.27 ($629,766.36) $780,347.00 $945,476.28 $946,423.16 $2,129,762.34
$0.00 ($2,798,961.62) $3,468,208.88 $4,202,116.80 $4,206,325.14 $9,077,689.20
Series A MIRR 56.06%
Series B MIRR 45.28%
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 In order to ensure that, at this increased throughput from the originally proposed project, 
sales would still be at 100%, the customer demand at this annual output was analyzed. The 
market price and market sales for whole genome sequencing from the past 5 years were 
analyzed, along with a 2-year forward projection of the increased market demand as the market 
price of whole genome sequencing continues to drop (GenomeWeb, 2010) (Kleiner, 2008) (Next 
Big Future, 2008) (Complete Human Genome Sequencing Technology Overview, 2009). The 
results of this analysis are displayed in Table 9.21. 
 
Figure 9.14 Global Genome Sequencing Industry Demand from years 2007-2011, projected to 2013 
   
 From Table 9.21, it can be seen that the demand-set market price does not go as low as 
Micro$eq’s proposed market price of ~$1000 per genome. The lowest projected market price is 
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for year 2013, which will be the first year of sales for Micro$eq, is projected to be $5,000 per 
genome at a market demand of ~85,000 genomes per year – nearly quadruple Micro$eq’s 
proposed throughput of ~25,000 genomes per year. This implies that Micro$eq should easily be 
able to operate at full capacity with full sales of ~25,000 genomes per year. Additionally, 
Micro$eq should be able to gain an effective monopoly on the industry if it can offer a market 
price one quarter below what the customer would be willing to pay. 
 
9.11 WHAT-IF SCENARIOS 
  Thus far, all previous financial analyses hold under certain stated assumptions. 
However, the cases where these assumptions are no longer true and need to be examined for their 
effects on the financial analysis. 
 Several different cases where previously stated assumptions were no longer upheld were 
examined and the financial analyses were redone, with the adjusted effects of the changes in 
these assumptions. The different possible scenarios were broken up into assumptions involved in 
the three main stages of company development. The different cases examined are summarized in 
Table 9.22 and the results of financial analyses for each of these scenarios are summarized in 
Table 9.23. The complete financial analysis summaries for each of the What-If Scenarios may be 
found in Appendix D. 
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What-if Scenarios         
       
Research Stage           
 R1 The start up takes one year, as planned  
 R2 The start up stage takes two years   
Scaleup stage           
 SU1 The forst years of sales ruls at 50% design capacity  
 SU2 The first year of sales runs at 30% design capacity  
Sales Stage           
 S1 The company remains at 100% sales  
 S2 The company sales decline ~15% each year  
 S3 The company is forced to liquidate after the first year of sales 
Table 9.22 What-if Scenarios, where Combination of R1, SU1, and S1  is the base case scenario discussed in the 
preliminary financial analysis earlier in this chapter 
  
Scenario Summary     
Base Case (R1, SU1, S1) NPV Series A MIRR Series B MIRR 
  $4,556,104.14 89.11% 77.34% 
Research Stage       
 R2 $1,559,155.11 115.93% 55.01% 
     
Scaleup stage       
 SU2 $3,808,686.63 84.39% 72.79% 
Sales Stage       
 S2 $2,239,434.81 75.08% 63.79% 
 S3 ($5,756,801.69) -22.6% -38.2% 
Table 9.23 What-If Scenario Summary, MIRR and NPV Values (all amounts in $US)  
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For the Research stage, if the start up stage takes two years instead of one years, the 
initial required investment by series A investors would increase. The amount of fixed costs 
(equipment, etc.) may be assumed relatively unchanged, but an additional year of all annual costs 
(Personnel Salary Costs, Rental  and Utilities Costs, etc.) will need to be supplied by the series A 
investors. However, as the series A investors will then be invested for two years prior to the 
series B investors, their increased MIRR over the series B investors will be even larger than in 
the one-year research case phase. Post the Research stage, if all other stages go as previously 
assumed, the remainder of the financial analysis should be relatively similar to the base case. It 
can be seen that, in such a short lifetime as Micro$eq has, an additional year (another 20% of the 
lifetime) without profit, and will decreased the company’s overall profit.  However, even with 
this decrease it can be seen that the company still operates at a final NPV of ~$1.5 million, and 
the while the series A investors actually have an increased MIIR (~116%) the series B investors, 
while having a decreased MIRR (~55%) still have greater than 50% margins. Thus, even in the 
event that the research stage takes twice as long as projected, Micro$eq will still be financially 
feasible and a wise investment, particularly for series A investors. 
 For the Scale Up stage, if the company only reaches 30% capacity instead of 50% 
capacity, revenues for that year will be decreased by 40%. In the long term, this will simply 
decreased the Terminal Value of Micro$eq, and it will take the company longer to turn a profit 
during the sales stage. However, it can be seen that the company is still able to turn a profit in 
this case, with a final NPV of ~$3.8 million. Additionally, while both series of investors have 
decreased margins from the financial base case, it can be seen that they both still have 
significantly greater than 50% returns (84% and 72% for series A and series B investors, 
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respectfully). Hence, even in the event of a decreased scale up stage, Micro$eq is still not only 
financially feasible, but a wise investment for both series of investors. 
 For the Sales stage, if the company sales decrease by a fixed percentage each year, the 
annual revenues will decline, as will the NPV and investors MIRR’s. However, within in a 
certain limit of sales percentage decrease, the company should still be able to break even. 
Additionally, if sales decrease due to competition, it is possible that by this time, the R&D of the 
company will have been able to develop improvements on the prototype such that production 
costs are decreased. If this is the case, the market price may be able to be decreased such that 
sales percentages may be rescued. Even if an improved prototype is not available, as shown 
earlier in this chapter, Micro$eq is capable of operating above the breakeven point for any 
market price greater than $466 per genome. Thus, it is possible for Micro$eq to ward off 
decreased sales due to competition by further decreasing its market price so that its new 
competitor no longer remains competitive.  
The case shown above for S2, a sales decrease of 10% each was assumed. It can be seen 
at this sales decrease, the company is still able to function well above the breakeven line with a 
final NPV of ~$2.2 million and investor MIRR’s of ~75% and ~64% for series A and series b 
respectively.   
The only what-if scenario that leave Micro$eq financially unfeasible is case S3, where 
the company never reached full capacity and instead is forced to liquidate after its first year of 
sales. For this case the company ends a final NPV of ~($2.2 million) and investor MIRR’s of ~-
22% and -38% for series A and series B investors, respectively. 
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This What-if Analysis shows promise for Micro$eq, that, with the exception of the highly 
unlikely S3 case, if is still financially feasible and significantly profitable even when the base 
case assumptions are tested. Micro$eq’s financial robustness even in variable scenarios should 
be further evidence of its value as an investment. 
 
9.12 GROWTH CASE SCENARIO 
 Thus far, it has been assumed that the company has no growth. However, with the base 
case financial analysis indicating that the companies margins are well above the breakeven point, 
it is feasible that the company could – and would – expand. This expansion would happen once 
the company has entered the sales phase. For the purpose of this discussion, a growth rate of 
25% for each of the sales stage years will be assumed. In this case, the projected NPV is 
~$8.1Million, and the series A and series B investors MIRR’s are 107% and 94.7% respectively. 
As, in reality, it will most likely be feasible for the company to expand, these projections are 
very positive with respect to Micro$eq’s projected growth. The full financial analysis of the 
growth case may be found in Appendix D. 
 
9.13 LARGE-SCALE OPERATION SCENARIO 
 As previously discussed in both intital Market Analysis (section 1.1 of this report) and 
earlier in this Financial Analysis chapter, a potential modified business model for Micro$eq is a 
large-scale operation that targets the Pharmaceutical industry. Over the past five years, an 
average number of 25,153 different FDA-approved clinical trials per year take place globally, 
with an average of 2,186 participants per trial for an average total of 54.98 million trial 
participants per year. (CISCIP). Pharmaceutical companies pay an average of $12 thousand per 
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participant (CISCIP). As previously discussed, it would be a long-term benefit for 
Pharmaceutical companies to being to accumulate a database of trial participants’ whole genome 
sequences that can then be cross-analyzed with their drug-responses in order to further develop 
the field of personalized drug response based on genetic predisposition. By using the database 
they had built by sequencing all of their trial participants, companies could tailor their 
recommended drug treatments for patients with specific genotype mutations and thus increase 
both their sales and theoretical efficacy of their products. Thus, Micro$eq could hope to 
capitalize on this available market by offering a bulk-discount rate to client such as large 
pharmaceutical companies for use in their clinical trials.  
 If companies are spending an average of $12 thousand per patient, an additional 1.0%-
5.0% cost per participant would not be unreasonable for a company to be willing due to the 
enormous benefits with minimal additional cost. Therefore, in order to participate in the market, 
Micro$eq must be able have a profitable large scale market price of $120-$600 per genome. It 
will be assumed that Micro$eq can serve 90% of this market, assuming no other competition. 
This assumption seems valid, as no company is even within an order of magnitude of Micro$eq’s 
small-scale market price, much less its further reduced large-scale market price. This requires 
Micro$eq’s target large-scale annual throughput to be ~52 million genomes.  
 The large-scale model involves adjustments of required personnel, inventory, and 
equipment costing scalable to the increase in throughput. Additionally, increases in rental and 
utility costs must be accounted for. Additionally, the CEO and CTO will have higher salaries, as 
fitting for a larger-scale biotech company.  The adjusted cost estimates spreadsheat for the large-
scale case may be found in Appendix D of this report.  
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The breakeven point for a target annual throughput of 52.2 million genomes is found to 
be $197 per genome (full financial analysis summary found in Appendix D). As this is on the 
low end of the acceptable price range, the large-scale market price will be set at $299 per 
genome, which is just under a 2.5% cost increase for the Pharmaceutical companies, and is in the 
middle of the allowable price range. Setting the market price below the maximum allowable 
helps ensure that a true 90% of the market share may be achieved. The financial summary 
analysis for the Large-scale case is displayed in Table 9.34 on the next page. It can be seen that 
for the target throughput rate of 52.2 million genomes per year, at a market price of $299 per 
genome, the projected NPV is ~2.7 trillion, with MIRR margins for series A and series B 
investors being 325% and 302%, respectively. These margins may seem artificially high, but the 
initial required investments follow economies of scale as the company size is expanded, and thus 
the relative margins increase with the company scale up.  
This financial analysis shows that not only would a target market of the Pharmaceutical 
companies, specifically as they concern clinical trial participants, would be feasible, but it would 
be highly profitable. As previously discussed, this market has yet to be tapped into by the whole 
genome sequencing industry, as market price points are still too high. Micro$eq’s ability to 
achieve a low price point not only eliminates competition on the small-scale level, but also opens 
up a whole new, and extraordinarily large, market sector.  
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Table 9.34 Large Scale Financial Analysis Summary (amounts in US$) 
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9.14 FINANCIAL CONCLUSIONS 
 The preliminary financial analysis has provided sufficient evidence that Micro$eq would 
be a profitable investment. The what-if scenarios have shown that under most circumstances the 
company may cease to be profitable. Only in the worst possible case scenario, which is highly 
unlikely to actually occur, did Micro$eq prove to be an unwise inestment. The growth case 
scenario of the company shows promising opportunity for Micro$eq’s growth and subsequent 
increase in profitability. Finally, the large-scale alternative business model illustrates the 
potential of immense financial benefit from a large-scale whole genome sequencing company 
that targets the Pharmaceutical company market. 
 It is important to note, however, that this entire discussion must be taken within the 
context that all of the projected figures are just that – projections. While financial models are 
useful guides for how the company’s financial status may proceed, they are far from set in stone. 
These models provide the investors with the tools to make their investment decision, by making 
them aware of potential risks and gains in they do become financially involved with Micro$eq. 
However, as they are only estimations, any investment involves at least a nominal degree of risk.  
 It is also important to emphasize the novelty of this company and this impact on its 
potential profitability. As previously discussed, Micro$eq shows the capacity of bringing whole  
human genome sequencing to the market at 10% of the current market price. This would make 
Micro$eq the only vendor of this product, at least for its first year on the market. While other 
companies have claimed to be able to provide genome sequencing at prices within Micro$eq’s 
order of magnitude, no company has yet to actually come close. In such a short lifetime as 
Micro$eq’s it is most likely that the company will be able to remain the exclusive – or at least 
one of the few - providers of this product, even within such a dynamic industry. Additionally, 
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this large price discrepancy between Micro$eq’s product and other competitors’ products allows 
Micro$eq the flexibility of exploring the new market of Pharmaceutical companies for Bulk-
Sequencing. The company’s positive financial projections allow for the possibility that a small-
scale Micro$eq would be able to expand, at least to some percentage, during its limited lifetime. 
It is also possible that, if a sufficient third round of investors were available, Micro$eq could 
make the transition to a large-scale company after a year of operating as a small-scale company. 
During this first year of operation, Micro$eq would establish its reputation for a high-end 
product and thus have a better chance of achieving 100% sales on the large-scale right away. 
Micro$eq’s potential ability to open this new market will not only be enormously financially 
beneficial to the company, but will also be a huge step in the field of Personalized Medicine.  
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CHAPTER 10  
 
Conclusions 
 
The ultimate goal of this project was to design a whole human genome sequencing 
strategy for a start-up Biotech company, Micro$eq’s, that would allow high-throughput, low-cost 
sequencing. Micro$eq’s original objective was to produce a minimum of 12 genomes per day at 
a market price of less than $1000 per genome. The proposed sequencing approach was to utilize 
Raindance Technology’s microdroplet based technology as a platform for a continuous 
sequencing process.   
Micro$eq’s proposal of a continuous rather than batch sequencing process has the 
potential to revolutionize the Biotech industry’s approach to genome sequencing. Current batch 
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processes methods such as those used by companies such as Illumina, Helicos Bioscience’s, and 
Roche/454 Sequence require large numbers of flushing, scanning, and washing cycles. Similarly, 
current single molecule approaches require costly optical setups and long scanning times. 
Micro$eq’s continuous, multi-molecule method avoids both of these bottlenecks which currently 
limit the growth of the Human Genome Sequencing Industry.  
Fundamental to Microseq’s innovative whole genome sequencing approach are several 
novel technologies or novel applications of existing technologies. The preseqeuncing DNA 
preparation process involves a unique approach to small fragment cutting and amplification that 
allows the generation of exactly-sized DNA fragments at a set concentration – a nearly 
impossible task due to molecular biology limitations. The small scale of the reaction due the 
microfluidic platform requires only small volumes of reagents, thus reducing presequencing 
costs. Additionally, the microfluidic platform used for the presequencing DNA preparation 
requires a very minimal amount of input DNA, allowing for the quality of product for a variable 
quality of input samples. The high level of control inherent in the DNA preparation process not 
only reduces the amount of required preparation time, but allows the optimal inputs for the 
sequencing and genome assembly steps of the process.  
The sequencing stage of the process uses fluorescence hybridization to detect DNA 
sequence, but unlike most of the current processes does do by hybridizing 6bp oligonucleotides 
rather than single nucleotide hybridization. This approach reduces the required sequencing time 
by reducing the number of hybridization events required for whole genome sequencing. Like the 
presequencing preparation, the sequencing process also capitalizes on the unique advantages 
associated the microfluidics platform.  Large numbers of molecules are placed in each droplet 
allowing Micro$eq to have increased design control over the process as well as increased 
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throughput.  The Large numbers of molecules in each droplet is advantageous over current 
microfluidic sequencing platforms which use a single molecule per droplet approach. The 
increased concentration decreases the signal to noise ratio during scanning and allows a higher 
scanning speed without compromising accuracy. By the use of multiple parallel scanning 
processes, the sequencing step in Micro$eq’s process is reduced to 24 hours per unit of 
throughput genomes and thus sets the total process turnover time as 24 hours. 
The genome assembly stage of this process developed an original algorithm using the 
MATLAB computational platform which allowed the assembly of the 6mer readouts from the 
sequencing step into large enough fragments so that the conventional method of shotgun 
sequencing might be performed to fully compiled the genome. The optimal values of fragment 
length, number of fragments to be inserted in each parent droplet, and number of coverage for 
maximum computational efficiency were determined, and the presequencing preparations were 
designed accordingly. The final process error rate was estimated to 9.98x10-6 (or ~1bp in every 
100,000bp). This error rate is competitive with any available genome sequencing surface on the 
market as of December 2011 (yang, Dorman, & Aluru, 2010). The sequence processing time was 
also optimized such that total processing for a genome was 19.1 hrs, and thus still allowed the 
total process turnover time to be 24 hours.  
The financial analysis of Micro$eq using this innovative process showed that both a 
small-scale company producing 72 genomes per day at a market price of $999 would yield 
between 77%-89% margins for investors, and a large-scale company producing 52.2 million 
genomes per year at a market price of $299 per genome would yield between 300-325% margins 
for investors. The achievement of a profitable market price under $1000 per genome makes 
Micro$eq the lowest price on the current market by a factor of 10.  Micro$eq’s distinct 
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advantage in costing-efficiency will most likely allow the company to be the exclusive provider 
of whole genome sequencing –either to the private wealth sector in the form a small-scale 
company, or to the Pharmaceutical Industry in the form of a large scale company.  
Additionally, Micro$eq’s ability to profitably bulk produce genomes at a $299 per 
genome market price allows it to open the new market sector of Pharmaceutical companies for 
Whole Genome Sequencing Industry. While Micro$eq’s venture into this unexplored sector will 
be financially profitable, and thus renders Micro$eq a wise investment, its ability to open this 
new market is also a major necessary step for the development of the field of Personalized 
Medicine.  
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Appendix A: 
 
Protocol and Reagent Specifications 
 
 A.1 Presequencing Protocols and Reagents 
  A.1.1 Oragene Saliva Kit (Genotek) 
  A.1.2 s2 Shearer Protocol (Covaris) 
  A.1.3 Adenosine Ligation Quick Start Protocol (Qiagen) 
  A.1.4 Adenosine Ligation Quick Start Protocol (Qiagen) 
  A.1.5 Exonucleolysis Protocol (NEB) 
  A.1.6 MmeI Digestion Protocol (NEB) 
  A.1.7 End-it DNA Repair Kit Protocol (Epicenter Biotechnologies) 
  A.1.8 PCR Basic Kit Protocol (Qiagen) 
 A.2 Sequencing Protocols and Reagents 
  A.2.1 BODIPY Dyes-Used for Fluorescent Barcoding of Oligonucleotides 
  A.2.2 BODIPY Dyes Absorbance Spectra 
  A.2.3 Barcading the Oligos Lirary using Fluorescent Polymers 
 
 
 
 
 
 
 
 
 
245 | P a g e  
 
Micro$eq – Chomvong, King, Mahmoud 
A.1 Presequencing Protocols and Reagents 
 A.1. 1 Oragene Saliva kit (Genotek) 
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  A.1. 2 s2 Shearer Protocol (Covaris) 
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A.1. 3 Adenosine Ligation Quick Start Protocol (Qiagen) 
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A.1. 4 Adenosine Ligation Quick Start Protocol (Qiagen) 
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A.1. 5 Exonucleolysis Protocol (NEB) 
Exonuclease degradation of linear DNA 
 
Exonuclease cocktail: 
Step 1:  
Mix: 5 μl of NEB Buffer 1 
        6μl of exonuclease I (E. coli, 20 units/μl, NEB) 
        3μl of exonuclease III (100 units/μl, NEB) 
        3μl of lambda exonuclease (100 units/μl, NEB). 
Step 2: 
Add: 36 μl of water 
Exonucleolysis Reaction 
Step 3: 
Add: 0.5μl aliquot from the circular assembly ligation reaction to  20μl of exonuclease cocktail 
from steps 1-2  
Step 4: 
Incubate: total reaction mixture at 37ºC for 45 min. 
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A.1. 6 MmeI Digestion Protocol (NEB) 
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A.1. 7 End-it DNA Repair Kit Protocol (Epicenter Biotechnologies) 
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A.1. 8 PCR Basic Kit Protocol (Qiagen) 
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A.2 Sequencing Protocols and Reagents 
A.2.1 BODIPY Dyes-Used for Fluorescent Barcoding of Oligonucleotides 
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A.2.2 BODIPY Dyes Absorbance Spectra 
 
Dye Catalog Number:D2183 
 
D217 
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D6116 
 
D2228 
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D100001 
  
D10000 
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558/568 
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A.2.3 Barcading the Oligos Lirary using Fluorescent Polymers 
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Finding an optical strategy of ‘barcoding’ the oligos library using fluorescent polyers.  Bangs 
Laboratories Inc. manufactures fluorescent polymers with varying intensities.  The fluorescent dye spectra 
of the polymeric microsphere manufactured are given below (absorbance spectra are dotted, while 
emission spectra are given by a solid li 
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Appendix B: 
 
Equipment Specifications 
 
 B.1 Presequencing Equipment 
  B.1.1 2s Shearer (Covaris) 
  B.1.2 ND-1000 (NanoDrop) 
  B.1.3 Magtration System 12GC Plus (PSS Bioinstruments) 
  B.1.4 BioMetra ThermoCycler - Small 
  B.1.5 Velp Scientifica RX3 Vortex Mixer 
  B.1.6 UNICO Micro-Hematocrit Lab Centrifuge with 24 Place Rotor C-MH30 
 B.2 Sequencing Equipment 
  B.2.1 CCD Image Sensors 
  B.2.2 Laser 
  B.2.3 Lens 
  B.2.4 Prism 
  B.2.5 Mitos Duo-XS Pump Basic (3200066) 
  B.2.6 Syringe for Mitos Duo XS-Pump, 100 µl 
  B.2.7 HP S2031 
 B.3 Genome Assembly Equipment 
  B.3.1 Quad-Core AMD Opteron Processor 8356 
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B.1 Presequencing Equipment 
B.1.1 s2 Shearer (Covaris) 
 
Specifications for s2 shearer 
Parameter 
 
Setting 
Base Pair Size 1000(bp) 
Duty Cycle 5% 
Intensity 3 
Cycles per burst 200 
Power Mode Frequency Sweeping 
Z Height 6mm 
Temperature 6-8 ( °C) 
Time 40 (s) 
Degassing mode Continuous 
Volume 200ml 
DNA mass <5mg 
Starting material >50kb 
Water level(FILL/RUN) S2 – level 12 
E210 – level 6 
AFA Intensifier Yes 
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B.1.2 ND-1000 (NanoDrop) 
Micro-Volume UV-Vis Spectrophotometer for Nucleic Acid and Protein Quantitation 
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B.1.3 Magtration System 12GC Plus (PSS Bioinstruments) 
 
Specifications for Magtration 12GC Plus 
Dimension W500xD535xH574mm 
Weight Approximately 55kg 
Power AC100-120V 50/60Hz 240VA 
AC220-240V 50/60Hz 240VA 
Throughpu Sample number 1-12 samples/batch 
Process time 30 min~/1-12 samples 
*depends on application 
Temperature Control Heating block:room temp ±5°C-80°C 
Handling Volume 25-1000μL 
Pipetting accuracy 25 μL±10% 
50 μL±5% 
25 μL±3% *Using DN1—N tip with DW at room temp(20-25°C) 
Protocol IC Card 
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B.1.4 BioMetra ThermoCycler - Small 
 
Specifications for  T3000 Thermocylcer 20 
T3000 Thermocylcer 
48 
T3000 Thermocylcer Combi 
Block Formats 3  blocks for  
20 x 0.5 ml tubes each 
3 blocks for  
48 x 0.2 ml tubes  
or 48 well 
microplates or  
6 x 8 well strips each 
3 combi blocks for  
18 x 0.5 ml tubes* or  
48 x 0.2 ml tubes or  
48 well microplates  
or 6 x 8 well strips 
Block Aluminium 
Aluminium Aluminium 
Max Heating 2.1 °C/sec 
2.2 °C/sec 1.4 °C/sec 
Max Cooling 1.7 °C/sec 
2.0 °C/sec 1.2 °C/sec 
Temp Uniformity +/- 0.5 °C 
Temp Range 3 °C to 99 °C 
Control Accuracy +/- 0.1 °C 
Software Program steps are easily entered in a spread sheet 
Options:  Time increment, temperature increment, set ramping rate, direct 
mode (for use as thermoblock), program storage in 10 individual subdirectories 
Memory 10 individual subdirectories, total capacity of 1.500 program steps (equivalent 
to 250 average programs) 
Display High brightness CFL backlight graphical LC Display, viewing area 124 mm x 34 
mm, resolution 256 x 64 dots 
Auto restart after 
power failure 
Yes 
Heated Lid High Performance Smart Lid (HPSL) 
Lid Temperature 
Range 
30 to 99 °C 
Power consumption max. 420 Watt 
Power Supply 110, 230 Volt / 50-60 Hz 
Noise emission Very low 
Unit Price $4000 
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B.1.5 Velp Scientifica RX3 Vortex mixer 
 
Specifications for RX3 Vortex mixer  
Construction material:  epoxy painted aluminum structure 
Support system:  4 holdfast feet for strong fixing and high stability  
Orbital diameter:  5 mm 
Power:  45 W  
Power supply:  115 V or 230 V / 50 or 60 Hz 
Weight: 2 Kg (4.4 lb)  
Dimension (WxHxD): 150x134x150 mm (5.9x5.3x5.9 in) 
Unit Price: $179.99 
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B.1.6 UNICO Micro-hematocrit Lab Centrifuge with 24 Place Rotor C-MH30  
 
 
 
 
 
 
 
Specifications for UNICO Micro-hematocrit Laboratory Centrifuge: 
Nominal speed:  12000 RPM 
Size: 11.6 in x 10.3 in x 9.3 in (295 mm x 261 mm x 235 mm) 
Weight: 17.4 lbs (7.9 kg) 
Unit Price: $679.68 
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B.2 Sequencing Equipment 
B.2.1 CCD Image Sensors 
 
Cost of custom equipped camera+chip that is compatible with chip above~$25,000 
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B.2.2 Laser 
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B.2.3 Lens 
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B.2.4 Prism 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
282 | P a g e  
 
Micro$eq – Chomvong, King, Mahmoud 
B.2.5 Mitos Duo-XS Pump Basic (3200066) 
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B.2.6 Syringe for Mitos Duo XS-Pump, 100 µl 
 
 
 
B.2.7 HP S2031 – 20” – widescreen TFT Active Matrix LCD Display 
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B.3 Genome Assembly Equipment 
 
B.3.1 Quad-Core AMD Opteron Processor 8356 
Model Linux PC (Quad-Core AMD Opteron(tm) Processor 8356) 
Operating System Linux 2.6.18-92.1.13.el5 x86_64 
Processor Quad-Core AMD Opteron 8356 
Processor ID AuthenticAMD Family 16 Model 2 Stepping 3 
Processor Frequency 2.40 GHz 
Cores 16 
Processors 4 
Threads 16 
Memory 128 GB 
Unit Price $1588.99 
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Appendix C:  
MATLAB Simulation Code 
 
 C.1 Raw Sequencing Data Simulation (Individual Fragments) 
 C.2 Raw Sequencing Data Simulation(Doubled Strand DNA) 
C.3 6mer Hybridization Simulation 
C.4 de Bruijn Graph Generation 
 C.5 de Bruijn Graph Interpretation 
 C.6 Conversion of Simplified Graphs to Simplified Base Sequences 
 C.7 Shotgun Sequencing Coverage Requirement 
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C.1 Raw Sequencing Data Simulation (Individual Fragments) 
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function [MatchedOligos] = RawSeqData(nFrag,nBp,kmer) 
%--** Simulate raw sequencing data expected from genome **--% 
%     Only oligos which bind to complementary sequence are returned   
%           nFrag   :expected number of fragments per drop 
%           nBp     :expected fragment length 
%           kmer    :oligos library size 
%           Oligos  :all 4^kmer possible combination of oligos library 
%           Seq     :complementary sequence 
  
clear Seq row temp three i j row Oligos; 
  
%--Generate random sequences for nFrag fragments, each with nBp bases--% 
for i = 1:nFrag 
    Seq(i,:) = randseq(nBp); 
end 
Seq = nt2int(Seq); 
  
%--Generate oligos library, size = kmer, 4^kmer possible combination--% 
row = 4^kmer; 
Oligos = zeros(row, kmer+1); 
temp = fi(zeros(row,1)); 
three = fi(3,1,length(dec2bin(4^kmer)),0); 
temp2 = zeros(1,kmer); 
for i = 0:(row-1) 
    for j = 1:kmer 
        temp1 = bitshift(fi(i,1,length(dec2bin(4^kmer)),0),-2*(kmer-j)); 
        Oligos(i+1,j) = (bitand(temp1,three))+1; 
        temp2(1,j) = Oligos(i+1,j); 
    end 
end 
  
%--Search for oligo which is identical to complementary sequence--% 
%  These oligos are the ones which bind to the fragment in droplets% 
for i = 1:(4^kmer) 
    Oligos(i,(kmer+1)) = FindFrag(Oligos(i,(1:kmer)),CompSeq,nBp,kmer); 
end 
  
%--Select only those oligos that match and assign to 'MatchedOligos'--% 
clear MatchedOligos i n; 
n = 0; 
for i = 1:(4^kmer) 
    if Oligos(i, kmer+1) == 1 
        MatchedOligos(n+1,1:kmer) = Oligos(i,1:kmer); 
        n = n+1; 
    end 
end 
end 
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C.2 Raw Sequencing Data Simulation (Doubled Strand DNA) 
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function [MatchedOligos] = SequencingDoubleStrand(nDFrag,nBp,kmer) 
%--** Simulate raw sequencing data expected from genome for doubled strand DNA fragment**--% 
%     Only oligos which bind to complementary sequence are returned   
%           nDFrag  :expected number of doubled strand DNA per drop 
%           nBp     :expected fragment length 
%           kmer    :oligos library size 
%           Oligos  :all 4^kmer possible combination of oligos library 
%           Seq     :complementary sequence 
  
clear Fragment row temp three i j MatchedOligos Obind mo Oligos; 
  
%--Generate random sequences for nFrag fragments, each with nBp bases--% 
for i = 1:nDFrag 
    Fragment(2*i-1,:) = randseq(nBp); 
    Fragment(2*i,:) = seqcomplement(Fragment(2*i-1,:)); 
end 
Fragment = nt2int(Fragment); 
  
%--Generate oligos library, size = kmer, 4^kmer possible combination--% 
row = 4^kmer; 
Oligos = zeros(row, kmer+1); 
temp = fi(zeros(row,1)); 
three = fi(3,1,length(dec2bin(4^kmer)),0); 
temp2 = zeros(1,kmer); 
for i = 0:(row-1) 
    for j = 1:kmer 
        temp1 = bitshift(fi(i,1,length(dec2bin(4^kmer)),0),-2*(kmer-j)); 
        Oligos(i+1,j) = (bitand(temp1,three))+1; 
        temp2(1,j) = Oligos(i+1,j); 
    end 
end 
  
%--Search for oligo which is identical to complementary sequence--% 
%  These oligos are the ones which bind to the fragment in droplets% 
for i = 1:(4^kmer) 
    Oligos(i,(kmer+1)) = FindFrag(Oligos(i,(1:kmer)),Fragment,nBp,kmer); 
end 
  
%--Select only those oligos that match and assign to 'MatchedOligos'--% 
clear MatchedOligos i n; 
n = 0; 
for i = 1:(4^kmer) 
    if Oligos(i, kmer+1) == 1 
        MatchedOligos(n+1,1:kmer) = Oligos(i,1:kmer); 
        n = n+1; 
    end 
end 
end 
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C.3 6mer Hybridization Simulation 
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function [IsMatch] = FindFrag( Oligo, Fragment, nBp, kmer) 
%--** Determine whether a given Oligo of kmer would bind with inserted fragment(s)**--% 
%     function returns 1 if a given Oligo binds with complementary sequence 
%     and o otherwise 
%           Oligo   :one combination of kmer oligo library 
%           Fragment:sequences of inserted doubled strand fragments            
%           nBp     :expected fragment length 
%           kmer    :oligos library size 
  
clear IsMatch k m i row; 
  
IsMatch = 0; 
k = nBp - (kmer-1); 
row = 1; 
  
while (IsMatch == 0) && (row <= length(Fragment(:,1))) 
    i = 1; 
    while(IsMatch ==0) && (i <= k) 
        if(isequal(Fragment(row,i:(i+(kmer-1))),Oligo)) 
            IsMatch = 1; 
        end 
        i = i+1; 
    end 
    row = row+1; 
end         
end 
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C.4 de Bruijn Graph Generation 
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function [Link OutIn] = deBrujinGeneration( MatchedOligos, kmer ) 
%--** Generate de Bruijn Graph **--% 
%           MatchedOligos   :initial reads with kmer size 
%           kmer            :oligo library size (bp) 
%           n               :number of initial reads 
%           Link            :relationship matrix the first column is the 
%                            starting point while the second colum (in the  
%                            same row) is the ending point. The number of  
%                            node represented in Link matrix comes from the  
%                            number of row the oligo belongs to in 
%                            MatchedOligos 
%           OutIn           :relationship matrix, the number of row 
%                            represents number of row the oligo belongs to  
%                            in MatchedOligos. The number in the first column 
%                            represents number of times the node has  a link  
%                            pointing out. The number in the second column 
%                            represents number of times the node has a link 
%                            pointing in.  
  
clear i k Link ismatch SparseM n temp1 temp2; 
  
%--Link initial reads using de Bruijn algorithm--% 
%--the last kmer-1 bases of node x must be idential to the first kmer-1 bases of node y in 
order for the link from x to y to be generated--% 
n = length(MatchedOligos(:,1)); 
k = 1; 
for i = 1:n 
    for j = 1:n 
        if(isequal(find(MatchedOligos(i,2:kmer) == MatchedOligos(j,1:(kmer-1))), [1:(kmer-
1)])) && (i ~= j) 
            Link(k,1) = i; 
            Link(k,2) = j; 
            k = k+1; 
        end 
    end 
end 
  
%--de Brujin graph is graphically displayed--% 
temp1 = max(Link(:,1)); 
temp2 = max(Link(:,2)); 
temp1 = max(temp1,temp2); 
SparseM = sparse(Link(1:k-1,1),Link(1:k-1,2),true,temp1,temp1); 
view(biograph(SparseM)) 
  
  
%--the OutIn matrix is generated--% 
clear OutIn; 
OutIn = zeros(n,2); 
for i = 1:n 
    for j = 1:k-1 
        if (i == Link(j,1)) 
            OutIn(i,1) = OutIn(i,1)+1; 
        end 
        if( i == Link(j,2)) 
            OutIn(i,2) = OutIn(i,2)+1; 
        end 
    end 
end 
    
end 
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C.5 de Bruijn Graph Interpretation 
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function [ SimpFrag ind Link] = deBruijnInterp( Link, OutIn ) 
%--** Interprete de Bruijn Graph; assemble secondary reads from initial reads **--% 
%           SimpFrag        :secondary read assembled 
%           ind             :number of generated secondary reads 
  
clear SecReads first last i l f FragTemp SimpFrag k sf ind; 
sf = 1; ind = 0; 
Link(:,3) = 0; 
l = 0; f = 0; 
for i = 1:length(OutIn(:,1)) 
    if(OutIn(i,1) == 0) 
        l = l+1; 
        Last(l) = i; 
    elseif(OutIn(i,2) == 0) 
        f = f+1; 
        First(f) = i; 
    end 
end 
  
clear i; 
  
for i = 1:f 
    % Reassemble from left to right (first to last) 
    clear FragTemp ft row x loop;  
    ft = 1; k = 1; 
    FragTemp(ft) = First(i); 
    [Link FragTemp] = ConnectNext(Link,OutIn,1,FragTemp); 
    ft = sum(FragTemp ~= 0); 
    if(OutIn(FragTemp(ft),1) == 2) 
        if(OutIn(FragTemp(ft),2) == 2) 
            k = 2; 
            FragTemp(2,:) = FragTemp(1,:); 
            row = find(Link(:,1) == FragTemp(1,ft)); 
            for j = 1:length(row) 
                FragTemp(j,ft+1) = Link(row(j),2); 
                [Link x loop] = ConnectNext(Link,OutIn,1,FragTemp(j,:)); 
                FragTemp(j,1:length(x)) = x; 
                if(j==1) && (loop == 1) 
                    FragTemp(2,1:end) = 0; 
                    break; 
                elseif(j==2) && (loop ==1) 
                    FragTemp(1,:) = FragTemp(2,:) 
                    FragTemp(2,:) = 0; 
                end 
            end 
        elseif(OutIn(FragTemp(ft),2) ==1) 
            %go left first, right becomes the beginning 
            k = 4; 
            FragTemp(3,:) = FragTemp(1,:); 
            row = find(Link(:,1) == FragTemp(1,ft)); 
            %go left first 
            FragTemp(1,ft+1) = Link(row(1),2); 
            FragTemp(2,1) = Link(row(2),2); 
            [Link x loop] = ConnectNext(Link,OutIn,1,FragTemp(1,:)); 
            FragTemp(1,1:length(x)) = x; 
            [Link x loop] = ConnectNext(Link,OutIn,1,FragTemp(2,:)); 
            FragTemp(2,1:length(x)) = x; 
            %then go right 
            FragTemp(3,ft+1) = Link(row(2),2); 
            FragTemp(4,1) = Link(row(1),2); 
            [Link x loop] = ConnectNext(Link,OutIn,1,FragTemp(3,:)); 
            FragTemp(3,1:length(x)) = x; 
            [Link x loop] = ConnectNext(Link,OutIn,1,FragTemp(4,:)); 
            FragTemp(4,1:length(x)) = x;             
        end 
    end 
    SimpFrag(sf:(sf+k-1),1:length(FragTemp(1,1:end))) = FragTemp; 
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68 
69 
70 
71 
72 
73 
74 
75 
    sf = sf + k; 
    if(k == 1) || (k == 2) 
        ind = ind+1; 
    elseif (k == 4) 
        ind = ind+2; 
    end 
end 
end 
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C.6 Conversion of Simplified Graphs to Simplified Bases 
Sequences 
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function [ SimpFragSeq ] = Node2Seq( SimpFrag, MatchedOligos,kmer ) 
%--** Convert coded graph sequence to base sequence for shotgun sequencing assembly**--% 
%           SimpFrag        :simplified de Bruijn graph 
%           MatchedOligos   :set of kmer oligo library which binds with inserted fragment           
%           kmer            :oligos library size 
%           SimpFragSeq     :base sequence of simplified assembled output 
  
clear row i j col; 
  
row = length(SimpFrag(:,1)); 
  
for i=1:row 
    col = sum(SimpFrag(i,:) ~= 0); 
        for j = 1:col 
            if(j == 1) 
                SimpFragSeq(i,1:kmer) = MatchedOligos(SimpFrag(i,j),1:end); 
            else 
                SimpFragSeq(i,kmer+j-1) = MatchedOligos(SimpFrag(i,j),end); 
            end 
        end 
    end 
end 
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C.7 Shotgun Sequencing Coverage Requirement 
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function [ Prob, TotErr ] = PoissonError( ExpectedCov, BpErr) 
%--** Calculate error rate of shotgun sequencing associated with each actual coverage for a 
given expected coverage and read error **--% 
%           ExpectedCov     :expected number of coverage 
%           BpErr           :read error = probability that a given base in 
%                            secondary reads is incorrect  
%                            = (genome length)/4^(fragment length)×1.5 ( 
%                            see Eqn VI-7) 
%           TotErr          :summation of error for all actual coverage 
%           Prob             
%           column 1        :the number of actual coverage 
%           column 2        :probability of actual coverage existence for a 
%                            given ExpectedCov 
%           column 3        :the error per base for a given BpErr, which is the 
%                            error rate of read for each basepair 
%           column 4        :total error = column 2*column3 for each possible 
%                            actual coverage 
  
clear i MinErr j TotErr; 
TotErr = 0; 
for i = 0:ExpectedCov*2 
    Prob(i+1,1) = i; 
    Prob(i+1,2) = (ExpectedCov^i)*exp(-ExpectedCov)/factorial(i); 
    if(i == 0) 
        Prob(i+1,3) = 1; 
    % for odd actual coverage (e.g. 1, 3, 5,...), the incorrect base has be 
    % equal or greater than i/2+0.5 times for the error to exist 
    else 
        if(mod(i,2) == 1) 
            MinError = i/2+0.5; 
        elseif(mod(i,2) == 0) 
            MinError = i/2; 
        end 
        Prob(i+1,3) = 0; 
        for j = MinError:i 
            Prob(i+1,3) = Prob(i+1,3) + factorial(i)/(factorial(j)*factorial(i-
j))*(BpErr^j)*(1-BpErr)^(i-j); 
        end 
    end                 
    Prob(i+1,4) = Prob(i+1,2)*Prob(i+1,3); 
    TotErr = TotErr + Prob(i+1,4); 
end 
end   
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function [ OptCov ] = OptimalCov(BpErr) 
%--** Calculate minimum expected coverage required to acheive total error rate of 1e-5 for a 
given BpErr **--% 
%           OptCov     :minimum number of expected coverage required 
  
clear i Prob; 
for i = 30:-0.01:0 
    [ Prob, TotErr ] = Poisson( i, BpErr); 
    if (TotErr > 1e-5) 
        OptCov = i+0.01; 
        break; 
    end 
end 
end 
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Appendix D:  
Financial Pro Forma 
 
 D.1 Supplementary Financial Analysis Summaries and Cost Estimates 
  D.1.1 24 Genomes per Day Throughput Analysis 
  D.1.1 35 Genomes per Day Throughput Analysis 
  D.1.3 48 Genomes per Day Throughput Analysis 
  D.1.4 60 Genomes per Day Throughput Analysis 
  D.1.5 What-if Scenario SU2 
  D.1.6 What-If Case R2 
  D.1.7 Growth Case Financial Summary 
  D.1.8 What-if Scenario S2 Financial Analysis Summary 
  D.1.9 What-if Scenario S3 Financial Analysis Summary 
  D.1.10 Large-Scale Cost Estimates (part 1) 
  D.1.11 Large-Scale Cost Estimates (part1) 
  D.1.12 Large Scale Breakeven Financial Analysis Summa 
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D.1 Financial Analysis Summaries 
D.1.1 24 Genomes per Day Throughput Analysis 
  
Preliminary Financial Summary - 24 genomes/day @$964/genome
Year 2012 2013 2014 2015 2016 2017
Stage Research Scale Up Sales Sales Sales T erminal
% of Design Capacity 0.00% 50.00% 100.00% 100.00% 100.00% 100.00%
Income Statement
Revenue $0.00 $3,816,163.91 $7,632,327.82 $7,632,327.82 $7,632,327.82
Cost of sales $172,000.00 $380,603.80 $382,207.60 $382,207.60 $382,207.60
Operateing, SG&A expenses $340,000.00 $1,183,434.55 $1,186,869.10 $1,186,869.10 $1,186,869.10
Depreciation $0.00 ($108.19) ($7,419.50) ($4,465.95) ($2,684.71)
Pre-tax income ($512,000.00) $2,252,125.56 $6,063,251.13 $6,063,251.13 $6,063,251.13
Tax @ 40% ($204,800.00) $900,850.23 $2,425,300.45 $2,425,300.45 $2,425,300.45
Net income ($307,200.00) $1,351,275.34 $3,637,950.68 $3,637,950.68 $3,637,950.68
Cash Flow Statement
Cash from Operating Activities
Plus:Depreciat ion $0.00 ($108.19) ($7,419.50) ($4,465.95) ($2,684.71)
Changes in Working Capital
Changes in AR $0.00 ($313,657.31) ($313,657.31) $0.00 $0.00
Changes in AP $14,136.99 $17,295.99 $282.29 $0.00 $0.00
Changes in Inv $0.00 $131.82 $131.82 $0.00 $0.00
Changes in CR ($85,000.00) ($210,000.00) $0.00 $0.00 $0.00
Total Change in Working capital ($70,863.01) ($506,229.50) ($313,243.20) $0.00 $0.00
Cash from Investing Activities
Purchase/Sale of Equipment ($54,093.67) ($2,264,392.14)
Cash from Financing Activities
Issuance of Common Stock $600,000.00 $3,000,000.00
Free Cash Flow $96,980.30 $1,074,316.01 $3,004,044.78 $3,633,484.73 $3,635,265.97 $11,444,091.80
NPV@25% Discount Rate $0.00
Equity Shares Investment
Series A Equity 600,000
Series B Equity 3,000,000
Divided Free Cash Flows
$87,282.27 $193,376.88 $540,728.06 $654,027.25 $654,347.87 $2,129,762.34
$0.00 $859,452.81 $2,403,235.83 $2,906,787.79 $2,908,212.77 $9,077,689.20
Se ries A MIRR 58.12%
Se ries B MIRR 47.30%
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D.1.2 36 Genomes per Day Throughput Analysis 
  
Preliminary Financial Summary - 36 genomes/day @$715/genome
Year 2012 2013 2014 2015 2016 2017
Stage Research Scale Up Sales Sales Sales Terminal
% of Design Capacity 0.00% 5000.00% 10000.00% 10000.00% 10000.00% 10000.00%
Income Statement
Revenue $0.00 $4,245,693.06 $8,491,386.13 $8,491,386.13 $8,491,386.13
Cost of sales $172,000.00 $380,603.80 $382,207.60 $382,207.60 $382,207.60
Operateing, SG&A expenses $340,000.00 $1,363,821.12 $1,367,642.25 $1,367,642.25 $1,367,642.25
Depreciation $0.00 ($108.19) ($11,042.53) ($6,646.72) ($3,995.69)
Pre-tax income ($512,000.00) $2,501,268.14 $6,741,536.28 $6,741,536.28 $6,741,536.28
Tax @ 40% ($204,800.00) $1,000,507.26 $2,696,614.51 $2,696,614.51 $2,696,614.51
Net  income ($307,200.00) $1,500,760.88 $4,044,921.77 $4,044,921.77 $4,044,921.77
Cash Flow Statement
Cash from Operating Activities
Plus:Depreciation $0.00 ($108.19) ($11,042.53) ($6,646.72) ($3,995.69)
Changes in Working Capital
Changes in AR $0.00 ($348,961.07) ($348,961.07) $0.00 $0.00
Changes in AP $14,136.99 $17,327.76 $314.06 $0.00 $0.00
Changes in Inv $0.00 $131.82 $131.82 $0.00 $0.00
Changes in CR ($85,000.00) ($255,000.00) $0.00 $0.00 $0.00
Total Change in Working capital ($70,863.01) ($586,501.49) ($348,515.19) $0.00 $0.00
Cash from Investing Activities
Purchase/Sale of Equipment ($54,093.67) ($3,396,588.21)
Cash from Financing Activities
Issuance of Common Stock $600,000.00 $3,000,000.00
Free Cash Flow $96,980.30 ($68,938.50) $3,336,848.86 $4,038,275.05 $4,040,926.08 $11,444,091.80
NPV@25% Discount Rate $0.00
Equity Shares Investment
Series A Equity 600,000
Series B Equity 3,000,000
Divided Free Cash Flows
$87,282.27 ($12,408.93) $600,632.79 $726,889.51 $727,366.69 $2,129,762.34
$0.00 ($55,150.80) $2,669,479.09 $3,230,620.04 $3,232,740.86 $9,077,689.20
Series A MIRR 57.61%
Series B MIRR 46.80%
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D.1.3 48 Genomes per Day Throughput Analysis 
  
Preliminary Financial Summary - 48 genomes/day @$590/genome
Year 2012 2013 2014 2015 2016 2017
Stage Research Scale Up Sales Sales Sales Terminal
% of Design Capacity 0.00% 50.00% 100.00% 100.00% 100.00% 100.00%
Income Statement
Revenue $0.00 $4,675,222.22 $9,350,444.43 $9,350,444.43 $9,350,444.43
Cost of sales $172,000.00 $380,603.80 $382,207.60 $382,207.60 $382,207.60
Operateing, SG&A expenses $340,000.00 $1,544,207.70 $1,548,415.40 $1,548,415.40 $1,548,415.40
Depreciation $0.00 ($108.19) ($14,665.56) ($8,827.49) ($5,306.66)
Pre-tax income ($512,000.00) $2,750,410.72 $7,419,821.43 $7,419,821.43 $7,419,821.43
Tax @ 40% ($204,800.00) $1,100,164.29 $2,967,928.57 $2,967,928.57 $2,967,928.57
Net  income ($307,200.00) $1,650,246.43 $4,451,892.86 $4,451,892.86 $4,451,892.86
Cash Flow Statement
Cash from Operating Activities
Plus:Depreciation $0.00 ($108.19) ($14,665.56) ($8,827.49) ($5,306.66)
Changes in Working Capital
Changes in AR $0.00 ($384,264.84) ($384,264.84) $0.00 $0.00
Changes in AP $14,136.99 $17,359.54 $345.84 $0.00 $0.00
Changes in Inv $0.00 $131.82 $131.82 $0.00 $0.00
Changes in CR ($85,000.00) ($300,000.00) $0.00 $0.00 $0.00
Total Change in Working capital ($70,863.01) ($666,773.48) ($383,787.18) $0.00 $0.00
Cash from Investing Activities
Purchase/Sale of Equipment ($54,093.67) ($4,528,784.28)
Cash from Financing Activities
Issuance of Common Stock $600,000.00 $3,000,000.00
Free Cash Flow $96,980.30 ($1,212,193.01) $3,669,652.94 $4,443,065.37 $4,446,586.19 $11,444,091.80
NPV@25% Discount Rate $0.00
Equity Shares Investment
Series A Equity 600,000
Series B Equity 3,000,000
Divided Free Cash Flows
$87,282.27 ($218,194.74) $660,537.53 $799,751.77 $800,385.51 $2,129,762.34
$0.00 ($969,754.40) $2,935,722.35 $3,554,452.29 $3,557,268.96 $9,077,689.20
Series A MIRR 57.10%
Series B MIRR 46.29%
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Preliminary Financial Summary - 60 genomes/day @$516/genome
Year 2012 2013 2014 2015 2016 2017
Stage Research Scale Up Sales Sales Sales Terminal
% of Design Capacity 0.00% 50.00% 100.00% 100.00% 100.00% 100.00%
Income Statement
Revenue $0.00 $5,104,751.37 $10,209,502.73 $10,209,502.73 $10,209,502.73
Cost  of sales $172,000.00 $380,603.80 $382,207.60 $382,207.60 $382,207.60
Operateing, SG&A expenses $340,000.00 $1,724,594.28 $1,729,188.55 $1,729,188.55 $1,729,188.55
Depreciat ion $0.00 ($108.19) ($18,288.58) ($11,008.26) ($6,617.64)
Pre-tax income ($512,000.00) $2,999,553.29 $8,098,106.58 $8,098,106.58 $8,098,106.58
Tax @ 40% ($204,800.00) $1,199,821.32 $3,239,242.63 $3,239,242.63 $3,239,242.63
Net income ($307,200.00) $1,799,731.97 $4,858,863.95 $4,858,863.95 $4,858,863.95
Cash Flow Statement
Cash from Operating Activities
Plus:Depreciation $0.00 ($108.19) ($18,288.58) ($11,008.26) ($6,617.64)
Changes in Working Capital
Changes in AR $0.00 ($419,568.61) ($419,568.61) $0.00 $0.00
Changes in AP $14,136.99 $17,391.31 $377.61 $0.00 $0.00
Changes in Inv $0.00 $131.82 $131.82 $0.00 $0.00
Changes in CR ($85,000.00) ($345,000.00) $0.00 $0.00 $0.00
Total Change in Working capital ($70,863.01) ($747,045.48) ($419,059.17) $0.00 $0.00
Cash from Investing Activities
Purchase/Sale of Equipment ($54,093.67) ($5,660,980.35)
Cash from Financing Activities
Issuance of Common Stock $600,000.00 $3,000,000.00
Free Cash Flow $96,980.30 ($2,355,447.51) $4,002,457.02 $4,847,855.68 $4,852,246.31 $11,444,091.80
NPV@25% Discount Rate $0.00
Equity Shares Investment
Series A Equity 600,000
Series B Equity 3,000,000
Divided Free Cash Flows
$87,282.27 ($423,980.55) $720,442.26 $872,614.02 $873,404.34 $2,129,762.34
$0.00 ($1,884,358.01) $3,201,965.61 $3,878,284.55 $3,881,797.05 $9,077,689.20
Series A MIRR 56.58%
Series B MIRR 45.79%
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What-if SU2 Scenario Financial Analysis - 72 genomes/day @ $999/geome
Year 2012 2013 2014 2015 2016 2017
Stage Research Research Scale Up Sales Sales T erminal
% of Design Capacity 0.00% 30.00% 50.00% 100.00% 100.00% 156.00%
Income Statement
Revenue $0.00 $7,127,928.72 $23,759,762.40 $23,759,762.40 $23,759,762.40
Cost  of sales $172,000.00 $380,603.80 $382,207.60 $382,207.60 $382,207.60
Operateing, SG&A expenses $340,000.00 $1,550,691.89 $1,561,383.79 $1,561,383.79 $1,561,383.79
Depreciation $0.00 ($108.19) ($21,911.61) ($13,189.04) ($7,928.62)
Pre-tax income ($512,000.00) $5,196,633.03 $21,816,171.01 $21,816,171.01 $21,816,171.01
Tax @ 40% ($204,800.00) $2,078,653.21 $8,726,468.41 $8,726,468.41 $8,726,468.41
Net income ($307,200.00) $3,117,979.82 $13,089,702.61 $13,089,702.61 $13,089,702.61
Cash Flow Statement
Cash from Operating Activities
Plus:Depreciat ion $0.00 ($108.19) ($21,911.61) ($13,189.04) ($7,928.62)
Changes in Working Capital
Changes in AR $0.00 ($585,857.16) ($1,367,000.03) $0.00 $0.00
Changes in AP $14,136.99 $17,892.48 $878.79 $0.00 $0.00
Changes in Inv $0.00 $131.82 $131.82 $0.00 $0.00
Changes in CR ($85,000.00) ($300,000.00) $0.00 $0.00 $0.00
Total Change in Working capital ($70,863.01) ($867,832.85) ($1,365,989.42) $0.00 $0.00
Cash from Investing Activities
Purchase/Sale of Equipment ($54,093.67) ($6,793,176.42)
Cash from Financing Activities
Issuance of Common Stock $600,000.00 $7,000,000.00
Free Cash Flow $96,980.30 $1,589,029.51 $10,335,812.15 $13,076,513.57 $13,081,773.99 $38,180,109.52
NPV@25% Discount Rate $3,808,686.63
Equity Shares Investment
Series A Equity 600,000
Series B Equity 7,000,000
Divided Free Cash Flows
$87,282.27 $138,399.34 $900,215.90 $1,138,922.15 $1,139,380.32 $3,404,199.98
$0.00 $1,435,252.46 $9,335,572.27 $11,811,044.52 $11,815,795.86 $34,397,665.10
Series A MIRR 84.39%
Series B MIRR 72.79%
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What-if Case R2 Financial Summary -72 Genomes Per Year @ $999/genome
Year 2012 2013 2014 2015 2016 2017
Stage Research Research Scale Up Sales Sales Terminal
% of Design Capacity 0.00% 0.00% 50.00% 100.00% 100.00% 156.00%
Income Statement
Revenue $0.00 $0.00 $11,879,881.20 $23,759,762.40 $23,759,762.40
Cost of sales $172,000.00 $172,000.00 $380,603.80 $380,603.80 $380,603.80
Operateing, SG&A expenses $340,000.00 $1,545,345.95 $1,550,691.89 $1,550,691.89 $1,550,691.89
Depreciation $0.00 ($108.19) ($21,911.61) ($13,189.04) ($7,928.62)
Pre-tax income ($512,000.00) ($1,717,345.95) $9,948,585.51 $21,828,466.71 $21,828,466.71
Tax @ 40% ($204,800.00) ($686,938.38) $3,979,434.20 $8,731,386.68 $8,731,386.68
Net income ($307,200.00) ($1,030,407.57) $5,969,151.30 $13,097,080.02 $13,097,080.02
Cash Flow Statement
Cash from Operating Activities
Plus:Depreciation $0.00 ($108.19) ($21,911.61) ($13,189.04) ($7,928.62)
Changes in Working Capital
Changes in AR $0.00 $0.00 ($976,428.59) $0.00 $0.00
Changes in AP $14,136.99 $17,453.09 $439.39 $0.00 $0.00
Changes in Inv $0.00 $131.82 $131.82 $0.00 $0.00
Changes in CR ($85,000.00) $0.00 ($300,000.00) $0.00 $0.00
Total Change in Working capital ($70,863.01) $17,584.91 ($1,275,857.38) $976,428.59 $0.00
Cash from Investing Activities
Purchase/Sale of Equipment ($54,093.67) ($6,793,176.42)
Cash from Financing Activities
Issuance of Common Stock $600,000.00 $7,000,000.00
Free Cash Flow $96,980.30 ($395,345.93) $3,602,348.51 $15,036,748.17 $13,089,151.41 $31,429,882.46
NPV@25% Discount Rate $1,559,155.11
Equity Shares Investment
Series A Equity 600,000
Series B Equity 7,000,000
Divided Free Cash Flows
$87,282.27 ($69,114.43) $629,763.09 $2,628,726.48 $2,288,247.33 $5,564,904.74
$0.00 ($318,552.12) $2,902,611.75 $12,115,940.97 $10,546,654.37 $25,246,654.98
Series A MIRR 115.93%
Series B MIRR 55.01%
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Growth Case Financial Summary - 72 genomes/day @$999/genome & 25% annual growth
Year 2012 2013 2014 2015 2016 2017
Stage Research Scale Up Sales Sales Sales Terminal
% of Design Capacity 0.00% 50.00% 100.00% 125.00% 156.00% 156.00%
Income Statement
Revenue $0.00 $11,879,881.20 $23,759,762.40 $29,699,703.00 $37,065,229.34
Cost of sales $172,000.00 $380,603.80 $382,207.60 $382,207.60 $382,207.60
Operateing, SG&A expenses $340,000.00 $1,550,691.89 $1,561,383.79 $1,561,383.79 $1,561,383.79
Depreciation $0.00 ($108.19) ($21,993.29) ($13,238.20) ($7,958.17)
Pre-tax income ($512,000.00) $9,948,585.51 $21,816,171.01 $27,756,111.61 $35,121,637.96
Tax @ 40% ($204,800.00) $3,979,434.20 $8,726,468.41 $11,102,444.65 $14,048,655.18
Net  income ($307,200.00) $5,969,151.30 $13,089,702.61 $16,653,666.97 $21,072,982.77
Cash Flow Statement
Cash from Operating Activities
Plus:Depreciat ion $0.00 ($108.19) ($21,993.29) ($13,238.20) ($7,958.17)
Changes in Working Capital
Changes in AR $0.00 ($976,428.59) ($976,428.59) $0.00 $0.00
Changes in AP $14,136.99 $17,892.48 $878.79 $0.00 $0.00
Changes in Inv $0.00 $131.82 $131.82 $0.00 $0.00
Changes in CR ($85,000.00) ($300,000.00) $0.00 $0.00 $0.00
Total Change in Working capital ($70,863.01) ($1,258,404.29) ($975,417.99) $488,214.30 $605,385.73
Cash from Investing Activities
Purchase/Sale of Equipment ($54,093.67) ($6,818,702.50)
Cash from Financing Activities
Issuance of Common Stock $600,000.00 $7,000,000.00
Free Cash Flow $96,980.30 $3,633,532.04 $11,116,873.34 $17,616,857.36 $22,275,796.06 $54,740,039.10
NPV@25% Discount Rate $8,149,772.81
Equity Shares Investment
Series A Equity 600,000
Series B Equity 7,000,000
Divided Free Cash Flows
$87,282.27 $316,468.92 $968,243.81 $1,534,371.45 $1,940,149.98 $4,846,516.43
$0.00 $3,281,899.91 $10,041,046.89 $15,912,000.19 $20,120,073.86 $49,355,020.85
Series A MIRR 107.09%
Series B MIRR 94.64%
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What-If Scenario S2 Financial Summary - 72 genomes/day @$999/genome
Year 2012 2013 2014 2015 2016 2017
Stage Research Scale Up Sales Sales Sales Terminal
% of Design Capacity 0.00% 50.00% 100.00% 90.00% 81.00% 10000.00%
Income Statement
Revenue $0.00 $10,731,492.68 $21,462,985.37 $19,316,686.83 $17,385,018.15
Cost  of sales $172,000.00 $380,603.80 $382,207.60 $382,207.60 $382,207.60
Operateing, SG&A expenses $340,000.00 $1,549,658.34 $1,559,316.69 $1,559,316.69 $1,559,316.69
Depreciat ion $0.00 ($108.19) ($21,882.37) ($13,171.43) ($7,918.03)
Pre-tax income ($512,000.00) $8,801,230.54 $19,521,461.08 $17,375,162.54 $15,443,493.86
Tax @ 40% ($204,800.00) $3,520,492.22 $7,808,584.43 $6,950,065.02 $6,177,397.54
Net income ($307,200.00) $5,280,738.32 $11,712,876.65 $10,425,097.53 $9,266,096.32
Cash Flow Statement
Cash from Operating Activities
Plus:Depreciat ion $0.00 ($108.19) ($21,882.37) ($13,171.43) ($7,918.03)
Changes in Working Capital
Changes in AR $0.00 ($882,040.49) ($882,040.49) $0.00 $0.00
Changes in AP $14,136.99 $17,807.54 $793.84 $0.00 $0.00
Changes in Inv $0.00 $131.82 $131.82 $0.00 $0.00
Changes in CR ($85,000.00) ($300,000.00) $0.00 $0.00 $0.00
Total Change in Working capital ($70,863.01) ($1,164,101.14) ($881,114.84) ($176,408.10) ($158,767.29)
Cash from Investing Activities
Purchase/Sale of Equipment ($54,093.67) ($6,784,037.45)
Cash from Financing Activities
Issuance of Common Stock $600,000.00 $7,000,000.00
Free Cash Flow $96,980.30 $3,168,390.40 $9,928,764.61 $10,059,109.90 $8,940,643.71 $32,193,888.91
NPV@25% Discount Rate $2,239,434.81
Equity Shares Investment
Series A Equity 600,000
Series B Equity 7,000,000
Divided Free Cash Flows
$87,282.27 $275,956.58 $864,763.37 $876,116.02 $778,701.23 $2,882,819.47
$0.00 $2,861,771.98 $8,967,916.42 $9,085,647.65 $8,075,420.12 $28,990,756.16
Series A MIRR 75.08%
Series B MIRR 63.79%
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What-if S3 Scenario Financial Analysis - 72 genomes/day @ $999/genome
Year 2012 2013 2014
Stage Research Scale Up Terminal
% of Design Capacity 0.00% 50.00% 50.00%
Income Statement
Revenue $0.00 $7,127,928.72 $0.00
Cost of sales $172,000.00 $380,603.80 $0.00
Operateing, SG&A expenses $340,000.00 $1,540,000.00 $1,540,000.00
Depreciation $0.00 ($108.19) $0.00
Pre-tax income ($512,000.00) $5,207,324.92 ($1,540,000.00)
Tax @ 40% ($204,800.00) $2,082,929.97 $0.00
Net income ($307,200.00) $3,124,394.95 $0.00
Cash Flow Statement
Cash from Operating Activities
Plus:Depreciation $0.00 ($108.19) $0.00
Changes in Working Capital
Changes in AR $0.00 ($585,857.16) $0.00
Changes in AP $14,136.99 $17,013.70 $0.00
Changes in Inv $0.00 $131.82 $0.00
Changes in CR ($85,000.00) ($300,000.00) $0.00
Total Change in Working capital ($70,863.01) ($868,711.64) $0.00
Cash from Investing Activities
Purchase/Sale of Equipment ($54,093.67) ($6,793,176.42)
Cash from Financing Activities
Issuance of Common Stock $600,000.00 $7,000,000.00
Free Cash Flow $96,980.30 $1,593,687.07 $0.00
NPV@25% Discount Rate ($5,756,801.69)
Equity Shares Investment
Series A Equity 600,000
Series B Equity 7,000,000
Divided Free Cash Flows
$87,282.27 $138,805.00 $0.00
$0.00 $1,439,459.29 $0.00
Series A MIRR -22.60%
Series B MIRR -38.12%
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D.1.11 Large-Scale Cost Estimates (part 2) 
In
ve
nt
or
y 
Co
st
s
It
em
U
ni
t c
os
t
Q
ua
nt
ity
T
ot
al
 C
os
t
It
em
U
ni
t c
os
t
Q
ua
nt
it
y
T
ot
al
 C
os
t
no
ne
*
$0
.0
0
0
$0
.0
0
Re
ag
en
ts
*N
o 
in
ve
nt
or
y 
is 
us
ed
 d
ur
in
g 
re
se
ar
ch
 st
ag
e
Pr
es
eq
ue
nc
in
g
$8
.4
9
52
20
00
00
$4
43
,1
78
,0
00
.0
0
Se
qu
en
ci
ng
$1
9.
22
52
20
00
00
$1
,0
03
,2
84
,0
00
.0
0
M
ic
ro
Ch
ip
s
$0
.8
1
39
60
$3
,2
07
.6
0
Pr
es
eq
ue
nc
in
g
$2
.3
4
52
20
00
00
$1
22
,1
48
,0
00
.0
0
Se
qu
en
ci
ng
To
ta
l
$0
.0
0
To
ta
l
$1
,5
68
,6
13
,2
07
.6
0
Re
nt
al
 C
os
ts
It
em
Co
st
/ft
2
T
ot
al
 C
os
t
It
em
C
os
t/f
t2
ft
2
T
ot
al
 C
os
t
La
b 
sp
ac
e
$1
00
.0
0
50
0
$5
0,
00
0.
00
La
b 
sp
ac
e
$1
00
.0
0
75
00
$7
50
,0
00
.0
0
Se
qu
en
ci
ng
 S
pa
ce
$1
00
.0
0
20
0
$2
0,
00
0.
00
Se
qu
en
ci
ng
 S
pa
ce
$1
00
.0
0
10
00
0
$1
,0
00
,0
00
.0
0
O
ff
ic
e 
Sp
ac
e
$3
0.
00
10
00
$3
0,
00
0.
00
O
ff
ic
e 
Sp
ac
e
$3
0.
00
20
00
0
$6
00
,0
00
.0
0
It
em
Co
st
/m
on
th
M
on
th
/y
r
T
ot
al
 C
os
t
It
em
C
os
t/m
on
th
M
on
th
/y
r
T
ot
al
 C
os
t
U
til
ite
s
$5
,0
00
.0
0
12
$6
0,
00
0.
00
U
til
ite
s
$1
00
,0
00
.0
0
12
$1
,2
00
,0
00
.0
0
M
ai
nt
en
an
ce
$1
,0
00
.0
0
12
$1
2,
00
0.
00
M
ai
nt
en
an
ce
$2
0,
00
0.
00
12
$2
40
,0
00
.0
0
To
ta
l
$1
72
,0
00
.0
0
To
ta
l
$3
,7
90
,0
00
.0
0
O
pe
ra
ti
ng
 C
os
ts
It
em
Sa
le
s
T
ot
al
 C
os
t
It
em
Sa
le
s
%
 o
f S
al
es
T
ot
al
 C
os
t
no
ne
$0
.0
0
0
$0
.0
0
Re
se
ar
ch
$1
0,
30
4,
84
6,
45
1.
31
6.
00
%
$6
,1
82
,9
07
.8
7
Sa
le
s
$1
0,
30
4,
84
6,
45
1.
31
3.
00
%
$3
,0
91
,4
53
.9
4
To
ta
l
$0
.0
0
To
ta
l
$9
,2
74
,3
61
.8
1
To
ta
l A
nn
ua
l C
os
ts
$5
66
,0
93
.6
7
To
ta
l A
nn
ua
l C
os
ts
$1
8,
08
9,
45
8,
49
2.
13
307 | P a g e  
 
Micro$eq – Chomvong, King, Mahmoud 
D.1.12 Large Scale Breakeven Financial Analysis Summa 
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